Bioprocessing of human Pluripotent Stem Cells for cardiac cell therapy and pre-clinical research by Correia, Cláudia Susana Pedreira
Cláudia Susana Pedreira Correia 
 








Bioprocessing of human Pluripotent Stem 
Cells for cardiac cell therapy and pre-
clinical research  
  
  







Orientador: Paula M. Alves, PhD, ITQB-NOVA 
 

































































Bioprocessing of human Pluripotent Stem Cells for cardiac cell therapy and pre-clinical 
research 
Copyright © Cláudia Susana Pedreira Correia, Faculdade de Ciências e Tecnologia, Universidade 
Nova de Lisboa. 
A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e 
sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos 
reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a 
ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e 
distribuição com objectivos educacionais ou de investigação, não comerciais, desde que seja dado 


















































Ao Meu melhor Amigo 
 
 
















I would like to express my gratitude to all the people, directly or indirectly, involved in this 
thesis, which supported and helped me during this journey 
To my supervisor, Dr Paula Alves, for the scientific support, knowledge and experience shared 
with me throughout these years. Thank you for all the professional advices, for the challenges and 
for all the opportunities provided, including courses, conferences and the visit to MGH/HMS that 
contributed for my development as a scientist. 
To my co-supervisor, Dr Margarida Serra, for all the endless scientific duscussions, support, 
guidance, confidence, motivation and friendship provided during this journay. Thanks for always 
believing in me and for promoting my independence, pushing me towards my goals and 
broadening my scientific perspectives. 
To Professor Manuel Carrondo, for being an inspiring example of leadership and for 
transmitting us the excellence, rigor, hard work and pro-activity that are fundamental for success in 
science. 
To Dr. Ibrahim Domian, for such a warm welcome in your laboratory at MGH/HMS, Boston. 
I’m thankful for your scientific enthusiasm and all the knowledge shared. Thank you also to all 
Domian’ group members, specially, DJ and Abir, for all the help, from bench work, to data analysis, 
to scientific discussions. 
To Dr. Tomo Saric, from University of Cologne, for being part of my CAT and for all the 
scientific support and guidance provided during our collaborative projects.  
To Dr. Pedro Lima, from FCM-UNL, for the help with the electrophysiology analyses, for all the 
advices and good sense of humour. 
To Alexey Koshkin, Patrícia Duarte and Nuno Espinha, I would like to emphasize my very 
special “thank you”. It was a pleasure to teach you and also to learn from you. Seeing you growth, 
every day, as scientists was a truth reward! Thank you for having shared with me the hurdles and 
joys of working with such amazing and full of energy cells, for your hard work and commitment, for 
your loyalty, for always maintaining the enthusiasm and being in the lab with a smile, particularly 
during those long working marathons, for your true friendship, for always being there when I most 
needed, for supporting me and believing in me and in my ideas, for all the shared laughs and 
pleasant conversations in the lab. Thank you very much to each one of you for being who you are. 
To Dr Ana Teixeira for the support in cellular metabolic analysis, for being always available 
(even when far away from the lab), and for the fruitful discussions. 
To Dr Madalena Carido, for helping me with the hypothermic storage studies, for all the 
scientific and personal advices, for one year of very funny and pleasant lunch breaks, for always 
motivating me, and for being a good friend in and outside the lab. 
To the MIT-Portugal program and to all my Professors for a year of intense learning and 
experiences, which stimulated further my interest in the bioengineering field, to Dr José Silva 
Lopes for always being available to help in any subject, to my colleagues, in special to Patricia and 
Tomás, my CandiFriends, it was really a pleasure to work with you, we did an amazing team. 
iv 
 
To the hosting institutions, iBET and ITQB-NOVA, for the excellent working conditions. To the 
financial support provided by Fundação para a Ciência e Tecnologia (SFRH/BD/51573/2011). 
To all animal cell technology unit colleagues, in particular to those of the Stem Cell team for 
the scientific discussions, critical suggestions and good working environment in the lab, to Marcos 
Sousa for the support with bioprocess operations in the beginning of this journey, to Dr Catarina 
Brito for helpful discussions, to Dr Carina Silva for always being available to help, to Hugo Soares 
for all the encouraging words and friendship, and to all the people who contributed to the great 
environment in the lab and during lunch times. 
To Katrina and Chuck for having received me with open arms in Boston, for made me feel 
welcome in your lovely home, for your endless kindness and friendship. It was a great pleasure to 
meet you during this journey. 
 
Pessoalmente gostaria de agradecer,  
Aos meus amigos da licenciatura (e de hoje), ao Hélio, à Lúcia, à Cristiana, à Joana, ao 
André e à Ana Cláudia por me fazerem rir e descontrair. 
Aos meus amigos de longa data, em especial às minhas amigas do PN, por todos estes anos 
de amizade. 
Ao Hélio, por todo o apoio que me deu durante todos estes anos, por me ter ajudado a 
crescer e a ter coragem e força para vencer todos os obstáculos. 
Ao meu melhor amigo, pelo apoio incondicional, por sempre me dar força, elogiar e acreditar 
em mim, por toda a confiança, por estar sempre presente tanto nas alegrias como nas tristezas. 
Obrigada pelas infindáveis gargalhadas, pelo carinho, amizade e paciência. Esta tese não teria 
sido a mesma sem ti. 
A toda a minha família. Aos meus tios, primos e priminhos. Em especial à minha prima Telma 
por sempre acreditar em mim como cientista e por ter tanto gosto em ouvir e perceber o meu 
trabalho. Ao Bob pela boa disposição e palavras de incentivo. Aos meus queridos Pais, por serem 
a base de tudo. Pelo apoio incondicional que me dão e que me ajuda a enfrentar tudo na vida. 
Obrigado por estarem sempre presentes, por toda a confiança e por toda a imensurável ajuda. À 
minha irmã por ser o meu exemplo de coragem, perseverança, força e determinação. À minha 






Cardiovascular diseases remain the leading cause of death worldwide. Some of these 
diseases, e.g. myocardial infarction (MI), are associated with a massive and permanent loss of 
cardiomyocytes (CMs), a non-proliferative and terminally differentiated cell population in the heart. 
Available pharmacological and interventional therapies are not suitable to amend the effects of this 
cell loss, mainly due to the limited regenerative capacity of the myocardium, and heart 
transplantation is limited by the number of compatible organs donated. Recently, human pluripotent 
stem cells (hPSCs), have emerged as attractive candidate cell sources to obtain CMs. Due to their 
inherent capacity to proliferate indefinitely and to differentiate into all mature cells of the human 
body, hPSCs constitute the unique cell source that can provide, ex-vivo, an unlimited number of 
functional CMs suitable for cell therapy and other applications including disease modeling and 
cardiotoxicity drug testing. Nonetheless, the complex nets of signaling pathways involved in 
cardiomyogenesis as well as the line-to-line variability compromise the effectiveness of the existing 
differentiation protocols to reproducibly produce high-quality CM from multiple hPSC lines. The 
immature phenotype of the produced hPSC-CMs and the lack of efficient methods for worldwide 
shipment of these cells also constrain the applicability of these cells in the clinic and industry. 
The main aim of this thesis was to devise robust, scalable and integrated approaches for the 
production and maturation of hPSC-CMs. The strategy consisted in exploring the impact of 
environmental factors, cell culture configuration, and metabolic substrate availability on bioprocess 
yields and cell’s quality using a set of “-omic” tools, namely transcriptomics, metabolomics and 
fluxomics, and cell characterization assays.  
In Chapter 1, the recent advances on the use of hPSC for cardiac cell therapy were reviewed.  
In Chapter 2, the effect of dissolved oxygen and bioreactor hydrodynamics on CM 
differentiation was explored. It was demonstrated that combining a hypoxia culture (4% O2 tension) 
with wave-induced agitation enables the differentiation of iPSCs towards CMs at faster kinetics and 
with higher yields.  
Chapter 3 focused on the development and characterization of a robust protocol for directed 
differentiation of hPSC towards CMs, suitable to generate CMs in both 2D monolayer and 3D 
aggregate culture formats. The culture of hPSC-cardiac progenitors as 3D aggregates revealed to 
be an efficient approach to improve CM enrichment and commitment. Although hPSC-CMs 
generated from both methods revealed to be highly glycolytic, 3D aggregate cultures showed 
slightly improved metabolic energetics (including increased TCA-cycle activity and ATP 
production). Chapter 4 assessed whether alterations in hPSC-CM culture medium composition to 
mimic in vivo substrate availability during cardiac development would induce hPSC-CM maturation 
in vitro. It was demonstrated that shifting hPSC-CMs from glucose-containing to galactose- and 
fatty acid-containing media promotes their maturation into adult-like CMs with higher oxidative 
metabolism, transcriptional signatures closer to ventricular CMs, higher myofibril density and 
alignment, improved calcium handling, enhanced contractility, and more physiological action 
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potential kinetics, within 10-20 days. The feasibility to cold store hPSC-CMs monolayers and 
aggregates in a fully-defined clinical compatible formulation was evaluated in Chapter 5. It was 
demonstrated that hPSC-CMs are more resistant to prolonged hypothermic storage–induced cell 
injury in 3D aggregates than in 2D monolayers, showing high cell recoveries, typical (ultra)structure 
and functionality after 7 days of storage. 
Chapter 6 consists of a general discussion, where the main scientific and technological 
outcomes of this thesis are outlined. 
Overall, by pursuing an holistic approach that brought together a quantitative molecular and 
metabolic characterization, this thesis provides novel insights into the interaction of metabolism 
and CM differentiation/maturation but also establishes robust and scalable methods for production, 
functional maturation and short-term storage of hPSC-CMs. This will pave the way for the 








As doenças cardiovasculares constituem uma das principais causas de morte a nível mundial 
e estão normalmente associadas a uma perda massiva e permanente de cardiomiócitos (CMs), 
uma população celular não proliferativa e completamente diferenciada. As terapias farmacológicas 
disponíveis actualmente não são adequadas para reparar os efeitos nefastos causados pela 
destruição destas células e a implementação do transplante cardíaco como tratamento 
convencional é restringida pelo número limitado de órgãos compatíveis doados. Recentemente, as 
células estaminais pluripotentes humanas (hPSCs), surgiram como uma fonte celular promissora 
para a obtenção de CMs. Devido à sua inerente propriedade de proliferação ilimitada e 
capacidade de se diferenciar em todas as células adultas do corpo humano, as hPSCs constituem 
a única fonte de células que pode proporcionar, ex-vivo, um número ilimitado de CMs funcionais 
adequados para terapia celular e outras aplicações, como por exemplo o rastreio de novos 
medicamentos ou como modelo celular para avaliar o desenvolvimento e progressão de várias 
doenças. No entanto, a complexidade do processo de desenvolvimento cardíaco aliado à elevada 
variabilidade entre diferentes linhas de células tem vindo a dificultar o desenvolvimento de um 
protocolo de diferenciação que reprodutivamente origine CMs com elevada qualidade a partir de 
linhas diferentes de hPSC. O fenótipo imaturo dos hPSC-CMs produzidos e a falta de métodos 
eficientes para o transporte adequado destas células a nível mundial também têm restringido a 
aplicabilidade destas células na clínica/indústria. 
Esta tese teve como principal objectivo o desenvolvimento de métodos robustos, 
escalonáveis e integrados para a produção e maturação de hPSC-CMs. A estratégia consistiu em 
explorar o impacto de factores ambientais, configuração do sistema de cultura, e disponibilidade 
de substratos metabólicos nos rendimentos do bioprocesso e na qualidade das células usando um 
conjunto diversificado de ferramentas incluindo transcriptomica, metabolomica e fluxómica, e 
ensaios de caracterização celular. 
No Capítulo 1, foram descritos os avanços mais recentes no uso de hPSC para terapia 
celular cardíaca. No Capítulo 2, foi explorado o efeito da concentração de oxigénio dissolvido e da 
hidrodinâmica de biorreactores na diferenciação em CMs. Demonstrou-se que a cultura celular 
num bioreactor  do tipo Wave em condições de hipoxia permite acelerar a cinética de 
diferenciação de iPSCs em CMs e aumentar os rendimentos de diferenciação cardiaca. 
O Capítulo 3 foca-se no desenvolvimento e caracterização de um protocolo robusto para a 
diferenciação dirigida de hPSC em CMs, capaz de produzir CMs em monocamadas e em 
agregados. A cultura de células progenitoras cardíacas derivadas de hPSCs sob a forma de 
agregados revelou ser uma abordagem eficiente para melhorar a diferenciação em CMs e a 
pureza final da cultura. Demonsostrou-se que apesar de os hPSC-CMs produzidos em ambos os 
tipos de cultura apresentarem um metabolismo principalmente glicolitico, as culturas de agregados 




 No Capítulo 4 avaliou-se o efeito da alteração da composição do meio de cultura de hPSC-
CMs, de modo a mimetizar a disponibilidade de substratos durante o desenvolvimento cardíaco, in 
vivo, na maturação de hPSC-CMs in vitro. Demonstrou-se que substituir o meio de cultura base 
rico em glucose por um meio sem glucose suplementado com ácidos gordos e galactose promove 
a maturação de hPSC-CMs, após 10-20 dias em cultura, originando hPSC-CMs que apresentam: 
um metabolismo mais oxidativo, um perfil de transcrição de genético mais semelhante a CMs 
ventriculares, miofibrilas em maior densidade e mais alinhadas, e melhorias na funcionalidade.  
A possibilidade de preservar monocamadas e agregados de hPSC-CMs numa formulação 
compatível com o uso clínico foi avaliada no Capítulo 5. Foi demonstrado que hPSC-CMs na 
forma de agregados são mais resistentes aos danos provocados por um armazenamento 
hipotérmico prolongado que na forma de monocamadas, mostrando recuperações celulares 
elevadas após o descongelamento e uma (ultra)estrutura e funcionalidade típica de CMs após 7 
dias de armazenamento. 
O Capítulo 6 consiste em uma discussão geral, onde são identificados os principais 
resultados científicos e tecnológicos desta tese. 
Em suma, esta tese contribuiu para o estado da arte no campo das células estaminais, 
apresentando uma abordagem holística que reuniu uma caracterização molecular e metabólica 
quantitativa, proporcionando novas perspectivas sobre a interacção do metabolismo com a 
diferenciação e maturação de CMs. Além disso permitiu desenvolver métodos robustos e 
escalonáveis para a produção, maturação funcional e armazenagem a curto prazo de hPSC-CMs, 
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GLUT glucose transporter 
GPI glucose-6-phosphate isomerase 
GSK3-β glycogen synthase kinase-3 beta 
hCMs human cardiomyocytes      
HCN4 hyperpolarization activated cyclic nucleotide-gated potassium channel 4  
hESCs human embryonic stem cells  
hESC-CMs human embryonic stem cell derived cardiomyocytes  
hiPSC human induced pluripotent stem cells  
hiPSC-CMs human induced pluripotent stem cell derived cardiomyocytes  
HIS histidine 
HPLC high performance liquid chromatography 
hPSC human pluripotent stem cells 
hPSC-CMs human pluripotent stem cell derived cardiomyocytes 
ICM inner cell mass     
IgG immunoglobulin G  
IgM immunoglobulin M  
ILE iIsoleucine 
IPA ingenuity pathway analysis 
ISL-1 insulin gene enhancer protein ISL-1  
IWR inhibitors of Wnt response    
KDR kinase insert domain receptor  
LAC lactate 
LDH lactate dehydrogenase  
LEU leucine 
Lin28 Lin-28 homolog A     
LYS lysine 
MAL malate 
MDH malate dehydrogenase  
MEF mouse embryonic fibroblast     
MET methionine 
MFA metabolic flux analysis     
MI myocardial infraction      
MID mass isotopomer distributions  
MSCs mesenchymal stem cells    
MYH6 gene encoding myosin heavy chain, α isoform protein  
MYH7 myosin, heavy chain 7  
MYL2 myosin light chain 2 (myosin regulatory light chain 2, ventricular/cardiac muscle isoform)  
MYL7 myosin regulatory light chain 2 (myosin regulatory light chain 2, atrial isoform (MLC2a))  
NCX sodium-calcium exchanger 
NKX-2.5 NK2 homeobox 5   
NMR nuclear magnetic resonance    
OA oleic acid 
OAA oxaloacetate 




OXPHOS oxidative phosphorylation      
P5P pentose-5-phosphate  
PA palmitic acid 
PBS phosphate-buffered saline 
PC pyruvate carboxylase  
PDGFRα platelet-derived growth factor receptor α  
PDH pyruvate dehydrogenase  
PFA paraformaldehyde  
PHE phenylalanine 
PK pyruvate kinase  
PPP pentose phosphate pathway  
PRO proline 
PYR pyruvate  
qMet specific metabolic rate 
R5P ribose-5-phosphate       
ROS reactive oxygen species     
RT-qPCR real time-quantitative polymerase chain reaction   
RYR ryanodine receptor 
SER serine 
SERCA sarco/endoplasmic reticulum calcium atpase 
SIRPα/β signal-regulatory protein alpha/betta  
SR sarcoplasmic reticulum 
SSEA-1 stage-specific embryonic antigen-1  
SSEA-4 stage-specific embryonic antigen-4  
sTnI slow skeletal muscle isoform of troponin I 
SUC succinate 
TALDO transaldolase 
TCA Citric acid cycle  
TGF-β transcription growth factor β   
THR threonine  
TNNT2 cardiac muscle troponin T  
TRA-1-60 the human embryonal carcinoma marker antigen  
TYR tyrosine 
VAL valine  
VCAM1 vascular cell adhesion molecule 1  
VEGF vascular endothelial growth factor    
WB washing buffer 
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1.1. Stem cell-based therapies for cardiac repair 
Despite the recent advances in medicine, cardiovascular diseases remain the leading cause of 
death worldwide (Moran et al., 2014; WHO, 2016). Several of these diseases, e.g. myocardial 
infarction, are associated with a massive and permanent loss of CMs (CMs), a non-proliferative 
and terminally differentiated cell population (Chien and Olson, 2002; Saraste et al., 1999). The 
current pharmacological and interventional therapies are not suitable to amend the effects of this 
cell loss, mainly due to the limited regenerative capacity of the myocardium (Beltrami et al., 2003; 
Saraste et al., 1999). Bergmann et al. estimated that the renewal rate in human CMs gradually 
decreases from 1% per year at age of 25 to 0.45% annually at the age of 75 (Bergmann et al., 
2009). Even though a subpopulation of cardiac stem cells reside in the adult human heart, their 
minor contribution towards CM renewal (estimated to be 0.03% to 0.008%) (van Berlo et al., 2015) 
is insufficient  to assure a meaningful functional recovery after a myocardial infarction that can 
damage approximately 1 billion CMs (Saraste et al., 1999). Additionally, the proliferation and 
migration of fibroblasts to the injury site forms scar tissue with impaired contractile function that 
ultimately leads to the progression of cardiac damage (Deb and Ubil, 2014). The only current 
treatment to address CM loss and fully restore cardiac function is heart transplantation, however 
this procedure is limited by the number of compatible organs donated and the requirement of 
lifelong immunosuppression (WHO, 2014). Therefore, the development of novel regenerative 
therapies as well as the generation of more reliable human cardiac disease models for cardiac drug 
discovery and toxicology testing represents a major public health priority. 
Stem cell technology is a great promise in regenerative medicine, due to stem cells’ ability to 
proliferate indefinitely, while maintaining an unspecialized state, and to differentiate into multiple 
cell lineages (Evans and Kaufman, 1981; Thomson et al., 1998). In fact, numerous groups have 
reported the use of different stem cells types, derived from different sources, to improve cardiac 
function after injury (Chong et al., 2014; Menasché et al., 2008). The promising results in pre-
clinical studies using animal models rapidly led to clinical trials, initially using bone marrow-derived 
mononuclear cells, mesenchymal stromal cell populations and, more recently, progenitor cells from 
the adult heart itself (Le et al., 2016). Though the efficacy of these in the clinical trials has been 
inconsistent. Various studies suggested that most of the beneficial effects of these cells are 
mediated through paracrine actions (secretion of exosomes, anti-apoptotic, immunomodulatory or 
proangiogenic factors), and modulation of extracellular matrix (ECM), rather than providing a true 
cardiomyogenic ability (reviewed in (Gnecchi et al., 2008; Le et al., 2016)). An ideal cell type for 
regeneration of the failing heart, besides ensuring safety and be expandable should integrate and 
synchronize with the rest of host myocardium (Carvajal-Vergara and Prósper, 2016). Thus, human 
pluripotent stem cells (hPSCs), including human embryonic stem cells (hESC) and human induced 
pluripotent stem cells (hiPSC), have emerged as more attractive candidates for cardiac 
regeneration due to their theoretically ability to produce unlimited numbers of multiple cardiac cell 
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types (including CMs) that can directly replace the damage cells and contribute to 
remuscularization of the infarcted  tissue. The capability of hPSC-derived cardiomyocytes (hPSC-
CMs) and cardiac progenitors (hPSC-CPCs) to engraft in the infarcted heart and contribute to 
cardiac function improvement has been demonstrated in many pre-clinical studies in both small 
and large animal models of myocardial infarction (Chong and Murry, 2014; Chong et al., 2014; 
Funakoshi et al., 2016; Laflamme et al., 2007; Shiba et al., 2012, 2016). A clinical trial ESCORT 
(ClinicalTrials.gov identifier: NCT02057900; phase I) that relies on the transplantation of cardiac 
progenitors derived from hESC, embedded in a fibrin scaffold for the treatment of severe heart 
failure is currently ongoing (Menasche et al., 2015).  
1.2. Human pluripotent stem cells (hPSCs): Characteristics and Applications 
Murine embryonic stem cells (ESCs) were first isolated in 1981 (Evans and Kaufman, 1981) 
and their human counterparts in 1998 (Thomson et al., 1998) from the inner cell mass of 
blastocysts, pre-implanted embryos at day 5 of embryonic development. Despite their enormous 
potential for cell-based therapies, ESCs are inevitably associated with ethical issues, are 
technically difficult to derive and induce immune rejection after transplantation (Nussbaum et al, 
2007). 
In 2006 a major breakthrough occurred in the stem cell field. The reversion of somatic cells to 
a pluripotent state, by overexpression of 4 transcription factors (Oct4, Sox2, Klf4 and c-Myc), was 
reported for the first time in mice (Takahashi and Yamanaka, 2006). This finding had such impact 
in the scientific community that the reprogramming of human induced pluripotent stem cells 
(hiPSC) derived from human dermal fibroblast was described shortly after the initial discovery in 
mice (Takahashi et al., 2007). These iPSCs exhibited characteristics very similar to ESCs. 
However, it was demonstrated that occasional reactivation of one of the reprogramming 
factors, c-Myc, could result in tumour formation (Okita et al., 2007). Therefore, in a later study 
reported by Thomson and co-workers, c-Myc and Klf4, well known proto-oncogenes, were replaced 
by Nanog and Lin28 (Yu et al., 2007).  
The first reprogramming protocols relied on the use of integrating vectors to deliver desired 
transgenes into the genome of somatic cells. These integrating vectors were mainly retroviral or 
lentiviral (Takahashi et al., 2007; Thorrez and Sampaolesi, 2011). Even though reprogramming 
was possible, random transgene insertion could interrupt existing genes causing tumor formation 
(after transplantation) and disturb the maintenance of the undifferentiated cell state. This approach 
presents other drawbacks such as low stability, difficult cellular targeting and possible insertion of 
mutagenesis. To overcome these limitations and establish safer iPSC lines, methods that allow the 
expression of pluripotency genes without integrating the genome of the host are currently being 
explored. Some examples include the use of: i) non-integrating virus (e.g. adenoviruses, 
baculoviruses, Sendai virus), ii) episomal vectors or excisable transposon systems (e.g. PiggyBac 
or Cre/loxP systems), which integrate the cells but can be removed by transposase, without leaving 
genetic material behind, iii) exogenous plasmids, protein factors, small molecules and microRNAs 





Since the ability to generate iPSC in culture from adult human skin fibroblasts has been 
established, pluripotency has been induced in a variety of somatic cells including cardiac 
fibroblasts (Linares et al., 2016), keratinocytes (Aasen et al., 2008), T-lymphocytes (Brown et al., 
2010), cord blood (Giorgetti et al., 2009), placenta (Ge et al., 2012), neural stem cells (Kim et al., 
2009), adipose tissue (Zapata-Linares et al., 2016) and renal epithelial cells present in urine 
samples (Zhou et al., 2012). In the last few years, iPSC technology has boosted the field of 
regenerative medicine, offering numerous advantages over adult stem cells and ESCs. iPSCs can 
circumvent the need for embryo use, being ethically less controversial. Also, differentiated cells 
derived from iPSCs have been shown to present limited immunogenicity and could therefore be 
used in autologous personalized (Araki et al., 2013) (patient specific) or allogeneic off-the-shelf 
therapies (universal donor-derived cells).  
hPSCs inherent capability of unlimited self-renewal coupled with efficient directed 
differentiation protocols allow for the large-scale production of specific human cell types, which can 
be used not only in regenerative medicine (Hartman et al., 2016) but also in developmental biology 
(Ueno et al., 2007), human disease modeling (Drawnel et al., 2014), and drug screening (Drawnel 
et al., 2014). Even though animal models have been essential in biomedical research, intrinsic 
differences with human physiology limit the reliable use of these models. For instance, mouse CMs 
display shorter action potentials compared with human ones because of differential expression of 
ion channels (Nerbonne, 2004). As such, hPSCs and their differentiated progeny hold great 
potential as a human cellular model (Drawnel et al., 2014). Up to now more than 70 hiPSC models 
of human diseases have been published (Ko and Gelb, 2014). In particular, hPSC-CMs have been 
used as in vitro models of several monogenic diseases, such as channelopathies and 
cardiomyopathies (Hartman et al., 2016). These models will contribute to improve our 
understanding of disease mechanisms, and potentially lead to new therapeutic strategies. The 
ability to evaluate the direct effects and toxicity of new drugs on the patients’ own cells will 
ultimately enable the prediction of individual patient’s responses to target treatments, fostering the 
transition to personalized medicine. Importantly, since many new drugs have unexpected cardiac 
toxicity resulting in sudden cardiac death (Pacher and Kecskemeti, 2004), hPSC-CMs can provide 
a high-quality platform for drug toxicity screening unanticipated possible side-effects of these new 
drugs in earlier stage of the drug development process.  
Although hPSCs have proved promising in all these applications, there are still challenges to 
overcome in order to transfer hPSCs to cardiac cell therapy and pre-clinical applications including 
improved methods to consistently generate pure differentiated hPSC-CM populations with more 
mature structural and functional properties, and avoid or minimize graft cell death, immune 
rejection of graft cells, arrhythmogenesis, and the risk of tumorigenesis (Hartman et al., 2016). 
Figure 1.1 summarizes the main benefits and challenges of using hPSCs for heart regeneration 
and repair and indicates some of the solutions being pursued to address these issues.  
 




Figure 1.1. hPSC technology for cardiac cell therapy: Major benefits, limitations and possible 
solutions (adapted from (Le et al., 2016; Zwi-Dantsis and Gepstein, 2012))  
 
1.3. Differentiation of hPSC towards cardiomyocytes 
Differentiation of hPSCs to CMs was first reported in 2001 and since then distinct approaches 
have been thoroughly explored, namely differentiation with cells cultivated as embryoid bodies 
(EBs, three-dimensional aggregates of pluripotent stem cells) (Kehat et al., 2001), co-culture with 
inducer END-2 cells (Mummery et al., 2003) and guided differentiation strategies (induced by 
growth factors and/or small molecules) in two dimensional (2D) monolayers (Lian et al., 2013). 
Significant improvements in cardiac differentiation efficiency have been achieved through tightly 
timed, leveled and combined application of cardiogenic growth factors or small molecules that 
manipulate key signaling pathways (BMP, FGF, TGF/Activin/Nodal and WNT) involved in specific 
stages of in vivo cardiac development, including mesoderm formation, cardiac mesoderm 
specification and cardiac lineage specification (Figure 1.2) (Kadari et al., 2015; Kattman et al., 
2011; Lian et al., 2012; Paige et al., 2010; Sumi et al., 2008). The use of small molecules in guided 
differentiation protocols is currently preferred to growth factors and recombinant protein based 





cell layers within EBs to modulate signaling, thus yielding more consistent results. There are also 
less expensive than growth factors, offering greater flexibility and scale-up prospects to directed 
differentiation protocols (Wang et al., 2011). Table 1.1 lists the multiple and different combinations 
of growth factors and small molecules that have been used to induce directed differentiation of 
hPSCs towards CMs, in vitro.  
 
 
Figure 1.2. Schematic representation of signaling pathways and factors involved in cardiomyocyte 
differentiation in embryology. Factors that influence the progression through the five steps in cardiomyocyte 
differentiation and maturation: mesoderm differentiation, mesoderm specification, cardiac specification, 
cardiomyocyte differentiation and cardiomyocyte maturation. Transcription factors characteristic of each cell 
population during CM differentiation are presented in the respective boxes. Adapted from (Kamps and 
Krenning, 2016). 
 
Differentiation of hPSCs into CMs from a confluent monolayer was first reported for hESCs 
(cell line H7) in 2007 (Laflamme et al., 2007). hESCs were cultured in chemically defined RPMI-
B27 medium supplemented with Activin-A for 24 hours, and then 4 days in medium supplemented 
with BMP4. Spontaneous beating cells were observed on the 12
th
 day of differentiation, and the 
final cell population contained 30% of MHC positive cells. By the time of development, this 
technique was the most efficient one, outperforming EB-based techniques. In 2010, it was found 
that the mechanism of the Activin/BMP4 differentiation is dependent upon endogenous Wnt/β-
catenin signaling. Particularly, Wnt/β-catenin signaling has a biphasic role in cardiogenesis: Wnt 
activation is required for mesoderm formation and subsequent Wnt inhibition is necessary for 
cardiac specification (Ueno et al., 2007). Wnt pathway inhibits glycogen synthase kinase 3 beta 
(Gsk3-β) leading to accumulation of b-catenin that is translocated to the nucleus, where it binds to 
transcription factors that regulate Wnt-responsive genes (Ueno et al., 2007). Hence, CHIR99021, a 
small molecule that inhibits Gsk3-β, has been widely used in directed differentiation protocols to 
activate Wnt signaling, whereas subsequent inhibition has been explored with a wide range of Wnt 
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antagonist such as IWP4, IWP2, IWR1, Wnt-C59 or XAV939 (Burridge et al., 2014; Kadari et al., 
2015; Lian et al., 2012). Temporal modulation of Wnt signaling has shown great progress towards 
the generation of hPSC-CMs with high purity from both hESC and hiPSC lines (Lian et al., 2012, 
2013). Consequently, nowadays most protocols rely on the regulation of the Wnt pathway (Table 
1.1). Lian and colleagues also demonstrated the importance of understanding the role of media 
components used for differentiation. They showed that insulin, which is a component of the B27 
medium supplement, suppresses cell differentiation during the first five days. After insulin was 
removed from the medium, the consistency of the CM yields increased dramatically (83–95% of 
cTnT positive cells, Table 1.1) (Lian et al., 2013). However, the B27 medium supplement, normally 
used for CM differentiation still contains some media components with unknown effects on 
differentiation efficiency and phenotype of the generated hPSC-CMs. In an attempt to improve 
differentiation efficiency across different PSC lines a recent study focused on the development of a 
chemically defined medium (Burridge et al., 2014). This study demonstrated that using a chemically 
defined medium consisting of just three components (the basal medium RPMI 1640, l-ascorbic acid 
2-phosphate and rice-derived recombinant human albumin), along with small molecule–based 
induction of differentiation, is possible to obtain consistently high CM purities (80-95% of cTnT 
positive cells in 11 hiPSC lines, Table 1.1). 
Other small molecules with potential to enhance cardiomyogenesis have been studied 
(Lewandowski et al., 2016). For example, ascorbic acid, has been shown to enhance differentiation 
of iPSCs into CMs (Cao et al., 2012). More specifically, the addition of ascorbic acid at early stages 
of culture showed to improve by 7.3-fold and 30.2-fold the yields of mouse and human PSC-CMs, 
respectively. Ascorbic acid promotes CM differentiation by increasing collagen synthesis, 
enhancing proliferation of cardiac progenitor cells and upregulating late stage markers of 
cardiomyogenesis (Cao et al., 2012; Takahashi et al., 2003). Although efficiencies of > 80% 
positive cells for CM markers are now regularly reported for hPSC differentiation towards CMs 
(Table 1.1), several evidences suggest that cardiac differentiation efficiencies are still highly 
variable between batch-to-batch, different hPSC lines and different laboratories. Thus, there is still 
space to improve reproducibility, robustness and standardization of the protocols to ensure greater 
consistency between cell lines and laboratories. Also, cardiac differentiation protocols still generate 
a mixed population of CM subtypes, including ventricular-, atrial- and pacemaker-like cells (Table 
1.1) and cultures containing a single subtype are preferred for some applications. For example the 
transplantation of highly purified ventricular-like CMs might prove less likely to promote arrhythmias 
than the transplantation of cell preparations including significant quantities of nodal or other non-
ventricular CMs (Hartman et al., 2016). Retinoic acid (RA) and Wnt signaling appear to play a 
critical role in determining atrial versus ventricular cardiomyocyte fate in differentiating hPSCs 
(Karakikes et al., 2014; Zhang et al., 2011), however more studies need to be performed to validate 
their utility in CM sub-lineage specification. The cellular heterogeneity with respect to lineage 
commitment state and/or degree of maturation among the final differentiation population is also an 
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1.4. Improving scalability of cardiomyocyte differentiation protocols 
The average human heart contains approximately 4 billion CMs (Murry et al., 2006), and the 
typical infarct involves the loss of approximately one-quarter of these cells. Thus, cell-based 




 hPSC-CMs per patient to regenerate the amount of working 
myocardial lost in myocardial infarction. Recently, Chong and colleagues demonstrated the 
feasibility of CM production and transplantation at this scale in a preclinical study using a primate 
model (Chong et al., 2014). While a monolayer-based CM differentiation protocol has sufficed for 
this early preclinical work, the labour intensive nature of this method (approximately one-dozen 150 
cm
2
 flasks of human ESC-derived cardiomyocytes were harvested to obtain the cell dose needed 
for each primate (Hartman et al., 2016)) reveals that this method is not suitable for the large-scale 
and clinical-grade production that would be required for transplantation in humans. Also, large 
numbers of cells are needed for drug screening pipelines and in vitro toxicology tests (Mummery et 
al., 2012). Thus, there is a need to translate small-scale culture protocols developed at research 
laboratories into validated bioprocesses that can guarantee reproducibility, scalability, 
standardization, robustness and safety. One attractive strategy for manufacturing hPSC-CMs 
consists in engineering stem cell niches by identifying key factors inducing CM differentiation of 
hPSC and creating culture approaches that allow 3D cell organization in a bioreactor-based system 
where key environmental conditions can be manipulated and finely controlled (Serra et al., 2012, 
2014).  
 
1.4.1. Cell culture strategies: 3D aggregate vs 2D monolayers 
In the last years, several 2D cell monolayer protocols were described for the differentiation of 
PSCs into functional CMs. However, 2D culture systems do not resemble the in vivo 
microenvironment and can be misleading regarding phenomena related with cell-cell or cell-ECM 
interaction, tissue architecture and biochemical signals (Serra et al., 2012). These culture systems 
also present an inherit uncontrollability, low scalability and low differentiation yields, that make 
them unattractive for clinical and industrial applications  (Serra et al., 2012, 2014).  
By providing a cellular context closer to what occurs in a native microenvironment, 3D culture 
strategies can significantly improve cell viability, functionality and proliferation/differentiation 
potential, offering a higher degree of efficiency, robustness, and predictability to the resulting hPSC 
manufacturing process (Lund et al., 2009; Serra et al., 2014) (Table 1.2.).  
Formation of cell aggregates is one of the most common 3D cell culture strategies used in 
stem cell bioprocessing. When cultured as aggregates, cells re-establish mutual contacts allowing 
them to express a tissue-like structure, enhancing cell differentiation and functionality (Lund et al., 
2009; Pal et al., 2013). Cell aggregates offer easy handling, scalable and reproducible 
opportunities to process development. The main limitation of this approach is the need to control 
aggregate size, avoiding diffusion gradients inside the aggregate that lead to necrotic centers 
and/or spontaneous differentiation (Serra et al., 2012). Cell harvesting is also an issue as 





Several methods have been used to induce and/or accelerate cell aggregation including 
seeding single hPSCs or clumps in static low attachment dishes or in multi-well dishes to prompt 
cell agglomeration by gravity or through the use of external forces, such as centrifugation, 
ultrasound, magnetic or electrical forces (Günter et al., 2016; Matthys et al., 2016; Pettinato et al., 
2015). Nonetheless, these methods present several limitations including the generation of 
aggregates with variable size, the difficulty to scale-up and the use of a harsh production 
environment using external forces (Günter et al., 2016). Recently, STEMCELL Technologies 
introduced the AggreWell™ plates, the first commercially available plates for the generation of 
standardized EBs from hPSCs. These plates allow the generation of large quantities of uniform-
sized EB. EB size can be adjusted by altering the number of cells added to each well. However, 
commercially available single use microwell based consumables are still very costly and therefore 
large-scale experiments may be hardly affordable for most researchers. Some groups have 
reported the in-house production of microwell plates using soft lithography procedures (Dahlmann 
et al., 2013). 
 




1.4.2. The use of bioreactors for hPSCs culture 
One of the most used strategies for scaling-up the production of PSC derivatives consists in 
the use of suspension culture systems that have become the standard for industrial-grade 
production of other cell types. Spinner flasks (Figure 1.3A) have been widely used for PSCs 
expansion and/or differentiation into CMs (Chen and Couture, 2015; Chen et al., 2012; He et al., 
2012; Niebruegge et al., 2009; Serra et al., 2011; Zwi-Dantsis et al., 2011). However this culture 
system lacks culture control over parameters like temperature, pH or gas exchanges (e.g. oxygen). 
The use of fully controlled bioreactors overcomes this issue allowing accurately controlling and 
monitoring culture environment (e.g. pH, temperature, pO2, gas composition). Also, these systems 
offer enormous engineering prospects, as they are scalable, reproducible, versatile and fully 
automated. Different bioreactor types have been used for PSC culture such as microfluidic culture 
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systems, rotatory culture systems, stirred tank bioreactors, WAVE bioreactor, bioreactors using 
Vertical-Wheel™ technology (PBS-VW) (reviewed in (Placzek et al., 2009; Serra et al., 2012, 
2014)). Stirred tank bioreactors (Figure 1.3B-C) have been widely used for PSC culture and cardiac 
differentiation (Table 1.3 and 1.4). Impeller-controlled stirring characteristic of these bioreactors 
ensures homogeneous mixing and distribution of cells, nutrients and gases. The impeller design, 
stirring rate and the cell inoculation density can be adjusted to control initial cell aggregation and 
improve aggregate culture (Olmer et al., 2012). One of the main limitations of stirred tank 
bioreactors is the hydrodynamic shear stress caused by stirring (reviewed in (Fridley et al., 2012)) 
which could detrimentally affect aggregate culture and cell differentiation.  
 
 
Figure 1.3. Examples of different suspension culture systems used for large-scale stem cell 
production. A) Spinner flask. B) Stirred tank bioreactor (Fries et al., 2005). Single-use disposable 
bioreactors: C) Single-use stirred tank bioreactor (Mobius CellReady, Millipore) (www.millipore.com). D) Wave 
bioreactor (WAVE Bioreactor, GE Healthcare) (Fries et al., 2005).  
   
During the last decade, single-use disposable bioreactors have been developed and applied in 
pre-clinical, clinical, and production-scale biotechnological facilities (Löffelholz et al., 2014). In 
contrast to reusable bioreactors made from glass or stainless steel, single-use bioreactors are 
made of FDA (Food and Drug Administration) approved plastics. Single-use bioreactors offer 
several advantages such as reduced costs in construction of production facilities, reduced risk of 
cross-contamination, less cleaning validation needed and rapid changeover of processes (Eibl et 
al., 2010; Löffelholz et al., 2014; Shukla and Gottschalk, 2013). However, these bioreactors also 
present limitations including lack of instrumentation for single-use sensors, possible secretion of 





Today, there are different disposable bioreactor types commercially available (Eibl et al., 2010; 
Löffelholz et al., 2014; Shukla and Gottschalk, 2013). Some examples include spinner vessels, 
such as the SuperSpinner D 1000 (Sartorius); stirred tank disposables: Mobius CellReady 
(Millipore; Figure 1.3C), Univessel SU (Sartorius), CelliGen BLU (Eppendorf); and Vertical-Wheel
TM
 
bioreactors (PBS-VW) (PBS Biotech). Another example is the wave induced bioreactor (WAVE 
Bioreactor from GE Healthcare and BIOSTAT CultiBag from Sartorious-Stedim). This bioreactor 
(Figure 1.3D) has a rocking platform capable of inducing a wave motion in the culture media 
without an impeller or other invasive mixer. This rocking system promotes rapid medium 
homogeneity and provides the optimal oxygen transfer in the inflated bag (Shukla and Gottschalk, 
2013; Singh, 1999). A study has shown that this bioreactor presents lower shear stress when 
compared to the stirred tank bioreactor (Oncül et al., 2009). In addition, this bioreactor has a simple 
design, appealing to either biological engineers or medical professionals. Recently, it was reported 
that the lower shear experienced during hESC expansion on Cytodex 1 microcarriers in a rocker 
(wave type) platform resulted in higher CM yields  than when  cultured in spinner cultures (Ting et 
al., 2014). 
Optimization of PSC bioprocessing should result in large cell yields through process 
intensification, specialization and integration, rather than just scale-up technologies (Serra et al., 
2012). The majority of culture approaches described up to now are based on substantial pre-
expansion of hPSC (at the pluripotent state), before induction of cardiac differentiation, since cells 
become progressively post-mitotic along differentiation. The establishment of platforms capable of 
integrating expansion, differentiation, purification and harvesting would result in the scale-up of the 
production of differentiated cells to clinical relevant numbers (Serra et al., 2012). Also, significant 
benefits would derive from implementing sophisticated sensing/monitoring tools and devices (such 
as probes based on near infrared (NIR), Raman or fluorescence spectroscopy) within the 
manufacturing platform to assess real-time cell culture status, including cell viability, phenotype and 
functionality (Pais et al., 2014). Integration of online monitoring of metabolites such as glucose and 
lactate will also be of great value, further supporting the traceability, efficacy, safety and quality of 
the bioprocess. 
Several bioprocesses combining PSC expansion and CM differentiation have been reported in 
recent years (Kempf et al., 2016). For example, Kempf and colleagues recently published a 
protocol for integrated hPSC expansion and CM differentiation in 100 mL stirred tank bioreactors 
(Kempf et al., 2014). After 4 days of expansion directed differentiation was induced by applying 
chemical Wnt pathway modulators and approximately 40 million CMs were generated in one 
bioreactor run. Table 1.3 and 1.4 summarize the main results of recent studies reporting integrated 
expansion and cardiac differentiation of murine and human PSC (respectively) in stirred culture 
systems. However, as shown in Table 1.4, the efficiency of differentiation of human PSCs in 
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Table 1.3. Large scale culture systems used for CM differentiation of murine PSCs.  









CM/PSC ratio Reference 












(Bauwens et al., 
2005) 





(Schroeder et al., 
2005) 









Table 1.4. Large scale culture systems for CM differentiation of human PSCs.  
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1.5. Improving recapitulation of the native cardiac microenvironment in vitro - Biophysical 
signals 
The cardiac microenvironment represents a niche that harbours biochemical and biophysical 
cues required for normal cardiac function. In vivo, the myriad of biophysical stimuli that cardiac 
tissue is exposed to controls normal development, physiology as well as pathophysiology (Atmanli 
and Domian, 2016). Biophysical cues are sensed by CMs through mechanosensors that convert 
the physical stimulus into a biochemical signal that mediates cell structure, survival, migration 
proliferation and differentiation. These sensors typically comprise membrane-associated protein 
complexes that interact with the ECM and link it to the cytoskeletal scaffold. Numerous efforts have 
been made to simulate the biophysical properties of the heart in vitro by manipulating ECM 
composition, growth substrate stiffness and elasticity, and applying mechanical stress (Atmanli and 





and stretch, fluid shear stress and hydrostatic compression to CMs (Geuss and Suggs, 2013; 
Gwak et al., 2006; Happe and Engler, 2016; Schmelter et al., 2006; Stoppel et al., 2016). Under 
mechanical load hPSC-CMs have improved cellular alignment and enhanced levels of gene 
expression, calcium handling, and contractile force (Happe and Engler, 2016; Stoppel et al., 2016). 
Nevertheless, the  low  high-throughput  design  and  scalability  of  the  devices (typically custom  
built),  that apply  mechanical  strains  makes  them  unsuitable  to  generate  large  numbers  of  
cells  on  a therapeutically relevant scale. More sophisticated engineering techniques capable of 
providing mechanical stimuli to cells should be investigated. For example, perfusion and mixing in 
scalable bioreactor culture systems can be manipulated to apply mechanical stress to cells. 
However, further studies on the impact of these physical forces on cell functionality will be needed. 
1.6. Enrichment of hPSC-CMs 
The persistence of undifferentiated hPSC after the differentiation process is a great safety 
concern for clinical applications, as the tumorigenic potential of hPSC may lead to the formation of 
malignant tumors when transplanted into the host (Fujikawa et al., 2005). Thus, throughout the 
years several strategies have been explored to remove these cell contaminants and improve the 
purity of hPSC-CMs. For instance, the use of percoll gradients (Xu et al., 2002), Flow Activated Cell 
Sorting for specific surface markers (Skelton et al., 2014) and for cells incubated with mitochondrial 
dyes (Hattori et al., 2010) or molecular beacons (Wile et al., 2014)
 
have already been reported. 
Recently, synthetic miRNA switches were used to efficiently purify hPSC-CMs. However, these 
approaches are neither economically nor practically viable for large scale production of hPSC-CMs. 
Switches encoding the apoptosis inducer Bim improved enrichment of CMs without cell sorting 
(Miki et al., 2015). It remains to be validated whether this strategy can be applied for lineage 
purification in large-scale and the efficiency achieved. Nguyen and colleagues demonstrated that 
the combined technique of forced aggregation and 3D suspension culture is capable of robustly 
and rapidly enriching CMs from heterogeneous differentiation cultures (Nguyen et al., 2014). 
 One elegant, cheaper and more scalable approach is to culture hPSC-CM in medium 
containing lactate (Lac) instead of glucose (Glc) (Tohyama et al., 2013). Since in hPSC and 
fibroblasts, Glc is the major source of energy, only CMs, which can use both metabolites, survive 
when cultured in this medium (Tohyama et al., 2013). From an engineering perspective this method 
is perfectly compatible with large-scale bioreactor approaches for cell production (Natsuko et al., 
2014). 
1.7. Maturation of hPSC-CMs 
Notwithstanding the progress made in improving differentiation protocols, the generated  
hPSC-CMs obtained remain with a immature phenotype, consistent with mid-gestation of human 
foetal heart development (Veerman et al., 2015), in terms of structure/morphology (Snir et al., 
2003), gene expression (Synnergren et al., 2012), metabolism (Lopaschuk and Jaswal, 2010), 
contractile function and electrophysiology (Brito-Martins et al., 2008).
 
hPSC-CMs are smaller in size 
have irregular shapes (round/oval rather than rod-like shapes), show disorganized sarcomeres, 
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metabolic dependence on glycolysis, reduced contraction force, and small action potentials (APs) 
compared with adult working CMs (Veerman et al., 2015).  
Table 1.5 provides a summary of the main differences between hPSC-CMs and adult CMs. 
hPSC-CMs immaturity is currently a critical obstacle hampering the potential of these cells for 
clinical applications, modeling late-onset diseases, and accurate drug testing (White et al., 2016). 
In the context of tissue repair, their immature properties such as spontaneous activity and slow 
conduction may cause lethal arrhythmias after transplantation in the heart (Chong et al., 2014). 
Thus, a wide range of strategies (biochemical, molecular biology and bioengineering approaches) 
to improve maturation of hPSC-CM in vitro have been explored so far (Figure 1.4) (Tzatzalos et al., 
2016; Veerman et al., 2015; Yang et al., 2014a). These include the overexpression of microRNAs 
that regulate cardiac development (Kuppusamy et al., 2015); addition of chemical supplements to 
the culture medium, like the growth hormone T3 (Yang et al., 2014b); culture of hPSC-CMs in 
organic or synthetic scaffolds coupled with cyclic stretching (Mihic et al., 2014) and/or electrical 
cues (Heidi Au et al., 2009); co-culture of hPSC-CMs with non-CM (e.g. fibroblasts or endothelial 
cells; (Kim et al., 2010); growth as 3-D tissues (Zhang et al., 2013), which have been reported to 
improve the maturation status as assessed by the cell morphology, molecular assays (e.g. 
expression of cardiac markers) and functional assays. However up to now, there is no current 
consensus as to what constitutes a mature adult CM or which approaches for maturation 
assessment can be used to accurately and specifically track the maturity of hPSC-CMs, which 
hampers the comparison of the results obtained between different maturation approaches. Also 
various structural or physiological markers – e.g. Ca
2+
 handling, cell morphology/striation pattern, 
and beating – undergo developmental reversion under conditions of pathological hypertrophy or 
disease (Feric and Radisic, 2016), which may mislead the results. In sum, despite the recent 






















































































































































































































































































































































































































































































































































































































































































































































































































































1.7.1. Cardiomyocyte structure and contraction 
Adult CMs have an elongated rod-like shape and present a highly organized internal structure 
composed of numerous parallel myofibrils, which consist of longitudinal repetitions of sarcomeres, 
the functional units of muscle (Gerdes et al., 1992). CM shape and sarcomere alignment have 
functional implications in excitation-contraction coupling and in the generation of contractile force 
(Chung et al., 2007). During pathogenic hypertrophy CMs adopt a rounder shape and display 
disorganized sarcomeres (Dorn  2nd et al., 2005), as such pathogenic growth has been reported to 
accompany several forms of heart disease (Engelhardt et al., 1999). In contrast, in physiological 
hypertrophy, which occurs during normal heart development, the addition of new sarcomeric units 
is in longitudinal series or parallel to pre-existing ones thus maintaining sarcomere alignment and 
CM shape (Dorn  2nd et al., 2005). 
The sarcomere is composed of a complex assembly of both thick and thin filaments, the 
former consists of myosin while the latter includes actin, troponin and tropomyosin. Each 
sarcomere is delimited at either end by a Z-disc, which is included in the I-band, composed by thin 
filaments that extend in both directions (Figure 1.5). The A-band comprises the portion of the 
sarcomere where thick and thin filaments overlay, while the H-zone in the center of the A-band 
contains only thick filaments. In the middle of the H-zone is the M-line that corresponds to the 
center of the sarcomere (Huxley, 2002). 
During an action potential of adult CMs, membrane depolarization activates voltage gated 
calcium (Ca
2+
) channels allowing the entry of Ca
2+
 into the cell. This triggers the release of Ca
2+
 





(Altamirano and Bers, 2007). The binding of Ca
2+
 to troponin induces a conformational change and 
displaces tropomyosin, thereby exposing the binding sites of actin to which energized myosin 
heads will attach forming cross-bridges (Lehman et al., 1994). Consequent release of ADP and Pi 
(inorganic phosphate) bend the myosin heads, which switch to a low energy state, pulling the actin 
filaments toward the center of the sarcomere (M-line). Binding of ATP to the myosin heads lead to 
cross-bridge detachment, and ATP hydrolysis restores myosin to the energized state and raised 
conformation. Since thin filaments are anchored to the Z-discs, this process leads to sarcomere 
shortening, thus resulting in cell contraction (Huxley, 2002). During relaxation, Ca
2+
 is pumped back 
into the sarcoplasmic reticulum and to a lesser degree extruded from the cell, so as to return the 
cell to resting Ca
2+
 levels. As Ca
2+
 detaches from troponin, this protein returns to the initial 
conformation simultaneously moving tropomyosin to cover the actin binding sites. This blocks 
myosin from forming cross-bridges, therefore a new cycle of contraction is only possible after a 
new stimuli (Altamirano and Bers, 2007).   
 





Figure 1.5. Schematic representation of myofibril organization and ultrastructural features of 
sarcomeres. The critical role played by changes in [Ca
2+
] in the cytosol of CMs is also highlighted. Ca
2+
 ions 
are schematically shown as entering through the calcium channel that opens in response to the wave of 
depolarization that travels along the sarcolemma. These Ca
2+ 
ions “trigger” the release of more calcium from 
the sarcoplasmic reticulum (SR) and thereby initiate a contraction-relaxation cycle. Adapted from (Feric and 
Radisic, 2016; Opie, 2004). 
   
1.7.2. Metabolic dynamics during heart development 
hESCs and hiPSCs, rely mainly on glycolysis (Facucho-Oliveira and St John, 2009), to 
produce energy (ATP’s). PSCs have unlimited self-renewal capacity and thus to maintain high level 
of proliferation, these cells should balance energetic and biosynthetic needs (Zhang et al., 2012). 
Glycolytic flux is therefore elevated in PSCs to provide ATP and intermediate metabolites through 
the pentose phosphate pathway (PPP) for the synthesis of nucleotide and reducing equivalents in 
the form of nicotinamide adenine dinucleotide phosphate (NADPH).  
NADPH is particularly important to regulate the abundance of oxidative species (ROS) by 
maintaining glutathione (GSH) in the reduced state. The TCA cycle in PSCs provides intermediate 
metabolites such as citrate and a-ketoglutarate that are siphoned for lipid and amino acid 





heart, along with CMs minimal ability to store high-energy phosphates, results in a high metabolic 
demand requiring a continuous high production rate of ATP to sustain proper cell function 
(Lopaschuk and Jaswal, 2010; Schönfeld et al., 1996). However, the metabolic profile of the fetal 
heart is not compliant with this demand, since at this point of development CMs are highly 
dependent on glycolysis, and to a lesser extent lactate oxidation, to produce ATP (Lopaschuk and 
Jaswal, 2010). Hence, during heart development, a metabolic shift occurs from primarily glycolytic 
to an oxidative metabolism (Ellen Kreipke et al., 2016; Gaspar et al., 2014; Kolwicz et al., 2013).  
 
 
Figure 1.6. Metabolic pathways that are regulated to support stem cell growth in vitro. Glucose taken up 
by cells is phosphorylated and metabolized in glycolysis, the hexosamine biosynthesis pathway, or the 
pentose phosphate pathway (PPP). Glucose-derived pyruvate is either diverted to lactate or oxidized in the 
TCA cycle to support energy generation in mitochondria or biosynthesis in the cytosol. Anaplerotic pathways 
including glutaminolysis and pyruvate carboxylase are often necessary to maintain flux through the TCA cycle. 
Reduced glutathione (GSH) is synthesized from glutamate, cysteine, and glycine and protects cells from 
oxidative damage by reacting with ROS. Enzymes which are differentially regulated in stem cell populations 
are highlighted in yellow. Adapted from (Vacanti and Metallo, 2013). 
 
The fetal heart resides in a low oxygen environment where levels of circulating fatty acids are 
low (less than 0.1 mM (Lopaschuk and Jaswal, 2010)), therefore fetal CMs rely mainly on 
glycolysis for ATP generation, with fatty acid β-oxidation contributing for only a small fraction (less 
than 15%) of the total myocardial ATP production (Figure 1.7). The glycolytic phenotype of the fetal 
heart may in part be due to transcriptional changes mediated by HIF-1a. This transcription factor 
increases the activities of glycolytic enzymes and the regulation of the glycolytic pathway itself. 
Furthermore, the fetal heart predominantly expresses LDH-A, which effectively converts pyruvate 
to lactate, contributing to maintaining the high glycolytic levels. Despite the high reliance on 
glycolysis and low fatty acid oxidation rates, fetal hearts have the ability to readily extract and 
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oxidize lactate, which is present at high levels in the fetal heart. As such, lactate oxidation accounts 
for the majority of myocardial oxygen consumption in the fetal heart. In the neonatal heart, though, 
the metabolic profile of CMs undergoes a substantial shift. After birth, there is an increased 
workload placed on the heart, as well as a period of significant cellular growth characterized by 
hypertrophy (ie, increased cell size/growth) and binucleation. As such, the metabolic demands 
placed on the CMs greatly increase, exceeding the cells’ ability to keep pace via glucose and 
lactate oxidation alone. Furthermore, after birth blood levels of lactate drastically decrease (from 5–
7 mM to approximately 0.5 mM (Lopaschuk and Jaswal, 2010)). As such, the contribution of lactate 
oxidation to ATP production in neonatal period also markedly decreases. Nonetheless, the 
circulating levels of free fatty acids increase immediately after birth to levels that are normally seen 
in adults (0.2–0.4 mM (Lopaschuk and Jaswal, 2010)). Concomitantly there is also an increase in 
the contribution of fatty acid β-oxidation to overall cardiac energetics. This, combined with 
transcriptional regulation of proteins involved in fatty acid oxidation (e.g. through PGC-1a/PPARa 
(Lopaschuk and Jaswal, 2010)), mediates a switch in the metabolic profile of CMs from being 
glycolysis-dependent as immature CMs to predominately relying on oxidative metabolism as 
mature CMs (Lopaschuk et al., 2010). Nevertheless, CMs retain metabolic plasticity to use other 
substrates (glucose, lactate, amino acids, ketone), depending on their availability (Kolwicz et al., 
2013; Lopaschuk and Jaswal, 2010).   
Figure 1.7. Overview of the various pathways of energy substrate metabolism that contribute to the 
production of ATP for the purposes of maintaining contractile function and the requirements of basal 
metabolism in CMs. Percent contributions of glycolysis and oxidative metabolism including glucose oxidation, 
lactate oxidation, and fatty acid oxidation to cardiac ATP production during the immediate newborn/fetal period 
and the neonatal period (from 7 to 21 days) in the isolated working rabbit heart. Adapted from (Lopaschuk and 
Jaswal, 2010). 
 
In vitro, hPSC-CMs rely mainly on glycolysis when cultured in glucose media even if glucose is 
present at low concentrations and in combination with other substrates, such as fatty acids (Rana 
et al., 2012; Tohyama et al., 2013). In the absence of glucose, hPSC-CMs were able to metabolize 
other substrates, such as lactate and galactose to support cell function (Rana et al., 2012; 





induce the metabolic switch in hiPSC-CMs, as well as an increase in mitochondrial reserve and 
maximum respiratory capacity (Rana et al., 2012). Even so, a link between the metabolic shift and 
maturation of hPSC-CM in vitro has not been established yet.  
1.8. Characterization of hPSC-CMs 
Phenotypic characterization of the generated hPSC-CMs is essential to evaluate the outcome 
of the differentiation protocols. For cell therapies, characterization of the cells to be used in 
transplantation is important to minimize the risk of host rejection, tumor formation or arrhythmias 
(Dierickx et al., 2012). In the last few years, extensive characterization of PSC-CMs have been 
carried out to evaluate and confirm their cardiac phenotype through gene and protein expression, 
morphology, (ultra)structural, electrophysiology, calcium and contractility analysis (Figure 1.8A) 
(Mummery et al., 2012; Vidarsson et al., 2010).  
Flow cytometry (Figure 1.8B) provides a quantitative method to evaluate the purity of the 
differentiated and enriched population, by measuring the number of cells expressing cardiac-
specific proteins (Dierickx et al., 2012). Reverse transcription-polymerase chain reaction (RT-PCR, 
Figure 1.8C) can be used to assess changes in gene expression throughout the differentiation 
process. Recently, due to their robustness and unlimited data generated, proteomics and 
transcriptomics analysis are also becoming a routine approach for proteome and transcriptional 
profiling in some laboratories, replacing the more traditional techniques. 
Immunofluorescence microscopy (Figure 1.8D) using antibodies for specific cardiac proteins is 
routinely used for structural characterization of CMs (Mummery et al., 2012).  
CMs are also characterized based on their functional properties (Figure 1.8E-G). The 
hallmarks of CM function are the generation of an action potential, the influx of calcium ions, and 
the consequent cellular contraction and force generation. For a comprehensive assessment of CM 
function, all of these processes have to be simultaneously evaluated (Rajala et al., 2011; Vidarsson 
et al., 2010). Electrophysiological analyses (including patch clamp techniques) are often used to 
measure action potentials (APs, Figure 1.8E) and evaluate the response to adrenergic/cholinergic 
stimulation as well as to chemicals that can act on various types of ion channels. Calcium indicator 
assays (e.g. Fluo-4, Rhod-3) are routinely used to assess calcium transients (Figures 1.8G). Since 
intracellular Ca
2+
 concentration ranges from hundreds of nanomolar to millimolar, calcium imaging 
using a Ca
2+
 sensitive fluorescence dye and confocal microscopy revealed a convenient and 
reliable way to assess calcium transients. Small molecule voltage sensor probes (VSPs) like the 
ANEPPS dyes are also being used to study APs in CMs (Denning et al., 2015). These lipophilic 
fluorescent molecules bind to the cell membrane and alter their emission properties in response to 
changes in a transmembrane voltage potential as the membrane depolarizes, allowing action 
potential detection with high spatial and temporal resolution (Herron, 2016). Therefore VSPs show 
some advantages over the high complex, low-throughput, labour-intensive conventional patch 
clamp electrophysiology. The major limitations of the fluorescent dyes are their inherent 
phototoxicity, which can cause temporal degradation of sample and signal quality over time, 
 
Chapter 1  
24 
 
thereby limiting recording times (Liao et al., 2015). Also VSPs provide surrogates of membrane 
potentials and tend to overestimate action potential duration (Liao et al., 2015). 
Excitation–contraction coupling leads to force generation, which is the ultimate goal of the 
working myocardium (Figure 1.8F) (Denning et al., 2015; van Meer et al., 2016). CM force 
generation has been assessed previously by a number of different methods, including fluorescent 
microsphere-based traction force microscopy, atomic force microscopy, and micropost deformation 
measurements (Liu et al., 2012; McCain et al., 2014; Rodriguez et al., 2014). However, these 
techniques are highly specialized, require advanced instrumentation, and each method measures 
and reports force in a different way, which hampers cross-comparison of the values produced in 
different studies. 
Recently, Kijlstra and colleagues reported a novel method that is based on transmitted light 
microscopy to calculate the kinetics of contraction through an algorithm evaluating frame-to-frame 
similarities. This technique compares well with other measurement techniques, and can be applied 
simultaneously with other single-cell physiological assays for the quantification of calcium cycling 
and action potentials (Kijlstra et al., 2015).  
The metabolites involved in biochemical reactions can be identified and quantified using omic 
technologies (Smith et al., 2006; Sreekumar et al., 2009). Analysis of the metabolome, the 
complete set of small-molecule chemicals, can provide useful information on the metabolic flux 
distributions occurring in the cell, which by turn are a function of gene expression, protein 
modifications and interactions at different levels (Nielsen, 2003; Nöh and Wiechert, 2011). 
Comparing with regulatory networks composed of protein-DNA and protein-protein interactions, 
where there are still many unknown components, metabolic networks consisting of all metabolic 
reactions occurring in cellular metabolism can be described and predicted using mathematical 
models (Price et al., 2003). However, accurate estimation of metabolic fluxes can only be achieved 
using a combination of computational, intra-metobolomic (intracellular metabolites) and extra-
metabolomic (extracellular metabolites, that is, present in the cell culture medium) techniques, 
including  isotopic tracing studies (using substrate molecules in which one or more of the atoms is 
replaced by a different isotope) (Kelleher, 2004; Oldiges et al., 2007). Isotopic tracers have been 
used since the inception of metabolism investigation in the 20
th
 century. These were firstly 




H) administered to cells in small quantities followed by the 
measurement of radioactivity in end products and other metabolites (Gibbs et al., 1954; Kelleher, 
2001). The use of parallel radioisotope experiments allowed the determination of structures, 
precursors and activities of pathways such as PPP, TCA cycle, anaplerosis, gluconeogenesis and 







through nuclear magnetic resonance (NMR) and mass spectrometry (MS) have replaced the use of 
radioactive isotopes in metabolic studies, owing to easier experimental implementation and greater 
information generated (Bier, 1987). Stable isotope experiments, when combined with metabolic flux 








Figure 1.8. Methodologies routinely used for characterization of hPSC-CMs. A) Schematic 
representation of the phenotypic features of CMs typically assayed to determine the quality of the generated 
hPSC-CMs. These specific features range from expression of a panel of genes or the activation of a reporter 
transgene (such as α-MHC–GFP) to more complex functional characteristics, such as the ability to fire action 
potentials and show calcium oscillation. Other characteristics include the presence of cardiomyocyte-specific 
epigenetic marks, the ability of CMs to generate force, form gap junctions and electrically couple with host 
CMs after transplantation. B) Flow cytometry is a quantitative method to evaluate relative yield and purity of 
CMs. C) Reverse transcription-polymerase chain reaction is used as a first assessment for changes in gene 
expression typical of cardiogenesis. D) Immunofluorescence microscopy with antibodies specific for 
myofilament proteins determines whether cells exhibit organized sarcomeres typical of CMs. E) Functional 
assessment of CMs can be provided by cellular electrophysiology measurements to determine whether 
cardiac action potentials of different CM subtypes are present; F) Assessment of contractile kinetics quantifies 
the contraction force generated by CMs; G) Detection of Ca
2+
 transients typical of CMs providing another 
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In fact MFA is currently the preferred technique to obtain quantitative data about in vivo 
metabolism (Woo Suk and Antoniewicz, 2013). Initially, MFA studies relied on metabolite balances 
within an assumed network stoichiometry, where external rate measurements provided constraints 
to determine intracellular fluxes. However this approach could not distinguish fluxes of parallel 
pathways (e.g. glycolysis vs. PPP), reversible reactions, and cyclic pathways. A shortcoming 
overcome by combining MFA with measurement of the metabolic conversion of stable isotopic 
tracers, like 
13
C, by mass spectrometry or nuclear magnetic resonance (Goudar et al., 2010). Thus, 
providing additional independent constraints for flux estimation, greatly improving quantitative 
resolution of metabolic flux distributions, at the expense of increased experimental and 
computational complexity. The elementary metabolic unit (EMU) method is considered the most 
advanced and efficient computational approach for simulating isotopic labeling distributions 
(Antoniewicz et al., 2007).  
In summary, nonstationary 
13
C-MFA relies on computational simulation to estimate a set of 
feasible intracellular metabolic fluxes that minimize the variance-weighted sum of squared 
residuals between the predicted and measured transient 
13
C-labeling data and extracellular rate 
measurements (Woo Suk and Antoniewicz, 2013). Despite the increasing role of nonstationary 
13
C-
MFA in metabolism studies of a wide range of biological systems (Carinhas et al., 2016; Hofmann 
et al., 2008; Woo Suk and Antoniewicz, 2013), a metabolic network model of hiPSC-CMs has yet to 
be explored. 
1.9. Hypothermic storage of hPSC-CMs 
The therapeutic use of hPSC-CMs is also dependent on developing efficient and scalable 
methods for storage of CMs. Several companies and academic institutes have aimed at 
establishing good manufacturing practices (GMP) compatible, efficient and customized protocols 
for storage of hPSC-CMs (reviewed in (Abbasalizadeh and Baharvand, 2013)). For successful cell 
therapies, banking and recovery of stored cells must be accomplished without compromising cell 
viability or function (Abbasalizadeh and Baharvand, 2013). Preserving cells also allows the 
generation of master and working cell banks so that consistent and quality-controlled off-the-shelf 
cells are available for in vitro toxicology studies or drug screening purposes (Hunt, 2011). 
Nonetheless, cryopreservation of CMs is considered a critical step, since it can exert tremendous 
influence on CM viability and irreversible effects on CM quality. Cryopreservation-induced events, 
such as ice crystallization or osmotic shock induced-necrosis, activated apoptosis, disruption of 
cell–cell and cell–ECM adhesions, affect survival and fate of stored cells during cryopreservation 
(Preininger and Singh, 2016). Thus, developing of improved cryopreservation and storage 
processes that have minimal adverse effects on hPSC-CMs is crucial for successful banking and 
shipping (Coopman, 2011).  
Cold storage preservation (or hypothermic storage) may constitute an alternative approach for 
transport and delivery of cells during short time periods (Coopman, 2011). Hypothermic storage 
consists in the use of non-frozen temperatures to store biologics. The temperatures used often 





organ preservation, therefore several efforts have been made towards improving the hypothermic 
storage protocols including the development of efficient commercial and clinical grade hypothermic 
solutions. Specifically, commercially available hypothermic solutions (e.g. Prime-XV
TM
 Hypothermic 
Preservation Solution, Irvine Science, and HypoThermosol®-FRS, BioLife Solutions Inc.) were 
carefully formulated to maintain the ionic and osmotic balances, inhibit acidosis, and prevent cell 
swelling at low temperatures. These features facilitate preservation of cell homeostasis, which is 
not achievable when using standard culture medium as a preservation formulation. The 
development of efficient hypothermic storage strategies for hPSC-CMs will enable cell products to 
be manufactured off-site in certified companies and then shipped to clinical, biopharmaceutical 
companies or to research institutes worldwide. 
2. Scope of the thesis 
This thesis aims at developing novel approaches for robust generation of relevant numbers of 
hPSC-CMs with high purity and enhanced maturity to fulfill the needs of clinical and pre-clinical 
applications. The strategy consisted in modulating key environmental factors (such as oxygen 
tension and bioreactor hydrodynamics), cell culture configuration (3D cell aggregates vs. 2D 
monolayers), and metabolic substrate availability to improve reproducibility, scalability and 
efficiency of hPSC differentiation towards CMs in vitro. The impact of these parameters on cell 
production yields and on cell’s quality was assessed using a set of “-omics” tools (including 
transcriptomics, metabolomics and fluxomics) and a vast range of cell characterization assays. The 
design of efficient clinically compatible methods for short-term storage of the generated hPSC-CMs 
was also addressed to facilitate global distribution of these cells. 
The major aims of each chapter of this thesis are summarized in Figure 1.9. 
Briefly, Chapter 2 focused on the development of robust, scalable and integrated platforms for 
iPSC-derived CM production and enrichment using bioreactor systems with automated process 
control, including online measurement and adjustment of the culture parameters. The effect of 
dissolved oxygen and mechanical forces, on CM differentiation, using different hydrodynamic 
environments through the use of distinct bioreactor systems (Stirred tank and WAVE bioreactors), 
was evaluated. A spontaneous differentiation protocol was used to identify the impact of each 
process variable tested.  
Chapter 3 aimed to establish a reproducible protocol for directed differentiation of hPSCs 
towards CMs, suitable to generate CMs in both 2D monolayer and 3D aggregate culture formats. 
Specifically, 3D aggregation was promoted after addition of growth factors and small molecules, 
when the culture was enriched in hPSC-derived cardiac progenitors. An integrated experimental 
and computational systems biology approach was pursued to compare the differentiated 
populations obtained in both culture configurations in terms of CM purity, transcriptome, 
metabolome, fluxome and functionality. The modest expression of maturation features and the 
predominant fetal-like glycolytic metabolism observed in both culture conformations by the end of 
the directed differentiation process, motivated to investigate whether alterations in culture medium 
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composition to mimic substrate availability during in vivo cardiac development would promote in 
vitro hPSC-CM maturation. Therefore, in Chapter 4 several culture media compositions were 
tested based on the fact that during cardiac development CMs undergo postnatal metabolic 
changes, from a glycolytic to an oxidative metabolism, relying first on Lac and then on FA as major 
sources of energy (Lopaschuk and Jaswal, 2010). Transcriptomic, metabolomic and fluxomic 
analyses were carry out and the data obtained were combined with structural, morphological and 
functional analyses to provide a comprehensive molecular basis and a quantitative dissection of 
hiPSC-CM phenotypes. Noteworthy, this systems-level approach enabled the identification of the 
feeding strategy that most efficiently improved metabolic, structural and functional maturation of 
hiPSC-CM in 20 days. 
In Chapter 5 efficient strategies for short-term storage of the produced hPSC-CMs without 
affecting their viability, phenotype and function were developed. The feasibility to cold store 2D 
monolayers and 3D aggregates of functional hPSC-CMs using a fully-defined clinical compatible 
formulation was investigated and the time frame for hPSC-CM hypothermic storage without 
detrimentally affecting cell viability and metabolic activity recovery was determined. The efficiency 
of the method was also confirmed by assessing cell phenotype, including structure, ultrastructure, 
gene and protein expression, and functionality after storage.  
It is important to highlight that several analytical tools were implemented (or adapted) in the 
laboratory to evaluate the efficiency of the approaches developed and assess the quality of the 
generated CMs in terms of morphology/structure (immunofluorescent microscopy), gene and 
protein expression (quantitative RT-PCR, flow cytometry), metabolism (
13
C-MFA, GC-MS-based 
metabolite profiling, Seahorse Extracellular Flux Analysers) and functionality (using Ca
2+
 dyes). 
Other methodologies were established and performed in collaboration with other institutions; 
Instituto Gulbenkian de Ciência (IGC) (TEM analysis); Medical Faculty, University of Cologne and 
Faculdade de Ciências Médicas, Universidade Nova de Lisboa (FCM-UNL) (Electrophysiology 
analysis); and Massachusetts General Hospital, Harvard Medical School (MGH-HMS) (contractility 
analysis). 
In Chapter 6, the results described in Chapters 2-5, were discussed and contextualized with 
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Induced pluripotent stem cells derived cardiomyocytes (iPSC-CMs) hold great promise for 
patient-specific disease modeling, drug screening and cell therapy. However, existing protocols for 
CM differentiation of iPSCs besides being highly dependent on the application of expensive growth 
factors show low reproducibility and scalability. The aim of this work was to develop a robust and 
scalable strategy for mass production of iPSC-CMs by designing a bioreactor protocol that ensures 
a hypoxic and mechanical environment. 
Murine iPSCs were cultivated as aggregates in either stirred tank or WAVE bioreactors. The 
effect of dissolved oxygen and mechanical forces, promoted by different hydrodynamic 
environments, on CM differentiation was evaluated. Combining a hypoxia culture (4% O2 tension) 
with an intermittent agitation profile in stirred tank bioreactors resulted in an improvement of about 
1000-fold in CM yields when compared to normoxic (20% O2 tension) and continuously agitated 
cultures. Additionally, we showed for the first time that wave-induced agitation enables the 
differentiation of iPSCs towards CMs at faster kinetics and with higher yields (60 CMs/input iPSC). 
In an 11-day differentiation protocol, clinically relevant numbers of CMs (2.3 x10
9
 CMs/1L) were 
produced, and CMs exhibited typical cardiac sarcomeric structures, calcium transients, 
electrophysiological profiles and drug responsiveness.  
This work describes significant advances towards scalable cardiomyocyte differentiation of 
murine iPSC, paving the way for implementation of this strategy for mass production of their human 















The inability of mature cardiomyocytes (CMs) to proliferate leads to a permanent loss of 
functional cells after injury (Kawaguchi and Nakanishi, 2013). Previous studies in animal models of 
myocardial infarction have demonstrated that the function of a damaged heart may be improved by 
transplantation of sufficient numbers of functional CMs (Laflamme and Murry, 2011). Over the last 
years, pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs), have emerged as an attractive candidate stem cell source for 
obtaining CMs (Braam et al., 2009; Rajala et al., 2011). The inherent capacity to grow indefinitely 
and to differentiate into all mature cells of the human body make PSCs the only cell source that 
can provide ex-vivo an unlimited number of functional and potentially autologous CMs for 
transplantation. The clinical translation of human ESC-derivatives has been greatly hampered by 
the risk of immune rejection due to their allogenicity and by ethical concerns (Zwi-Dantsis and 
Gepstein, 2012). iPSCs can circumvent these drawbacks, allowing for ethically “acceptable” and 
safe patient-specific therapies (Oh et al., 2012; Yoshida and Yamanaka, 2011). Moreover, iPSCs 
constitute a promising tool to establish disease-specific models of human inherited cardiac 
disorders and platforms for drug discovery and toxicity testing (Grskovic et al., 2011; Oh et al., 
2012). 
In the last years, several methodologies have been described for the differentiation of murine 
(Kuzmenkin et al., 2009; Mauritz et al., 2008; Narazaki et al., 2008; Zwi-Dantsis et al., 2011) and 
human (Burridge et al., 2011; Lian et al., 2013; Lundy et al., 2013; Minami et al., 2012; Tohyama et 
al., 2013; Zhang et al., 2012) iPSCs into functional CMs based on the knowledge acquired in 
previous studies with ESCs. Still, several challenges remain that currently preclude their 
widespread application. Those protocols typically involve a complex stage-specific application of 
exogenous growth factors which are costly, degrade rapidly, do not readily diffuse into complex 3D 
aggregates and exhibit lot-to-lot variation in their bioactivity (Mummery et al., 2012). Moreover, 
despite recent improvements in cardiac differentiation protocols (Lian et al., 2013; Minami et al., 
2012; Tohyama et al., 2013; Zhang et al., 2012) these are still associated with low reproducibility 
and scalability (Zwi-Dantsis and Gepstein, 2012), being unsuitable to provide the large numbers of 
CMs needed to exert functional benefit after a heart attack (about 1-2x10
9
 CMs per patient) (Murry 
et al., 2006). Therefore, robust and scalable bioprocesses for CM production less dependent on 
the use of inductive factors are required for a faster transition of iPSCs to the clinical and industrial 
fields.   
One of the most powerful strategies for scaling-up the production of iPSC derivatives consists 
in cultivating the cells as 3D cell aggregates called embryoid bodies in bioreactor systems that 
continuously assure monitoring and control of the environmental conditions (pH, pO2 and agitation 
profile) (Serra et al., 2010, 2012). A close control of the physical environment was shown to be 
essential for guiding cell fate decisions through expansion and differentiation routes. Low oxygen 
tensions (2–5% O2) have been shown to enhance the proliferation of PSCs (Forsyth et al., 2006; 
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Gibbons et al., 2006; Serra et al., 2010) and their differentiation to CMs (Bauwens et al., 2005; 
Horton and Auguste, 2012; Niebruegge et al., 2009). Indeed, it is well known that cells in the early 
developing embryo are exposed to low-oxygen levels. In hamsters and rabbits, for example, 
intrauterine oxygen concentrations decrease during blastulation and implantation to 5.3% O2 and 
3.5% O2, respectively (Fischer and Bavister, 1993). Thus, lowering the oxygen concentration from 
normoxic atmospheric levels (20% O2) to more physiological levels (2–5% O2 or atmospheric 
hypoxia) might be beneficial in PSC cultures due to the importance of this environmental condition 
during embryonic development. 
Mechanical cues from the environment are also translated into biological signals that mediate 
cell structure, survival, migration, proliferation, and differentiation (Li et al., 2011; Nava et al., 
2012). Several studies have provided evidence that applied mechanical forces including cyclic 
strain and stretch, fluid shear stress and hydrostatic compression modulate differentiation of cells 
that reside in mechanically dynamic environments, such as CMs (Geuss and Suggs, 2013; Gwak 
et al., 2006; Schmelter et al., 2006), vascular smooth muscle cells (Shimizu et al., 2008), 
endothelial cells (Matsumoto et al., 2007) and chondrocytes (Elder et al., 2001). In particular, CMs 
are continuously subjected to cyclic mechanical strain promoted by the rhythmic heart beating 
(Keung et al., 2010). CM-enriched tissue constructs are often subjected to cyclic tensions to 
increase their force of contraction, facilitate organization of cellular structures and consequently 
improve their cardiac function in vivo (Zimmermann et al., 2002). Thus, the hypothesis that 
mechanical loading promotes cardiomyogenesis of PSCs has started to be explored (Gwak et al., 
2006; Shimko and Claycomb, 2008; Teramura et al., 2012). It was recently reported that ESCs 
cultured on elastic polymer [poly(lactide-co-caprolactone), PLCL] scaffolds and subjected to 1% 
cyclic uniaxial stretch, in a custom-made strain device, demonstrated commitment towards CM 
lineage as noted by an increased cardiac gene expression compared to unstrained controls (Gwak 
et al., 2006). Nevertheless, the low high-throughput design and scalability of these devices, custom 
built to apply mechanical strains, makes them unsuitable to generate large numbers of cells on a 
therapeutically relevant scale.  
In the present work we focused on the development of robust, scalable and integrated 
platforms for iPSC-CM production and purification using bioreactor systems with automated 
process control, including online measurement and adjustment of the culture parameters. Our 
strategy consisted on modulating key environmental parameters for efficient and reliable 
differentiation of iPSC towards the CM lineage, reducing the need of using inductive factors. We 
explored the impact of dissolved oxygen (DO) and mechanical forces on CM differentiation of 
iPSCs by using two distinct bioreactor systems, namely stirred tank and WAVE bioreactors. We 
applied mechanical forces to cells by manipulating the hydrodynamic environment, more 
specifically the type and profile of agitation. We describe for the first time a protocol for efficient 
mass production of functional CMs derived from murine iPSCs that combines a hypoxic 
environment with an intermittent stirring or a wave-induced agitation profile. 
 





2.1. iPSC culture on feeder layers 
A murine transgenic αPIG-iPS cell line, in which the puromycin-N-acetyl transferase and the 
enhanced green fluorescent protein (eGFP) genes are under the control of the cardiospecific 
alpha-myosin heavy chain (α-MHC) promoter (Halbach et al., 2013), was used in this study to 
facilitate bioprocess development. The fluorescence marker and the antibiotic resistance genes 
specifically expressed in CMs allow easy monitoring of the cardiac differentiation process and 
selection of a highly pure CM population upon addition of puromycin into the media, respectively. 
iPSCs were cultivated on a monolayer of mitotically inactivated murine embryonic fibroblasts 
(MEFs) in Dulbecco’s modified Eagle medium (DMEM) supplemented with 15% (v/v) fetal bovine 
serum (FBS), 1% (v/v) non-essential amino acids (NEAA), 2 mM L-glutamine, 50 μM β-
mercaptoethanol, 500 μg/mL neomycin sulfate (all from Invitrogen, UK), and 1000 U/mL leukemia 
inhibitory factor (LIF) (ESGRO, Merck Millipore, Germany), at 37ºC in a humidified atmosphere of 
5% CO2. Cells were passaged every two days as previously reported (Halbach et al., 2013). 
2.2. iPSC differentiation in stirred tank bioreactors 
To promote cell aggregation 0.7x105 cell/mL were inoculated into plastic Erlenmeyer flasks 
(Corning, USA) containing 100 mL of differentiation medium (Iscove’s modified Dulbecco’s medium 
(IMDM) with GlutaMAX, supplemented with 20% (v/v) FBS, 1x NEAA, 1% (v/v) Pen/Strep, 50 μM 
β-mercaptoethanol (all from Invitrogen, UK) and 100 μM ascorbic acid (Wako, Germany), and 
incubated at 37ºC in a 5% CO2 humidified atmosphere on an orbital shaker at 80-90 rpm. After two 
days aggregates were transferred into stirred tank bioreactors (DasGip cellferm-pro bioreactor 
system, Germany) and cultured at a concentration of 150 aggregates/mL in 200 mL of 
differentiation medium. Medium was partially changed at days 9 (50% v/v), 12 (70% v/v) and 14 
(50% v/v) by selection medium (differentiation media without ascorbic acid supplemented with 
puromycin at a final concentration of 8 μg/mL (InvivoGen, USA)) to eliminate non-CMs and 
promote CM selection. Antibiotic treatment resulted in the generation of pure aggregates of CMs 
(designated hereafter as cardiospheres). The experimental set up is illustrated in Figure 2.1 (Page 
49). All cultures were performed in computer-controlled stirred tank bioreactors equipped with a 
trapezoid shaped paddle impeller with arms and operated under defined conditions (CO2: 5%; 
temperature: 37°C; DO: 20% O2 tension (atmospheric normoxia) or 4% O2 tension (atmospheric 
hypoxia); surface aeration rate: 0.1 vvm (gas volume flow per unit of liquid volume per minute); 
agitation rate: 90 rpm for complete continuous stirred-tank reactor (CSTR) behavior; agitation 
profile: continuous or intermittent (ON: 30 sec, OFF: 0 sec) with or without direction change; cyclic 
mechanical frequency (defined by the number of stirring interruptions per unit of time): 0.033Hz). 
Data acquisition and process control were performed using DasGip Control Software 4.0. Three 
independent bioreactor runs were performed for every experimental setting. 
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2.3. iPSC differentiation in WAVE bioreactors 
Cell aggregation was promoted in Cellbag
TM
 – WAVE bioreactors (GE Healthcare, Sweden) 
for 2 days (Figure 2.1). Briefly, 0.7x10
5
 cell/mL were inoculated as single cells into WAVE 
bioreactors containing 500 mL of differentiation medium. At day 2, aggregate concentration was 
adjusted to 150 aggregates/mL by increasing the working volume to 1 L. At day 9 of differentiation, 
CM purification was initiated by exchanging half of the culture media with selection medium. 
Aggregates were cultivated for additional 2 days in these conditions. The experimental set up is 
shown in Figure 2.1. All cultures were performed in computer-controlled WAVE bioreactor systems 
under defined conditions (CO2: 5%; temperature: 37°C; DO: 4% O2 tension; surface aeration rate: 
0.1 vvm; rocking angle: 4; rocking rate (adjusted throughout culture time according to the 
aggregate size): 10 rocks/minute (day0-day1), 12 rocks/minute (day1-day2), 25 rocks/minute 
(day2-day7), 26 rocks/minute (day7-day11); cyclic mechanical frequency from day 2 to day 11 
(defined by the change in wave motion per unit of time): 0.82 to 0.86 Hz). Data acquisition and 
process control were performed using UNICORN* DAQ 1.0 software. Three independent 
bioreactor runs were performed for every experimental setting. 
2.4. Dissociation of cardioshperes 
At the end of the differentiation process, cardiospheres were harvested from the bioreactor, 
dissociated to single cells by incubation with 0.25% (w/v) Trypsin-EDTA (Invitrogen, UK) for 5-7 
minutes at 37°C and transferred to CELLstart™ (Invitrogen, UK) coated 6- or 24-well plates for 
further characterization. 
2.5. Evaluation of cell concentration and viability 
2.5.1. Cell membrane integrity assay 
The qualitative assessment of the cell membrane integrity during culture was done using the 
enzyme substrate fluorescein diacetate (FDA; Sigma-Aldrich, Germany) and the DNA intercalating 
dye propidium iodide (PI; Sigma-Aldrich, Germany) as previously described (Serra et al., 2011). 
2.5.2. Trypan blue exclusion assay 
Cell aggregates were dissociated to single cells by a 5-7 minutes incubation with 0.25% (w/v) 
Trypsin-EDTA (Invitrogen, UK) at 37°C. Cell concentration and viability was assessed by the trypan 
blue exclusion method using a 0.1% (v/v) solution prepared in PBS and counting cells in a Fuchs-
Rosenthal haemacytometer (Brand, Wertheim, Germany). 
2.5.3. Lactate dehydrogenase activity 
The extent of cell lysis during iPSC differentiation was assessed by measuring the activity of 
the intracellular enzyme lactate dehydrogenase (LDH) in the culture supernatant. LDH activity was 
determined by following spectrophotometrically (at 340 nm) the rate of oxidation of NADH to NAD
+
 





) was calculated for every time interval using the following equation: qLDH = ΔLDH/(Δt.ΔXV), 
where ΔLDH (U) is the change in LDH activity over the time period Δt (day) and ΔXv (cell) is the 
 




average of total cells during the same time period. The cumulative value (qLDHcum) was estimated 
by qLDHcum t+1 = qLDHcum t + qLDH t+1. 
2.5.4. Evaluation of aggregate concentration 
The number of total aggregates and beating/eGFP-positive aggregates was determined in 4-6 
wells of a 24-well plate containing 250-400 μL aliquots of bioreactor culture samples by using an 
inverted-microscope (DMI6000, Leica, Germany). 
2.5.5. Evaluation of aggregate size, elongation and roundness 
The aggregate size was determined using an inverted-microscope (DMI6000, Leica, 
Germany) by measuring two perpendicular diameters of each aggregate, from a minimum of 30 
aggregates. These measures were used to calculate the average diameter of each aggregate. The 
elongation and roundness of aggregates was analyzed using measurement analysis tool of ImageJ 
software. Elongation (or aspect ratio) is defined by the ratio between the major and the minor axis. 
Roundness is the measure of how closely the shape of an object approaches that of a circle and is 
defined by the following: 4 ×
𝐴𝑟𝑒𝑎
𝜋 × (𝑀𝑎𝑗𝑜𝑟 𝑎𝑥𝑖𝑠)2
. Both, elongation and roundness parameters were 
analyzed from a minimum of 30 aggregates per condition. 
2.6. Monitorization of CM differentiation  
2.6.1. Flow cytometry  
After dissociation of aggregates or cardiospheres with 0.25% (w/v) Trypsin-EDTA as 
described above, cells were re-suspended in washing buffer (PBS with 5% (v/v) FBS) and the 
percentage of live (as assessed with PI dye), eGFP-positive cells were analyzed in a CyFlow® 
space (Partec GmbH, Germany) instrument, registering 10000 events/sample. The results 
throughout this analysis constituted a measurement of the percentage of CMs in culture at each 
time point, reflecting the purity level of the culture.  
2.6.2. Semiquantitative and quantitative RT-PCR 
Aggregates or cardiospheres were washed with PBS and centrifuged at 300xg for 5 min. The 
pellet containing 10
6
 cells was snap-frozen by immersion in liquid nitrogen. Total RNA was 
extracted using the High Pure RNA Isolation Kit (Roche, Germany) and reverse transcription was 
performed with High Fidelity cDNA Synthesis Kit (Roche, Germany) using 200ng of RNA, following 
manufacturer’s instructions.  
Gene expression profiles of various markers during cardiac differentiation were analyzed by 
semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) using the DreamTaq 
Green PCR Master Mix (Thermo Scientific, USA). Analyses were performed in 20 µL reactions 
containing 0.5 µM of each primer and 1 µL of undiluted cDNA template. PCR products (10 µL) 
were electrophoretically separated on 1.5 % agarose (Invitrogen, UK) gel and ethidium bromide-
stained bands were detected with a CCD camera using Intas UV-System and Intas GDS 
application (Intas, Germany). The primer sequences used in RT-PCR are listed in Table A-2.1 
(Page 66). 
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Quantitative RT-PCR was performed in triplicate, for each sample and each gene, using 
SYBR Advantage qPCR Premix (Clontech, USA) in 10 μl reactions with 1:25 diluted cDNA 
template and 0.2 μM of each primer. The reactions were performed in 384-well plates using AB 
7900HT Fast Real Time PCR System (Applied Biosystems, Germany). Cycle threshold (Ct’s) and 
melting curves were determined by SDS 2.1 Software. All data was analyzed using the 2
-ΔΔCt
 
method for relative gene expression analysis. Changes in gene expression were normalized to 
GAPDH gene expression as internal control. 
2.7. Evaluation of cell growth and differentiation towards CMs 
2.7.1. Cell expansion fold 
The cell expansion fold was evaluated based on the ratio Xd9/Xd0, where Xd9 is the total cell 
number at day 9 (before purification) and Xd0, the total initial cell number. In Stirred tank bioreactors 
Xd0 represents the initial cell number corresponding to the 30000 aggregates inoculated per 
bioreactor at day 2. 
2.7.2. Final CM yield 
The final number of CMs was determined by flow cytometry of eGFP-positive cells at the end 
of the differentiation process. The CM yield was calculated by the number of eGFP-positive cells 
divided by the total initial number of iPSCs. 
2.7.3. CMs produced per liter of culture medium throughput 
The number of CMs produced per liter of culture medium throughput was determined by the 
number of eGFP-positive cells at the end of the process divided by the total volume of culture 
medium used throughout the differentiation process, considering all medium exchanges.  
2.8. Characterization of iPSC-CMs 
2.8.1. Immunocytochemistry 
At the end of the differentiation process, aggregates were dissociated and plated on CellStart-
coated 6-well plates. Adherent cells were fixed with 4% (w/v) buffered paraformaldehyde (pH 7.5) 
for 15 minutes at 37°C and permeabilized with 0.5 M ammonium chloride (Sigma-Aldrich), 0.25% 
Triton X-100 in PBS for 10 min at room temperature (RT). After blocking with 5% (v/v) FBS in PBS 
for 1 h at room temperature, cells were incubated with primary antibody overnight at 4°C in 0.8% 
(w/v) bovine serum albumin (BSA) in PBS. The primary antibodies used were anti-sarcomeric-α-
actinin (1:800; clone EA-53, Sigma-Aldrich, Germany), anti-titin (E-2; 1:100 dilution; Santa Cruz 
Biotechnology, USA), anti-troponin I (1:100 dilution; Merck Millipore, Germany), and anti-atrial 
natriuretic peptide (ANP; 1:200 dilution; Merck Millipore, Germany). After two washing steps with 
PBS, samples were incubated for 60 min at RT with the secondary antibody anti-mouse-IgG1 
AlexaFluor 594 (1:200 dilution in 0.8% (w/v) BSA in PBS; Invitrogen, UK). Nuclei were stained 
using Hoechst 33432 (1:5000 dilution in PBS; Sigma-Aldrich, Germany). Images were acquired 
using an inverted fluorescence microscope (DMI6000, Leica, Germany). For immunostaining of 
whole mounted aggregates, the permeabilization step was performed with 0.2% (w/v) fish skin 
gelatine and 0.1% (w/v) TX-100 in PBS for 2 h at RT. In this case, the anti-collagen type I (1:200 
 




dilution, Abcam, UK) and the anti-Ki-67 (1:200 dilution, Merck Millipore, Germany) antibodies were 
used. Aggregates were visualized using spinning disk confocal microscope (Andor Revolution XD, 
Nikon Eclipse Ti-E, confocal scanner: Yokogawa CSU-x1).  
2.8.2. Scanning electron microscopy 
For scanning electron microscopy analysis, aggregates were washed twice in Sorensen’s 
Buffer (0.1M NaH2PO4, 0.1M Na2HPO4, pH 7.4), fixed with 4% (w/v) formaldehyde and 2.5% (w/v) 
glutaraldehyde solution for 1 hour at RT, followed by overnight incubation at 4°C. Samples were 
then washed with Sorensen’s Buffer again. After dehydration all samples were dried, coated in a 
sputter-coater with a layer of gold and observed under a scanning electron microscope (FEG-SEM: 
JEOL 7001F/Oxford INCA Energy 250/HKL). 





 imaging was performed according to the standard protocol provided in Rhod-3 - Calcium 
Imaging kit (Invitrogen). Briefly, cardiospheres were plated onto eight-well culture slides coated 
with CellStart. After one week in culture to promote cell adherence to the plate, the beating CMs 
were loaded with the cell permeant calcium indicator dye Rhod-3 for 1h at 37°C, washed twice in 
PBS, and incubated for 1h with a water-soluble reagent to reduce baseline signal and washed 
again in PBS. Cells were imaged live using a spinning disk confocal microscope (Andor Revolution 
XD). Fluorescence was measured by manually defining each region of interest and quantified in 
relation to baseline fluorescence (F/F0) using Micro-Manager 1.4 and ImageJ softwares.  
2.8.4. Electrophysiological characterization 
Purified cardiac clusters were washed twice with PBS and dissociated using 0.05% 
Trypsin/EDTA 2 days before measurement. Single CMs were plated on glass cover slips coated 
with 0.1% gelatin. The patch clamp-experiments were performed as described previously 
(Kuzmenkin et al., 2009). Briefly, the cover slips were placed into a recording chamber (37°C) and 
cells were continuously perfused with extracellular solution. Cell membrane capacitance was 
determined online using Pulse software (Heka Elektronik, Germany). Action potential (AP) 
recordings of spontaneously beating CMs were performed utilizing the whole-cell current-clamp 
technique with an EPC-9 amplifier (HEKA Elektronik) and operated through the Pulse acquisition 
software. Response to hormonal regulation was analyzed by administering 1 µM isoproterenol (Iso, 
Sigma-Aldrich, USA) or 1 µM carbachol (Cch, Sigma-Aldrich, USA). 
2.9. Statistical analysis 
For each culture system evaluated, at least three independent experiments were performed. 
The results were presented as the mean±SD. For the electrophysiological characterization data are 
shown as mean±SEM. Statistical significance was assessed by one-way analysis of variance 











Figure 2.1. Experimental scheme for differentiation and purification of iPSC-CMs in stirred tank and 
WAVE bioreactors.In stirred tank bioreactors, an aggregation step was first performed in an Erlenmeyer for 
48 hours. After this time, aggregates were transferred to bioreactors to yield 150 aggregates/mL and cultured 
in the presence of ascorbic acid for additional 7 days. At day 9, puromycin was added to the medium to 
eliminate non-CMs. After 7 days of antibiotic-based CM selection, pure CM aggregates (cardiospheres) were 
harvested, dissociated and CMs were cultured in 2D plates for characterization studies (immunofluorescence 
microscopy and electrophysiological studies). In WAVE bioreactor cultures, cells were inoculated as single 
cells directly into the WAVE bioreactor and at day 2 the culture volume was adjusted to obtain 150 
aggregates/mL. Aggregates were cultured in the presence of ascorbic acid for additional 7 days. At day 9, CM 
lineage selection was initiated and lasted 3 days. At day 11, aggregates were harvested, dissociated and 
plated in 2D plates for further characterization. Culture conditions evaluated in each bioreactor system are 
depicted in the bottom of the schematic workflow. 
  
 





3.1. Effect of dissolved oxygen on CM differentiation of iPSCs in stirred tank bioreactors  
In order to establish a robust and scalable platform for production of functional iPSC-CMs, we 
first investigated the effect of DO on cardiac iPSC differentiation in stirred tank bioreactor systems. 
For that purpose, we compared the effect of normoxic atmospheric oxygen levels (20% O2 tension) 
with physiological oxygen levels (2–5% O2 tension or atmospheric hypoxia). Within this range of 
physiological oxygen levels, we selected a value of 4% O2 since previously reported studies 
showed that this oxygen concentration improves cardiomyocyte differentiation in ESC aggregate 
cultures (Bauwens et al., 2005; Niebruegge et al., 2009). 
Aggregation of single cell suspension was promoted in Erlenmeyers and orbital agitation for 
48 hours under normoxia conditions; these conditions resulted in the formation of small aggregates 
with a mean size of 155±56 μm that readily metabolized the vital dye fluorescein diacetate but not 
the dead cell marker propidium iodide (Figure A-2.1, Page 64). These aggregates were transferred 
to fully controlled stirred tank bioreactors and cultured under either normoxic (DO=20% O2) or 
hypoxic (DO=4% O2) conditions for additional 14 days (Figure 2.1).   
The results showed that a DO of 4% O2 maximizes cell proliferation and CM differentiation 
(Figure 2.2). In these culture conditions, the size of aggregates, the total number of cells and 
aggregates were higher throughout the culture (Figure 2.2A-C) resulting in a significantly higher 
expansion fold on day 9 of differentiation when compared to normoxic conditions (44.9±2.7 versus 
12.2±1.4 cells/initial iPSC, p=0.001, Table 2.1).  Moreover, first eGFP-positive cells and contracting 
areas in aggregates cultured under hypoxia were observed already on day 7 of differentiation, 
contrasting with cell aggregates cultured at 20% O2 where eGFP-positive cells and beating areas 
were rarely observed throughout culture time (Figure 2.2A). The higher overall cell expansion in 
hypoxic cultures corresponded to a significant improvement in CM yield as determined on day 16 
of differentiation, after 7 days of puromycin selection (11.3±3.7 vs. 0.05±0.02 CMs/input iPSC, 
p=0.045, Figure 2.2D), and to an approximately 210-fold enhancement in CM numbers compared 
to normoxia (33.6±7.6 x10
6
 CMs vs. 0.15±0.06 x10
6
 CMs per bioreactor run, p=0.01, Figure 2.2D). 
Since a low DO environment proved to be a key parameter in enhancing CM differentiation of 








Figure 2.2. Effect of dissolved oxygen on CM differentiation of iPSCs in stirred tank bioreactors. 
Aggregates were inoculated at day 2 in stirred tank bioreactors at DO of 20% O2 (atmospheric normoxia) or 
4% O2 (atmospheric hypoxia). A). Merged phase contrast and fluorescence images showing cell aggregates 
composed by eGFP-positive cells (green) at days 7, 9 and 16 of culture. Scale bars: 200 μm. B). Profile of 
total cell number during culture time. C). Total number of aggregates at days 2, 4, 9 and 16. The number of 
eGFP-positive aggregates is indicated by striped bars. D). Total number of CMs produced per bioreactor run 
(black bars) and CM yield (number of CMs at day 16/input iPSC, striped bars) obtained in both normoxic and 
hypoxic culture conditions. Error bars (B-D) represent SD of 3 individual bioreactor experiments. Significantly 
different, P<0.05 (*) and P<0.01 (**). 
3.2. Impact of agitation profile on CM differentiation of iPSC in stirred tank bioreactors 
The effect of different agitation profiles on CM differentiation was assessed using stirred tank 
bioreactors operating under hypoxic conditions. A continuous agitation was compared with an 
intermittent agitation with and without change in the agitation direction. Based on previous reports 
that mechanical stimulation enhances contractile function and up-regulates cardiac gene 
expression (Shimizu et al., 2008; Shimko and Claycomb, 2008), we hypothesized that the 
hydrodynamic environment imposed by an intermittent agitation composed of repeated and brief 
stops could provide cyclic mechanical forces to the cells and consequently potentiate iPSC 
differentiation towards contractile CMs.  
Our results show that an intermittent agitation profile without direction change led to a faster 
cell growth, higher cell number and enhanced CM differentiation when compared to the other 
agitation profiles evaluated (Figure 2.3, Table 2.1). At day 9, an increase of 73.4±7.6 fold in cell 
number was obtained in this culture condition (Table 2.1), reflecting more pronounced cell 
proliferation as compared to other two tested conditions. At this culture time point the percentage of 
eGFP-positive cells, as determined by flow cytometry analysis of dissociated aggregates, was 
significantly higher in this culture condition (43.9±6.6%) than in continuous (23.3±5.0%, p=0.01) or 
in intermittent agitation profile with direction change (16.5±3.7%, p=0.01) cultures (Table 2.1), 
 




suggesting enhanced cardiac differentiation efficiency. In accordance, lower cell death during 
antibiotic treatment, as indicated by a lower accumulation of intracellular LDH in culture 
supernatant, was observed (Figure 2.3C), indicating that a higher percentage of puromycin 
resistant iPSC-CMs and a lower amount of contaminating cells were present in culture. At the end 
of the process higher CM number (128.1±3.3x10
6
 CMs/bioreactor), yield (44.0±2.1 CMs/input 
iPSC) and purity (97.4±0.4%) were obtained in cultures operated under intermittent agitation 
without direction change (Figure 2.3D, Table 2.1); in comparison to continuous agitation and 
intermittent agitation with direction change profiles, this culture condition enabled a significant 
improvement of 4- and 6.5-fold in CM production, respectively (p=0.0001, Table 2.1).  
RT-PCR analyses of RNA isolated from intermittent agitation profile without direction change 
and continuous agitation cultures reflect the impact of cyclic mechanical forces promoted by the 
different hydrodynamic environments on cell phenotype (Figure 2.3E-F). A typical cardiac lineage 
gene expression pattern was observed in both culture conditions. The expression of the 
pluripotency marker Oct4 progressively decreased over the course of differentiation reaching very 
low levels by day 9 (Figure 2.3E-F) and being undetectable at day 16 purified CMs (Figure 2.3E). 
Additionally, the expression of the early mesoderm marker T brachyury was up-regulated from day 
4 to day 6 and down-regulated thereafter. These results allow us to assume that the marked 
proliferation observed up to day 7 (Figure 2.3B) in these cultures might have resulted from the 
prevalence of highly proliferative undifferentiated and mesodermal cells up to this timepoint. 
Afterwards, a progressive increase in the expression of cardiac-progenitor and cardiac-specific 
gene markers (Nkx2.5, cTnT, HCN4, Myl2 and Myl7) was observed. The higher band intensities at 
day 9 of differentiation (before initiation of CM selection) indicated that the majority of the cardiac-
specific markers were greater expressed in cells cultured under intermittent agitation conditions. 
RT-qPCR analyses further confirmed that the expression of the cardiac genes Nkx2.5, cTnT and 
Myl7 in cells at this time point was, respectively, 1.4- (p<0.01), 1.8- (p<0.01) and 1.6-fold (p<0.05) 
higher in cultures with intermittent agitation than in those with continuous agitation profile (Figure 
2.3F). In order to further assess the purity of puromycin-selected CM preparations, we monitored 
the expression of the endodermal marker -fetoprotein (AFP) in cells from both cultures. AFP 
transcripts were detected on days 6-12 in cell aggregates from both conditions but their expression 
was higher in cultures with continuous agitation profile. On day 12, the expression of AFP was still 
observed in these cultures but not in cultures operated under intermittent agitation profile without 
direction change, thus suggesting that this agitation profile may provide a favorable hydrodynamic 
environment for cardiac but not endodermal lineage differentiation. Nonetheless, in both culture 
conditions the expression of AFP was not detectable at the end of the selection process (day 16), 
confirming the final purity of antibiotic selected CMs (Figure 2.3E). Altogether, these results 
indicate that the mechanical stimulus provided to the cells by the agitation profile inherent to 
stirred-tank bioreactors can be modulated to enhance cardiomyogenesis. 
 




Figure 2.3. Impact of the agitation profile on CM differentiation of iPSCs in stirred tank bioreactors. 
Aggregates were inoculated at day 2 in stirred tank bioreactors operating in continuous and intermittent 
stirring with or without change of direction. A). Phase contrast and fluorescence images showing cell 
aggregates with eGFP-positive cells (green) at days 9, 12 and 16 of culture. Scale bars: 200 μm. B-C). Profile 
of total cell number (B) and cumulative values of specific rates of LDH release (C) in each bioreactor culture 
condition during time. D). Total number of CMs produced in each bioreactor run (black bars) and CM yields 
(striped bars). E). Semiquantitative RT-PCR analyses demonstrating the expression of pluripotency (Oct4), 
endoderm (AFP), early mesoderm (T-Brachyury) and CM-specific (Nkx2.5, cTNT, HCN4, Myl2, Myl7) genes in 
differentiating cells cultured in bioreactors operating in continuous agitation (left panel) and intermittent 
agitation without change of direction (right panel) profiles at different time points. F). Quantitative RT-PCR 
analysis showing the relative expression of Oct4, Nkx2.5, cTnT and Myl7 at day 9. Values were normalized to 
the continuous agitation culture condition, except Oct4 expression that was normalized to RNA from 
undifferentiated cells (day 0, black bar). Data are shown as mean ± SD of 3 individual bioreactor experiments. 












3.3. CM differentiation of iPSCs in WAVE bioreactors 
In order to further explore the beneficial impact of mechanical forces induced by bioreactor 
hydrodynamics on CM differentiation, we evaluated the capacity of iPSCs to differentiate towards 
CMs in WAVE bioreactors. 
Cell aggregation was initiated by inoculating single iPSCs into WAVE bioreactors. After 2 days 
of cultivation under hypoxic conditions aggregates presented a size of 167±43 μm, similar to those 
obtained in Erlenmeyer flasks (Figure A-2.1, Page 64). 
The comparison of CM differentiation efficiency in WAVE and optimized stirred tank 
bioreactors (operated under 4% O2 tension and intermittent agitation without direction change) 
revealed that WAVE bioreactor cultures favored CM lineage commitment, enabling a reduction in 
the differentiation time and increased CM yields (Figure 2.4). In these cultures, eGFP-positive cells 
and contracting areas in aggregates were observed from day 5 onwards, increasing rapidly in 
number and size (Figure 2.4A-C, Movie A-2.1). By day 7, 54.3±5.2% of the aggregates exhibited a 
considerable area of eGFP-positive and spontaneously beating cells (Figure 2.4A-B). In 
accordance with this result, flow cytometry analyses indicated that 38.6±6.0% of cells in 
aggregates were eGFP-positive, compared to less than 5% detected in stirred tank bioreactors at 
this time point (Figure 2.4C). Importantly, on day 9 of culture, i.e. before CM selection, the 
percentage of eGFP-positive cells among all cells dissociated from aggregates was almost 2-fold 
higher in WAVE bioreactors (76.0±5.8%) compared to stirred tank cultures (43.9±6.6, Figure 2.4C, 
Table 2.1). Consequently, only 2 days of antibiotic treatment were sufficient to obtain a 97.6 % 
pure CM population in WAVE bioreactors (Figure 2.4C, Table 2.1). In contrast, at day 11 of 
differentiation, aggregates in stirred tank bioreactors were not yet completely pure and additional 5 
days of antibiotic treatment were required to generate a 97.4 % pure CM population (Figure 2.4A, 
C). In terms of CM productivities, in optimized stirred tank cultures approximately 0.430-L medium 
throughput (total volume of medium used during the process) resulted in the generation of 0.1x10
9
 
CMs, which correspond to a coefficient of 0.2x10
9
 CMs/L. On the other hand, in WAVE bioreactor 
2.3x10
9
 CMs were produced in 1.5-L medium throughput (1L until day 9, 0.5L medium exchange at 
day 9) obtaining 1.5x10
9
 CMs/L (Table 2.1). 
 




Figure 2.4. Differentiation of iPSC into CMs in WAVE and stirred tank bioreactors. WAVE cultures were 
compared with optimized stirred tank bioreactor cultures (operated under 4% O2 and intermittent agitation 
without direction change) in terms of CM differentiation efficiency. A). Phase contrast and fluorescence 
images showing cell aggregates composed by eGFP-positive cells (green) at days 5, 7, 9 and 11. Scale bars: 
200 μm. B-C). Percentage of eGFP-positive aggregates during culture time. C. Percentage of eGFP-positive 
cells during culture time as determined by flow cytometry. D). CM yields (stripped bars) and number of CMs 
generated per liter of culture medium throughput (CMs/L, black bars). E). Semiquantitative RT-PCR analyses 
 




showing expression of pluripotency (Oct4), endoderm (AFP), mesoderm (T-Bra) and CM-specific (Nkx2.5, 
cTnT, HCN4, Myl2, Myl7) genes during the time course of differentiation process in WAVE bioreactors. F). 
Quantitative RT-PCR analysis of cells cultured in optimized stirred tank and WAVE bioreactors, at day 6, 
before (day 9) and after CM selection (day 16 and 11 for stirred tank and WAVE bioreactor cultures, 
respectively). Expression was normalized to RNA from stirred tank bioreactor cultures operating with 
intermittent agitation, except for Oct4 expression that was normalized to RNA of undifferentiated cells (day 0, 
black bars). Data are given as mean ± SD of 3 individual bioreactors experiments. Significantly different, 
P<0.05 (*) and P<0.01 (**). 
 
Overall, iPSC differentiation in WAVE bioreactors resulted in an improvement of about 40% in 
CM yield (60.8±0.7 CMs/input iPSC) and in a 5 times higher CM production per liter of culture 
medium throughput (CMs/L) in comparison to optimized stirred tank cultures (Figure 2.4D, Table 
2.1).  
RT-PCR analysis showed that early mesoderm, cardiac progenitor and cardiac-specific genes 
were expressed earlier and to a higher extent in aggregates from WAVE cultures than in stirred 
cultures (Figure 2.4E compare to Figure 2.3E). The expression of the pluripotency gene Oct4 
decreased more rapidly in aggregates cultured in WAVE bioreactors reaching very low levels on 
day 6 of differentiation and undetectable levels from day 8–9 onwards (Figure 2.4E–F). In contrast, 
the Oct4 transcripts were still expressed at this stage of differentiation in stirred cultures and were 
not detectable only in purified CMs (Figure 2.3E and Figure 2.4F). Additionally, in WAVE cultures 
the peak in the early mesodermal gene expression (assayed by the expression of T-Brachyury) 
occurred earlier (day 4, Figure 2.4E) than in stirred tank cultures (day 6, Figure 2.3E). By day 6, the 
cardiac mesodermal (PDGFRα) and cardiac progenitor (cKit and Nkx2.5) genes were significantly 
higher expressed in WAVE than in stirred tank bioreactor cultures. The expression of cardiac 
specific markers was also detected earlier in WAVE cultures and increased gradually in later 
stages of differentiation (Figure 2.4E). Importantly, the greater band intensities of cardiac 
transcripts Nkx2.5, cTnT and Myl7 observed in WAVE cultures before antibiotic selection (day 9) 
indicate that these cultures contained a substantially higher proportion of CMs than stirred 
bioreactor cultures (Figure 2.3E, 2.4E). RT-qPCR analyses confirmed that by day 9 of 
differentiation the expression of these three cardiac markers was significantly higher (1.3, 1.6 and 
1.6-fold, respectively) in WAVE cultures than in stirred tank bioreactors (Figure 2.4F). At the end of 
antibiotic selection, the expression of cTnT and Myl7 were very similar in both bioprocesses 
(Figure 2.4F) confirming the similar degree of CM purity in both groups (Table 2.1).  
Phase-contrast and scanning-electron microscopy (SEM) analysis of aggregates on day 9 of 
differentiation (i.e. before cell lineage selection) revealed that aggregates from WAVE and stirred 
tank bioreactor cultures differed in size and morphology (Figure 2.5A-B, Table A-2.1, Figure A-2.2). 
The mean size of aggregates cultured in WAVE bioreactors was higher (440.04±107.89 μm) and 
they were less spherical and more elongated than aggregates from stirred tank bioreactors 
(384.41±124.80 μm) (Figure A-2.2, Page 64 and Table A-2.2, Page 66). This higher size and 
reduced “sphericity” observed in the aggregates cultured in the WAVE bioreactor might be justified 
by the different hydrodynamic environment promoted by this type of bioreactor. Additionally, 
aggregates from WAVE bioreactors showed a smooth outer surface (Figure 2.5B), whereas 
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aggregates from stirred tank cultures exhibited a looser texture and a rough surface in which cell-
cell contacts could be discerned at a higher magnification (Figure 2.5A). Previous studies 
demonstrated that during cardiac differentiation of ESCs, the extracellular matrix (ECM) mainly 
composed by collagen type I is deposited on the surface of differentiating aggregates originating a 
smoother aggregate surface topography (Horton and Auguste, 2012; Taha et al., 2012). Thus, our 
findings may suggest that prior to CM selection the aggregates cultured in WAVE bioreactors 
present a higher deposition of extracellular matrix (ECM) than stirred tank aggregates. To further 
confirm these observations, we stained the whole-mount day 9 aggregates with collagen type I 
antibody to determine the amount and distribution of this ECM component by confocal microscopy. 
This analysis clearly revealed that aggregates from WAVE bioreactors contain considerably higher 
levels of collagen type I than aggregates from stirred tank bioreactors (Figure 2.5C, left panel) and 
that, based on the fraction of eGFP-positive cells in whole aggregates, the WAVE aggregates 
presented higher CM purity than the aggregates derived in stirred tank bioreactors, before 
induction of CM selection. Moreover, at this timepoint a lower percentage of proliferative cells (Ki-
67 positive cells) was observed in aggregate derived from WAVE bioreactors when comparing with 
aggregates from stirred tank bioreactor cultures (approximately 20% vs. 58% of the cells, 
respectively, Figure 2.5C).  
 
 
Figure 2.5. Scanning-electron and confocal microscopy of iPSC-derived cell aggregates and 
cardiospheres. A-B). SEM micrograph of differentiating cell aggregates collected from stirred tank (A) and 
WAVE (B) bioreactors at day 9 of differentiation. Higher magnification images evidence the differences in 
aggregate surface topography. C). Immunofluorescence and confocal microscopy images of the whole-mount 
day 9 aggregates (left panel) and cardiospheres collected at the end of selection process (right panel). The 
frequency and distribution of eGFP-positive (green), Ki-67 (red) and collagen type I-positive cells (red) is 








Taken together, our data show that iPSCs differentiate into CMs in WAVE bioreactors with 
faster kinetics and higher efficiency than in stirred tank bioreactors. At the end of the differentiation 
process and the puromycin selection procedure (day 16 for stirred tank and day 11 for WAVE 
bioreactor), collagen type I staining was similar in intensity and distribution in aggregates from both 
types of cultures (Figure 2.5C, right panel). 
3.4. Structural properties and action potential (AP) parameters of CMs generated in stirred 
tank and WAVE optimized bioprocesses 
Before CM selection, some aggregates were dissociated into single cells and seeded in static 
culture plates for structural analyses. Immunofluorescence staining for sarcomeric α-actinin, as well 
as the distribution of α-MHC protein (GFP staining), indicate that cells from WAVE cultures were 
more elongated and showed more organized sarcomeric structures, by day 9, when compared to 
cells from stirred tank cultures (Figure A-2.3, Page 65). These results are in agreement with the 
findings of other studies showing that cyclic tensions promote elongation of the cell membrane, 
orientation of actin filaments and a higher structural organization (Geuss and Suggs, 2013; Shimko 
and Claycomb, 2008).  
After the differentiation and selection process, beating cardiospheres (Movie A-2.2) were also 
dissociated into single cells and seeded in 2D plates for structural and functional characterization. 
Monolayers of pure CMs were obtained and cells maintained their spontaneous beating activity, 
which became synchronized over culture time (Movie A-2.3). Immunocytochemical analysis of 
cardiac-specific proteins α-MHC, sarcomeric α-actinin, titin and troponin I revealed that iPSC 
derived-CMs produced in both bioreactor systems stained positive for these cardiac structural 
proteins (Figure 2.6), presenting an organized striation pattern typical of CMs. 
 
Figure 2.6. Structural properties of CMs generated in stirred tank and WAVE optimized bioprocesses. 
Cardiospheres were dissociated into single cells, plated on 2D plates and after being cultured for up to 2 
weeks, stained for CM markers. Immunocytochemical analysis of eGFP-positive CMs (green) using 
sarcomeric α-actinin, titin and troponin I (red) antibodies. Nuclei are counterstained with DAPI (blue). Scale 
bars: 50 μm. 
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In order to assess the electrophysiological properties of CMs generated in both bioreactor 
systems, AP recordings in single CMs were performed. The great majority of puromycin selected 
CMs derived from both bioprocesses displayed an atrial-like AP morphology (stirred tank: 100%, 
WAVE: 92%). These findings are also in agreement with the enhanced expression of atrial 
transcripts (Myl7) and reduced expression of the transcripts specific for the pacemaker (HCN4) and 
ventricular-like phenotypes (Myl2) detected in the final differentiated population by RT-PCR (Figure 
2.3E and 2.4E). The AP characteristics of purified CMs generated in WAVE and stirred cultures 
were very similar showing comparable maximum diastolic potential (MDP), beating frequency, AP 
upstroke velocity (Vmax), velocity of diastolic depolarization (Vdd) and AP duration (APD) (Table A-
2.3, Page 66). Additionally, the CMs generated in WAVE and stirred tank bioreactor cultures 
exhibited AP parameters similar to the ones described in literature for atrial-like late stage 
development fetal CMs (day 16-19 of differentiation), such as MDP (-63.3±1.3 mV), frequency 
(234±19 beats/min), Vmax (27.9±0.7 V/s) and Vdd (0.115±0.017 V/s) (Kuzmenkin et al., 2009). 
Besides exhibiting largely indistinguishable AP properties, CMs produced in both bioprocesses 
also responded similarly to adrenergic and muscarinic agonists, isoproterenol and carbachol, 
respectively. When isoproterenol was administered to CMs a significant increase of AP frequency 
and a shortening of APD at 90% of repolarization (APD90) was observed (Figure 2.7A).  
 
 
Figure 2.7. Functional characterization of CMs produced in stirred tank and WAVE bioreactors.  A-D). 
Pharmacological response of CMs. Effect of 1 µM Isoproterenol (Iso, A-B) and 1 µM Carbachol (CCh, C-D) on 
beating frequency and on action potential (AP) duration at 90% repolarization (APD90) in iPSC-CMs. (B,D) 
Representative recordings of APs from WAVE bioreactor-derived CMs. APs were recorded before the 
application of the drug (Control) in the presence of the drug (Iso / CCh), and after washout of the drug 
(washout). E-F). Calcium transients of CMs produced in WAVE bioreactor. E) Graphical representation of 
calcium level cycling, during CMs contraction, determined by confocal imaging of the cell permeant calcium 
indicator dye Rhod-3, for three different cells. F) Pseudo-color images show minimal (Ca
2+
 min, left image) 
and maximal (Ca
2+
 max, right image) Rhod-3 fluorescence intensity in the three analyzed cells. Significantly 
different, P<0.05 (*) and P<0.01 (**). 
 
 




Moreover, positive chronotropic effects of isoproterenol were reversible upon washout (Figure 
2.7B). In contrast, the administration of carbachol, a synthetic acetylcholine analog, evoked a 
significant reduction in the beating rate in CMs from stirred tank and WAVE bioreactors, which was 
also reversible upon washout (Figure 2.7C-D). 
In order to further evaluate the functional integrity of CMs produced in WAVE bioreactors we 
performed real-time intracellular calcium imaging with the calcium indicator dye Rhod-3. This 
analysis revealed that distinct iPSC-CMs from a beating monolayer present synchronized 
oscillatory patterns of intracellular calcium concentrations (Figure 2.7E-F). Movie A-2.4 shows a 
representative live imaging recording of whole-cell calcium transients for contracting CMs produced 
in WAVE bioreactors.  
Overall, these results show that CMs produced using the protocol developed in this work 
exhibit intact molecular, structural and functional properties. 
4. Discussion 
In this study we developed a new method for mass production of murine iPSC-CMs using 
environmentally controlled bioreactors. The expansion and CM differentiation of human and murine 
pluripotent stem cells in stirred tank bioreactors have been reported by our group (Serra et al., 
2010) and others (Bauwens et al., 2005; Niebruegge et al., 2008, 2009). Aiming to further improve 
CM yields, we designed a bioreactor protocol that combine low oxygen concentrations with a cyclic 
mechanical rich environment by manipulating bioreactor hydrodynamics, more specifically the 
agitation type and profile. In this study, we showed for the first time that a DO of 4% O2 tension, 
along with the use of either an intermittent stirring or a wave-induced agitation, favors iPSC 
differentiation towards the CM lineage. Using an intermittent agitation in stirred tank bioreactors, 
we were able to improve by 1000-fold CM yields (up to 44 CMs/input iPSC) when compared to 
normoxic continuously agitated cultures. Moreover, we demonstrated that the wave-induced 
agitation in combination with 4% O2 tension from the beginning of iPSC differentiation increases 
the kinetics of cardiac differentiation, enabling a reduction of bioprocess duration by 5 days, and 
further improves the CM yields (60 CMs/input iPSC). To our knowledge, this is the first study 
reporting the use of the WAVE bioreactor for PSC culture. This type of bioreactor presents a simple 
design, appealing to either biological engineers or medical professionals and offers a low shear 
environment suitable for growth of sensitive cells such as stem cells (Houtzager et al., 2010).  
Oxygen tensions and mechanical cues have been shown to mediate PSCs proliferation and 
differentiation. In our study, we showed that hypoxic exposure (4% O2 tension) improves CM 
differentiation efficiencies by enhancing both cell proliferation and cardiomyogenesis when 
compared to normoxia conditions. This data is in accordance with previous studies (Niebruegge et 
al., 2009), reporting that low DO concentrations enhanced the proliferation of ESCs and the 
expression of mesodermal, early and late cardiac-specific genes (Niebruegge et al., 2009). It is 
also established that CMs actively respond to mechanical cues from the environment in a 
frequency-dependent manner and that those cues can modulate electric remodeling, alterations in 
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gene expression, autocrine and paracrine effects, and consequently cardiac tissue organization 
and development (Shimko and Claycomb, 2008). Cardiac cells experience mechanical strains with 
every heartbeat, i.e., at a pulsatile frequency close to 1 Hz (Gupta and Grande-allen, 2006). Aiming 
to mimic the physiological environment, previous studies have applied mechanical stimulation at 
frequencies of 1 Hz on commercial or custom built devices to engineered cardiac tissues (Gwak et 
al., 2006). In our protocol, cells were subjected to distinct mechanical forces by manipulating the 
hydrodynamic environment in scalable readily available bioreactor systems. In stirred tank 
bioreactors, using an intermittent stirring, mechanical forces at frequencies close to 0.033 Hz were 
generated, whereas with a wave-induced agitation higher frequencies were reached (0.82-0.86 
Hz). Thus, the differences in the temporal gene expression pattern and cardiac differentiation 
efficiency observed in stirred and WAVE cultures may be related to the frequency of mechanical 
loading applied in both systems. In accordance with literature, the effect of mechanical forces on 
cardiomyogenic differentiation is highly dependent on the experimental setup. Several variables 
including force magnitude, frequency, direction, duration of application, and at what stage of 
differentiation the force is applied, have been shown to affect cell fate decisions (Shimko and 
Claycomb, 2008; Teramura et al., 2012; Wan et al., 2011). In fact, these aspects were noted to 
also be critical for the success of the protocol herein described. Our results suggest that an 
intermittent agitation profile with change of stirring direction is not suitable for iPSC differentiation 
into CMs (low CM numbers and purities were achieved at the end of the differentiation process). 
Also, higher cell lysis was observed during all culture time, suggesting that this agitation profile 
may have induced high shear rate for cells, compromising cell viability, proliferation capacity and 
differentiation efficiency. Herein we considered that the major mechanical stimulus induced to the 
cells is the hydrodynamic environment provided by an intermittent and wave-induced agitation. 
However, it should be noted that fluid shear stress per se might also influence cell behavior. The 
effect of shear stress on cell pluripotency and cardiomyogenesis has already been described. For 
example, mESCs exposed to laminar shear stress (4 days at 5 dyn/cm
2
) expressed higher levels of 
mesodermal markers (Wolfe et al., 2012). On the other hand, fluid shear forces promoted by 
distinct types of impellers, such as single glass-ball stirring pendulum (1.52 dyn/cm
2
, 75 rpm) 
(Wang et al., 2013), pitched-blade impellers (2–5.2 dyn/cm
2
, 50–100 rpm) (Cormier et al., 2006) 
and paddled impellers (4.5–7.8 dyn/cm
2
, 80–120 rpm) (Kehoe et al., 2010) have shown to maintain 
or increase the expression of pluripotency markers in PSC cultured in bioreactor systems. In 
WAVE bioreactors the mean values of shear stress (0.05 Pa (0.5 dyn/cm
2
) in both 2 L and 20 L 
working volumes (Kalmbach et al., 2011)) were considerably lower than the ones indicated above 
for stirred bioreactors. In accordance, we observed a 6-times lower fold increase in the cumulative 
LDH in WAVE bioreactor cultures, from day 2 to day 9, when compared to stirred tank bioreactor 
cultures (Figure A-2.4, Page 65). These results reflect the reduced impact that fluid shear stress 
has on cell viability in WAVE bioreactor cultures. Future experiments using Computational Fluid 
Dynamics tools should be performed aiming at a deeper characterization of the hydrodynamic 
environment and quantification of the type and magnitude of the stresses generated in each 
bioreactor strategy.  
 




It should be pointed out that mechanical forces, besides promoting elongation of the cell 
membrane and orientation of actin filaments (Geuss and Suggs, 2013; Shimko and Claycomb, 
2008), regulate ECM synthesis, more specifically, result in enhanced synthesis of collagen, the 
most abundant protein in cardiac tissue (Gupta and Grande-allen, 2006). In this study, we showed 
that by day 9 of differentiation, cultures that have experienced higher mechanical loading (WAVE 
cultures) are composed by cells with more organized sarcomeric structures, and by aggregates 
with smoother surface topography due to a higher deposition of collagen type I. 
Aside from different hydrodynamic environments, cells were cultured at 4 % O2 tension during 
different periods of time in these systems (in WAVE bioreactor from day 0 to day 11 and in stirred 
tank bioreactor from day 2 to day 16). Therefore, exposing cells to reduced oxygen concentrations 
from the beginning of differentiation could also have contributed to the beneficial effect on CM 
differentiation observed in WAVE cultures. 
The establishment of pure CM preparations is imperative for future clinical application of these 
cells. Our finding that a hypoxic environment along with a wave-induced agitation enables the 
production of CMs at purity of 76% in nine days without growth factor- directed differentiation and 
without antibiotic selection represents a major advance towards development of robust and 
clinically applicable bioprocesses. To facilitate the optimization of the described method, we have 
used a transgenic murine iPSC line, in which the cardiac-restricted α-MHC promoter drives the 
expression of a puromycin resistance gene and eGFP. Therefore, antibiotic treatment, after day 9, 
resulted in the generation of an essentially pure CM population. In WAVE bioreactors, only two 
days were sufficient to achieve 97% CM purity by puromycin selection whereas in stirred tank 
cultures 7 days of selection were needed to reach the same purity. CMs generated at faster 
kinetics may have higher therapeutic potential in their in vivo applications. Namely, Boheler and 
coworkers showed that ESC-derived CMs isolated at day 11 of differentiation, in contrast to cells 
obtained at day 16-18 of differentiation, were more resistant to hypoxia in vitro and survived longer 
following injection into healthy hearts of athymic nude mice (Boheler et al., 2011). These data 
suggest that early-stage CMs may have greater potential to engraft and improve the myocardial 
contractile function following infarction. Therefore, it is appealing to hypothesize that day 11 CMs 
obtained in WAVE bioreactors may exhibit higher survival and engraftment potential after 
intramyocardial transplantation than day 16 CMs generated in stirred tank bioreactors. In order to 
increase the safety of the final CM preparation, non-genetic cell-lineage purification protocols 
should be considered. Procedures involving density-gradient centrifugation (Xu et al., 2002), the 
use a mitochondrial dye (Hattori et al., 2010) or antibodies targeting cardiac-specific surface 
markers (Dubois et al., 2011; Hoof et al., 2010; Uosaki et al., 2011) have been established for CM 
enrichment and can be combined with the developed bioprocess. However, these methods are 
either labor intensive or expensive which limit their scalability. Non-genetic CM lineage purification 
strategies based on distinct metabolic requirements of CMs and non-CM cell types have been 
described. For example, it has been shown that CMs survive in serum-free medium (Moon et al., 
2013; Passier et al., 2005) or in glucose-depleted culture medium containing lactate (Tohyama et 
al., 2013), while other cell types do not. In addition, selective elimination of remaining 
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contaminating pluripotent cells could be achieved by treatment of final CM preparations with small 
molecules that do not compromise CM viability and functionality but are toxic to pluripotent stem 
cells (Ben-David et al., 2013). From a large-scale production perspective this type of approaches 
are more appealing and could be easily incorporated in our bioreactor protocol aiming at 
establishing a clinically scalable and cost-effective integrated bioprocess for CM differentiation and 
purification. 
Another major requirement for the biomanufacturing of stem cell derivatives is to ensure that 
the final product fulfills the desired quality requisites for biomedical applications including 
phenotype, potency and functionality (Serra et al., 2012). Here, we showed that CMs obtained in 
both bioreactor systems presented typical cardiac morphology, electrophysiology, hormonal 
response to β-adrenergic and muscarinic receptor stimulation and rhythmic intracellular calcium 
transients. The most predominant CM subtype observed in both bioprocesses was the atrial-like 
phenotype, which was largely influenced by the type of cardiac specific promoter that was driving 
the expression of antibiotic resistance gene in our genetically engineered cells. The -MHC 
promoter is active mostly in atrial regions during embryonic and early fetal development (Franco et 
al., 1998), therefore it seems that the selection strategy used in this work is favoring the production 
of immature fetal-like cells that present action potentials resembling those found in atrial cells and 
that have not yet assumed more recognizable cardiac chamber subtypes. Future efforts should be 
directed towards improving the electrophysiological maturity of the produced CMs and enhancing 
cardiac subtype specification, for example by extending the time in culture after the selection 
process. 
In conclusion, this study describes a robust and scalable protocol for differentiation of murine 
iPSC into CMs in controlled hypoxic and mechanical environment. In this work we have focused on 
murine iPSC as a model system for bioprocess development, and on a simple non-directed 
differentiation protocol to clearly identify the impact of each culture condition tested on CM 
differentiation. Although human and mouse PSC lines utilize overlapping developmental pathways, 
much optimization is required when translating protocols between species. We are aware that 
further optimization to our protocol will be required when translating to human PSCs. For example 
the use of chemically defined and serum-free media supplemented with cytokines will be of major 
importance. Nevertheless, it is our conviction that the bioreactor protocol herein described (i.e. the 
controlled hypoxic and specific hydrodynamic environment promoted by an intermittent stirring or a 
wave induced agitation) will be able to further improve the protocols already reported for human 
PSC differentiation towards CMs by enhancing culture homogeneity, process reproducibility, CM 
yields and productivities. It is widely known that the use of chemically defined media and growth-
factor supplements considerably increases the cost of the differentiation process. Thus, the 
development of cost-effective bioprocesses is also highly dependent on increasing the number of 
CMs generated per liter of culture medium throughput (CMs/L). Here, by controlling key 
environmental conditions in cardiac development, we were able to produce up to 1.6x10
9 
CMs/L in 
a single WAVE 11-days bioreactor run. To our knowledge this is the highest value that has been 
reported to date (Niebruegge et al., 2008). Hopefully, our achievements will also contribute for the 
 




development of affordable bioprocesses for mass production of human PSC-derived CMs, by 
reducing the need/amount of expensive cytokine inductive cocktails and/or the cardiac 
differentiation protocol duration.   
5. Appendix  
 
Figure A-2.1. Viability analysis of cell aggregates from day 2 cultures. Aggregates from both stirred tank 
and WAVE bioreactors were stained with fluorescein diacetate to detect live cells (green) and propidium 




Figure A-2.2. Elongation and roundness of aggregates from day 9 cultures. Aggregates from day 9 
cultures, in both stirred tank (operated under continuous and intermittent agitation without direction change) 
and WAVE bioreactors, were analyzed based on their elongation (A) and roundness (B). Values were 








Figure A-2.3. Structural analysis of cells dissociated from day 9 aggregates cultured in Stirred tank 
and WAVE bioreactors. Day 9 aggregates were dissociated into single cells, plated on 2D plates and stained 
with the sarcomeric α-actinin (red) antibody. Fluorescence images of αMHC-eGFP-positive cells (green) are 




Figure A-2.4. Cumulative LDH release in stirred tank and WAVE bioreactors. Fold increase in the 
cumulative LDH release, from day 2 to day 9, in both stirred tank (operated under continuous and intermittent 





















Table A-2.1. Primers for RT-PCR and quantitative RT-PCR  
Genes Sequences (5’-3’) Size (bp) NCBI ID 
GAPDH F: ACCTTGCCCACAGCCTTG 142 NM_001289726.1 
NM_008084.3 R: GGCTCATGACCACAGTCCAT 
TNNT2 F: GGTGCCACCCAAGATCCCCG 199 NM_001130174.1 
R: AATACGCTGCTGCTCGGCCC 
NKX2.5 F: CAGCCAAAGACCCTCGGGCG 142 NM_008700.2 
R: TGCGCCTGCGAGAAGAGCAC 
HCN4 F: TGCTGTGCATTGGGTATGGA 337 NM_001081192.1 
R: TTTCGGCAGTTAAAGTTGATG 
MLC-2V F: TGCCAAGAAGCGGATAGA 328 NM_010861.3 
R: CAGTGACCCTTTGCCCTC 
MLC-2A F: AGTAGGAAGGCTGGGACCCG 306 NM_022879.2 
R: CTCGGGGTCCGTCCCATTGA 
T-BRACHYURY F: CTGCGCTTCAAGGAGCTAAC 91 NM_009309.2 
R: CCAGGCCTGACACATTTACC 
KIT F: ATTATGAACGCCAGGAGACG 497 NM_001122733.1 
 NM_021099.3 R: GAATCCCTCTGCCACACACT 
PDGFRA F: CGTCAAAGGGAGGACGTTCA 370 NM_011058.2 
 NM_001083316.1 R: GACGAAGCCTTTCTCGTGGA 
AFP F: CCCACTTCCAGCACTGCCTGC 374  NM_007423.4 
R: GGCTGCAGCAGCCTGAGAGT 




Table A-2.2. Mean aggregate size throughout time of iPSC-CMs produced in both stirred tank and 
WAVE bioreactor systems. 
Time (day) 
Stirred Tank BR 
(Continuous) 
Stirred Tank BR 
(Intermittent) 
WAVE BR 
2 142.65±69.85 155.34±55.57 169.37±45.90 
4 147.25±68.90 181.04±66.94 301.79±63.08 
7 307.38±116.39 277.84±131.39 371.23±74.79 
9 357.64±113.30 384.41±124.80 440.04±107.89 
 
 



















22 -59.8±1.0 321.9±23.3 26.5±1.8 0.1±0.0 84.4±16.4 18.1±1.1 5.3±1.3 
WAVE 
bioreactor* 
25 -58.0±1.2 296.4±25.1 21.0±2.4 0.1±0.0 84.0±7.3 23.0±1.9 4.1±0.5 
* Data are presented as means ± SEM.  
Abbreviations: N, total number of cells analyzed; MDP, average maximum diastolic potential for action 
potentials during the time period examined; Vmax, the maximum rate of rise of the action potential upstroke; 
Vdd, velocity of diastolic depolarization; APD90, action potential duration at 90% of repolarization; APD50, 
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Three dimensional (3D) cultures of human pluripotent stem cell derived cardiomyocytes 
(hPSC-CMs) are more predictable models of in vivo responses to be used for drug discovery and 
hold great promise in regenerative medicine applications. However, the transition of CM 
differentiation protocols from 2D to 3D cultures is not straithforward and often results in lower CM 
purity and reduced reproducibility. In this work, we relied on the aggregation of hPSC-derived 
cardiac progenitors to establish a differentiation protocol capable of generating highly pure CM 
aggregate cultures. In parallel to improved CM enrichment and commitment, we observed 
significant alterations in the extracellular matrix and metabolic transcriptomes, and a slight increase 
of TCA-cycle activity, amino acid metabolism and ATP production through glucose oxidation in 3D 
cultures when compared with 2D monolayer cultures. Although hPSC-CMs generated from both 
methods are still highly glycolytic, 3D aggregate cultures showed slightly improved metabolic 
energetics. 
Overall, this study provides novel knowledge on the impact of 3D culture on CM differentiation, 
gene expression and metabolism which will contribute to improve the control over CM 
differentiation and to enable the identification/characterization of the differentiated population 





















1. Introduction  
Human pluripotent stem cells (hPSCs) offer unique prospects for regenerative medicine, drug 
discovery, toxicity testing, disease modeling, and developmental biology studies due to their ability 
to proliferate indefinitely and differentiate into any cell type of the human body (Egashira et al., 
2011). Importantly, their capacity to produce cell types that are challenging to obtain from tissues, 
difficult to maintain in culture, and that present limited proliferative capacity, such as 
cardiomyocytes (CMs), brought great hope to the cell therapy field. In fact, hPSC derived 
cardiomyocytes (hPSC-CMs) became promising candidates for cardiac cell therapy and pre-clinical 
research (Hartman et al., 2016; Youssef et al., 2016). Within this context, an enormous effort has 
been made towards the development of protocols to direct the differentiation of hPSC towards the 
cardiac lineage. Most of them rely on the supplementation of culture medium with growth factors 
and/or small molecules that specifically induce mesoderm differentiation and cardiac lineage 
specification (Burridge et al., 2013). Laflamme and colleagues were the first to report a directed 
differentiation protocol in a 2D monolayer culture format, based on BMP4 and Activin A stimulation 
in RPMI/B27 medium (Laflamme et al., 2007). Nowadays most protocols rely on the temporal 
modulation of Wnt signaling, which has a biphasic role in cardiogenesis; Wnt activation is required 
for mesoderm formation (Lian et al., 2013; Ueno et al., 2007) and subsequent Wnt inhibition is 
necessary for cardiac specification (Ueno et al., 2007). The small molecule CHIR99021, has been 
widely used as a Wnt signaling activator, whereas subsequent inhibition has been explored with a 
wide range of Wnt antagonists such as IWP4, IWP2, IWR1, Wnt-C59 or XAV939 (Burridge et al., 
2014; Kadari et al., 2015; Lanier et al., 2012; Lian et al., 2012, 2013). These protocols originated 
CMs with a previously unmet purity of >80% (Lian et al., 2012, 2013). 
Suspension culture platforms have also been explored to support large-scale differentiation of 
hPSC towards CMs. Most of these studies have used embryoid bodies (EBs) as an initial step to 
induce cardiac differentiation (Bose and Shenoy P, 2016; He, 2003; Huber et al., 2007; Kehat et 
al., 2001; Liu et al., 2016; Yang et al., 2008; Zhang et al., 2009). More recently, directed 
differentiation protocols established in 2D monolayer cultures have been adapted to 3D cultures 
(aggregate and microcarrier based cultures), however final CM purities are typically lower than 
those obtained in 2D monolayer cultures (reviewed in (Kempf et al., 2016)). Protocol reproducibility 
is also an issue, particularly due to the difficulty in controlling aggregate size, which has been 
shown to affect differentiation potential (Niebruegge et al., 2009; Bauwens et al., 2008). These 
aspects still hinder the practical application of 3D culture methods for large scale production of 
differentiated cells.  
Despite all the progress that has been made in the establishment of CM differentiation 
protocols, there is still the need to: i) improve the reproducibility of differentiation protocols from 
batch-to-batch, and between different cell lines and different laboratories, ii) increase the final CM 
purity, avoiding the presence of undifferentiated hPSC and non-cardiac committed cells in the final 
differentiation population, and iii) reduce the heterogeneity of the final population of cardiac cells 
that often contain not only different subtypes of CMs but also cardiac fibroblasts, endothelial cells 
 
 




and smooth muscle cells. During the last years several strategies have been explored to improve 
the purity of hPSC-CMs including: percoll gradients (Xu et al., 2002), Flow Activated Cell Sorting 
for specific surface markers (Skelton et al., 2014) and for cells incubated with mitochondrial dyes 
(Hattori et al., 2010) or molecular beacons (Wile et al., 2014), or using synthetic modified mRNAs, 
which target tissue-specific miRNAs (miRNA switches) (Miki et al., 2015). However, these 
approaches are expensive and present reduced scalability. One elegant and efficient approach 
consists in culturing hPSC-CMs in medium containing lactate instead of glucose (Tohyama et al., 
2013), taking advantage of the different metabolic properties between different cell types: since 
hPSCs and fibroblasts rely highly on glucose, only CMs, which can use both metabolites, survive 
when cultured in this medium (Tohyama et al., 2013). In fact, energy metabolism has been shown 
to be one of the major regulated processes during development. Van Dartel and colleagues used 
transcriptome analysis to identify metabolic changes during the differentiation of ESC into CMs 
(van Dartel et al., 2014). Although this study has shown the regulation of common genes involved 
in energy metabolism during hPSC differentiation, it did not provide direct insights into the type of 
physiological alterations in energy metabolism that occur during hPSC differentiation. A detailed 
description of the type of metabolic and fluxomic changes that take place during hPSC 
differentiation towards CMs is currently lacking and might be useful to facilitate the identification 
and characterization of the differentiated population by their metabolic signature.  
In this work, we first established a robust protocol for directed differentiation of hPSCs towards 
CMs, suitable to generate CMs in both 2D monolayer and 3D aggregate culture formats, and then 
we compared both differentiated populations in terms of CM purity, transcriptome, metabolome, 
fluxome and functionality. More specifically, using an integrated experimental and computational 
systems biology approach we assessed the impact of a 3D aggregate culture of hPSC-derived 
cardiac progenitors on: i) CM enrichment and commitment and ii) transcriptional and metabolic 
signatures of hPSC-CMs. 
 
2. Methods 
2.1. hiPSC and hESC culture 
Four hPSC lines were used in this study, including two hESC lines (Mel1 and H3 reporter lines 
NKX2-5(eGFP/w) (Elliott et al., 2011), kindly provided by Dr. David Elliott from Murdoch Childrens 
Research Institute) and two hiPSC lines (DF19-9-11T.H (WiCell) and M4C4, kindly provided by Dr. 
Tomo Saric from University of Koln). All hPSC lines were propagated on Matrigel® (Corning) 
coated plates until reaching 80% confluency. hESCs were maintained in DMEM/F12 supplemented 
with 20% (v/v) KnockOut serum replacement, 1% (v/v) MEM non-essential amino acid, 1% (v/v) L-
glutamine, 1% (v/v) Pen/Strep and 50mM β-mercaptoethanol (all from ThermoFisher Scientific) 
while hiPSCs were cultured in mTESR1 medium (STEMCELL Technologies). The four hPSC lines 






2.2. Directed differentiation of hPSC toward cardiomyocytes  
Differentiation of hPSC into CMs was initiated when cell confluence reached 80-90%. Briefly 
expansion medium was replaced by RPMI Medium (ThermoFisher Scientific) supplemented with 
B27 without insulin (RPMI/B27, ThermoFisher Scientific), 12 µM CHIR99021 (Biogen Cientifica 
SL), 80 ng/mL Activin A (Tebu-bio) and 50 µg/mL Ascorbic acid (Sigma-Aldrich). After 24 hr, the 
medium was completely replaced by RPMI/B27 supplemented with 5 µM IWR-1 (Sigma-Aldrich) 
and 50 µg/mL ascorbic acid (Sigma-Aldrich). At day 3, i.e. 72 hr after day 0, medium was 
exchanged for RPMI/B27 supplemented with 5 µM IWR-1. At day 6 (when beating zones were 
observed), cells were dissociated by incubation with TrypLE Select (ThermoFisher Scientific) for 5 
min and replated either in 2D static tissue culture plates or in AgreeWell plates as described below. 
2.2.1. 2D monolayer culture 
Cells harvested at day 6 were inoculated at 200 000 cells per cm
2 
on Matrigel® (Corning) 
coated plates in RPMI Medium supplemented with B27 (with insulin). Medium was exchanged 24 
hr later, and then every two days, until day 15. hPSC-CMs obtained at day 15 were designated by 
hPSC-CM-2D. 
2.2.2. 3D Aggregate culture 
Cells harvested at day 6 were inoculated in AggreWell™400Ex (Stem cell technologies) at 
1500 cells/microwell (as previously described for aggregation of hPSC-CMs (Nguyen et al., 2014)), 
centrifuged at 100 g, during 3 min and cultured in RPMI Medium supplemented with B27 (with 
insulin). After 24 hr, medium was exchanged and aggregates were transferred to orbital 
suspension cultures (at an agitation rate of 90 rpm), and maintained for additional 8 days (total 
culture time: 15 days). Medium was replaced every two days. hPSC-CMs obtained at day 15 were 
designated by hPSC-CM-3D. 
2.3. Cell concentration and viability 
2.3.1. Cell concentration 
Cell concentration was determined by cell counting in a Fuchs-Rosenthal haemacytometer 
(Brand, Wertheim, Germany) using the trypan blue exclusion method (0.1% (v/v) solution in PBS).  
2.3.2. Fluorescein diacetate-propidium iodide staining 
The qualitative assessment of cell plasma membrane integrity was performed using the 
enzyme substrate fluorescein diacetate (FDA, Sigma-Aldrich), and the DNA-binding dye propidium 
iodide (PI, Sigma-Aldrich). Briefly, cells were incubated with 20 μg/mL FDA and 10 μg/mL PI in 
Dulbecco’s Phosphate Buffered Saline (DPBS, ThermoFisher Scientific) for 2-3 min and visualized 
by fluorescence microscopy (DMI 6000, Leica Microsystems GmbH).  
2.4. Cell/Aggregate structure and ultrastructure 
2.4.1. Immunocytochemistry 
hPSC-CMs were washed with DPBS and fixed in 4% (w/v) Paraformaldehyde (PFA) in DPBS 
solution for 15 min. After being permeabilized and blocked with 5% (v/v) FBS, 1% (w/v) BSA, 0.3% 
(v/v) Triton X-100 in DPBS for 1 hr, at room temperature (20-25°C), cells were incubated with 
 
 




primary antibodies diluted in 1% (w/v) BSA, 0.1% (w/v) TX-100 in DPBS overnight at 4°C. The 
following primary antibodies were used: α-sarcomeric actinin (1:200, Sigma-Aldrich), titin (1:100, 
Santa Cruz Biotechnology) and troponin T (1:100, Millipore). Afterwards, cells were washed in 
DPBS and incubated with secondary antibody, Alexa Fluor 594 goat anti-mouse IgG (1:500, 
ThermoFisher Scientific), in the dark for 1 hr at room temperature. Cell nuclei were counterstained 
with Hoechst 33342 nucleic acid dye (1:1000, Thermo Fisher Scientific). Representative images 
were taken using an inverted fluorescence microscope (DMI 6000, Leica).  
2.4.2. Transmission electron microscopy (TEM) 
Monolayers of hPSC-CMs were fixed in 2% (v/v) glutaraldehyde in 0.1 M HEPES buffer (pH 
7.4) for 20 min, washed in DPBS and stored in 1% (v/v) glutaraldehyde in DPBS until analyses. 
TEM analyses were performed as previously described (Correia et al., 2016).  
2.4.3. Evaluation of aggregate size 
The aggregate size was determined using an inverted-microscope (DMI 6000, Leica) by 
measuring two perpendicular diameters of each aggregate using imageJ software. These 
measurements were used to calculate the average diameter of each aggregate. 
2.5. Cell characterization: Protein Expression 
2.5.1. Flow cytometry 
2D monolayers and 3D aggregates were dissociated to single cells after incubation with 
TypLE
TM
Select for 5 min and then resuspended in washing buffer (WB) solution (5% (v/v) FBS in 
DPBS), centrifuged at 300 g during 5 min and washed again. Cells were incubated with the 
primary/conjugated antibody for 1 hr at 4°C.  Afterwards, cells were washed two times in WB 
solution. Whenever required, cells were incubated with secondary antibodies for 30 min at 4ºC. For 
determination of intracellular markers, cells were washed two times in BD Perm/Wash (PW) 
solution (BD Biosciences, diluted 1:10 in H2O MiliQ), and fixed for 20 min in BD CitoFix/Citoperm 
(BD Biosciences) solution at 4°C. After a washing step with PW solution, cells were kept in 1% 
(v/v) BSA solution at room temperature 30 min (for blocking non-specific interactions), washed in 
PW solution and then incubated with primary antibody at 4°C, during 1 hr. When required, cells 
were washed twice in PW, and incubated with respective secondary antibodies during 30 min in 
the dark. Cells were washed twice with WB (for extracellular markers) and with PW (for intracellular 
markers) before being analyzed in a CyFlow® space (Partec GmbH) instrument, registering 10,000 
events per sample. The antibodies used were: Oct4 (Santa Cruz Biotechnology, 6:100), Bry T 
(R&D Systems,1:10), KDR/VEGFRα (BioLegend, 5:100), VCAM-1 (CD106-PE, BD Biosciences, 
2:10), SIRPα/β (CD172a/b-PE, BioLegend, 5:100), cTNT (Thermo Fisher Scientific, 1:100) and 
isotype controls IgG1,κ-PE (BD Biosciences). 
2.6. Cell characterization: Gene Expression 
2.6.1. Quantitative Real Time PCR 
Total RNA was extracted using the High Pure RNA Isolation Kit (Roche), and reverse 






manufacturer’s instructions. Relative quantification of gene expression was performed using 
LightCycler 480 Probes Master (Roche) in 20 μL reactions with 50 ng cDNA template and 20x 
concentrated TaqMan probes. The reactions were performed in 96-well plates using a LightCycler 
480 Real-Time PCR System (Roche). Cycle threshold (Ct’s) were determined by LightCycler 480 
Software. All data was analyzed using the 2-ΔΔCt method for relative gene expression analysis. 
Changes in gene expression were normalized to GAPDH and RFLP0 gene expression as internal 
controls. The TaqMan probes used were: POU5F1 Hs00999632_g1, GATA4 Hs00171403_m1, 
NKX2.5 Hs00231763_m1, TNNT2 Hs00165960_m1, VCAM1 Hs01003372_m1, MYH7 
Hs01110632_m1, MYL2 Hs00166405_m1, MYL7 Hs99999905_m1, HCN4 Hs00221909_m1, 
CACNA1C Hs00175760_m1, ACTC1 Hs00167681_m1, MYH6 Hs00606316_m1, GAPDH 
Hs01101425_m1 and RPLP0 Hs99999902_m1. 
2.6.2. Microarray analysis 
The quality of RNA obtained from hiPSC-CM-2D and hiPSC-CM-3D at day 15, was assessed 
by the quotient of the 28S to 18S ribosomal RNA electropherogram peak using an Agilent 2100 
bioanalyzer and the RNA Nano Chip (Agilent). After this, Illumina HumanHT-12 v4 Expression 
BeadChio microarray technology (Illumina) was used for transcriptional profiling. Data were 
processed and normalized as described elsewhere (Silva et al., 2015). Genes differentially 
expressed were selected based on Student’s t test for p value < 0.05 and fold change |FC|≥1.3. 
Upstream regulators, canonical pathways and biological functions analyses were performed using 
IPA software. Upstream regulators were considered significantly activated when presenting an 
overlap p-value ≤ 0.05 and an IPA activation Z-score ≥ 2.0 and significantly inhibited when 
presenting an overlap p-value ≤ 0.05 and an IPA activation Z-score ≤ -2.0. The overlap p‐value 
measures whether there is a statistically significant overlap between the dataset genes and the 
genes that are regulated by a transcriptional regulator, and is calculated using Fisher’s Exact Test. 
Activation z‐score infers the activation states (“increased” or “decreased”) of predicted 
transcriptional regulators. Given the observed differential regulation of a gene (“up” or “down”) in 
the dataset, the activation state of an upstream regulator (“activated” or “inhibited”) is determined 
by the regulation direction associated with the relationship from the regulator to the gene 
comparing with a number of findings reported in the literature. Biological Function and Pathway 
analysis examines genes in the dataset that are known to affect each biological function/pathway 
and compares their direction of change to what is expected from the literature. If the observed 
direction of change is mostly consistent with a particular activation state of a biological function 
(“increased” or “decreased”), then a prediction is made about that activation state. For KEGG 
Pathways analysis, DAVID Resources (https://david.ncifcrf.gov/) were used. R-project was used to 
build: i) scatter plot with the absolute values of expression for all transcripts of hiPSC-CM-2D and 
hiPSC-CM-3D; and ii) volcano plot using Student’s t-test and fold changes of each gene in hiPSC-









2.7. Metabolic Analysis 
2.7.1. Quantification of extracellular metabolite concentrations 
Concentrations of glutamine (Gln), glutamate (Glu), glucose (Glc) and lactate (Lac) in cell 
culture supernatants were measured using YSI 7100 Multiparameter Bioanalytical System (YSI Life 
Sciences). The remaining amino acids were determined by HPLC using the Waters AcQ.Tag 
Amino Acid Analysis Method (Waters, Milford, MA) as described elsewhere (Carinhas et al., 2010). 
The specific metabolic rates (qMet, expressed in μmol/(10
6
 cell.h)) were calculated using the 
equation: qMet = ΔMet/(Δt x Xv), where ΔMet (mol/L) is the variation of metabolite concentration 
during the time period Δt (h), and Xv (cell/L) the average of cell concentration during the same time 
period. 
2.7.2. Isotopic tracer experiments, GC-MS analysis and nonstationary 13C-MFA 
For the isotopic labeling cultures, [1,2-
13
C]Glucose was added to glucose depleted RPMI 
medium, to achieve standard glucose concentration (11 mM). Label incorporation into intracellular 
metabolites was assessed 24 and 48 hr after label addition. Metabolic quenching, metabolite 
extraction and derivatization protocols were performed as described in the literature (Carinhas et 
al., 2016). The EI mode (70eV) mode of a QP2010 mass spectrometer (Shimadzu, Japan) with a 
HP-5 MS column (Agilent Technologies) was used to detect and analyze metabolites. Acquired 
spectra were analyzed and integrated using GC-MS Solution software version 2.50 SU1 
(Shimadzu, Japan). Mass Isotopomer Distributions (MID) were calculated after spectra integration 
and corrected for natural isotope abundance. Nonstationary Metabolic Flux Analysis (MFA) was 
performed using the software package INCA (Young, 2014), which generates and simulates 
material balance equations based on a user-defined metabolic network structure and experimental 
datasets. At least 10 restarts with random initial values for the parameters (intracellular fluxes and 
pools) were performed to find a global optimum (Crown and Antoniewicz, 2013). The parameter 
continuation method was used to determinate the 95% confidence intervals for intracellular fluxes 
values (Antoniewicz et al., 2006). 
2.7.3. ATP production 
ATP production was estimated by multiplying the number of ATP molecules generated in 




2.8. Analysis of cell functionality 
hiPSC-CM-2D were dissociated to single cells, as described above (Section 2.2) and 
inoculated on Matrigel-coated Fluorodishes at 2,000-6,000 cells/cm
2
. Single contracting hiPSC-CM 
and hiPSC-CM clusters (<10 cells) cultured on PDMS substrates for 3-5 days were chosen for 
image acquisition. hiPSC-CM-3D were also plated on Matrigel-coated Fluorodishes at 10-20 
aggregates/dish and allowed to slightly adhere for 3 days. For calcium imaging, culture medium 
was supplemented with 0.5 mM of Fluo-4
AM
 (Life Technologies) 10 min prior to image acquiring. 






al., 2012). Contractile kinetics of hPSC-CMs were assessed using the method developed by 
(Kijlstra et al., 2015). 
2.9. Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad Software 
Inc.). Values are represented as mean±standard deviation of independent measurements or 
assays (at least n=3 replicates were considered). Statistical significance was evaluated using 
Student's t-test with values of p<0.05. 
 
3. Results 
3.1. Directed differentiation protocol induced the robust generation of pure 2D monolayers 
of CMs from multiple hPSC lines 
In this study, we used a directed cardiac differentiation protocol (Figure 3.1A) adapted from 
previous studies (Kattman et al., 2011; Lanier et al., 2012; Lian et al., 2013) that relies on the 
sequential addition of growth factors and small molecules to modulate Activin and Wnt/β-catenin-
signalling pathways involved in mesoderm formation and cardiac lineage development (Cao et al., 
2012; Kattman et al., 2011; Lian et al., 2012; Paige et al., 2010). By monitoring key markers along 
differentiation, we confirmed the recapitulation of the developmental steps of cardiovascular fate 
specification in both hESC and hiPSC lines (Figure 3.1B-3.1K). Pure CM monolayers were 
consistently obtained with typical gene (Figure 3.1L) and protein expression profiles (Figure 3.1K 
and A-3.1, Page 96), organized sarcomeric structures (Figure 3.1M-1N) and an average sarcomere 
length (1.53±0.18 μm) similar immature hiPSC-CMs (1.50±0.15 µm) (Gherghiceanu et al., 2011). 
Comparable CM purities were obtained with independent hiPSC and hESC lines, as assessed by 
the expression of CM-specific markers: VCAM-1 and SIRPA (Figure A-3.1, Page 96). Altogether 
these results demonstrate the efficiency and robustness of the protocol to differentiate hPSCs 









Figure 3.1. Direct differentiation of hPSCs towards cardiomyocytes in 2D monolayer cultures. A) 
Schematic representation of the differentiation process. The predominant cell population at each timepoint is 
demarked. Timepoints in which growth factors (GFs) and/or small molecules (SM) were added are also 
highlighted. Characterization of the differentiation process in terms of: gene expression by qRT-PCR (B, D, F, 
H, J) and protein expression by flow cytometry analyses (C, E, G, I, K) in both hiPSC - DF19-9-11T.H (blue) 
and hESC - H3-NKX2-5(eGFP/w) (grey) lines. L) qRT-PCR analysis of gene expression of cardiac-related 






15 in both hiPSC-CMs and hESC-CMs. Data are presented as mean ± SD of at least three measurements. M) 
Immunofluorescence analysis of hPSC-CMs at the end of the differentiation process (day 15) for the CM-
specific markers: sarcomeric α-actinin, cardiac troponin T (cTNT) and Titin (red). Nuclei were counterstained 
with Hoescht (blue). Scale bars: 50 μm. N) Transmission electron microscopy (TEM) images of hiPSC-CMs at 
day 15. Myofibrils (MF), Z-disks (Z), sarcomeric bands: A- and I-bands, intercalated disks (ID) connecting 
adjacent CM and mitochondria (M) are highlighted. Scale bars: 500 nm. 
3.2. Metabolic characterization during hPSC differentiation towards cardiomyocytes    
To characterize the metabolic modulations along CM differentiation we analyzed the changes 
of the main nutrients and metabolic by-products in the culture medium of hiPSCs (day 0) and of cell 
populations enriched in mesorderm (day 1; as verified by the rapid transient upregulation of 
brachyury T (Figure 3.1D and 3.1E)), cardiac mesoderm (day 3; as verified by the upregulation of 
the MESP1 and KDR markers (Figure 3.1F and 3.1G)), cardiac progenitors (day 6; as verified by 
the appearance of spontaneous contractile areas and increased expression of NKX2.5 and GATA4  
markers (Figure 3.1H-I)), and cardiomyocytes (day 15; (Figure 3.1J-L)). Our results show that 
glucose consumption (qGlc) and lactate production (qLac) rates (Figure 3.2A-B) do not change 
much along the 15-day differentiation process, and the ratio qLac/qGlc (Figure 3.2C) remains high 
(close to 1.5), indicating that the sequential cell populations maintain the highly glycolytic 
metabolism of the pluripotent cells. 
Nonetheless, significant differences were observed in amino acid metabolism (Figure 3.2A 
and 3.2B). Most amino acids (glutamine, cysteine, arginine, serine, leucine, isoleucine, histidine, 
asparagine, phenylalanine, methionine, lysine and valine) were taken up by all cell populations, 
however the consumptions were higher until day 3 of the differentiation. From cardiac mesoderm to 
cardiac committed cells there was a clear decrease in the consumption of those amino acids 
(Figure 3.2A). In accordance, consumption of both essential and non-essential amino acids was 
determined as significantly lower in hiPSC-CMs (day 15) when compared to hiPSCs (day 0) 
(Figure 3.2D). These results reflect the dynamic differentiation of cells within the first days until they 
become committed to the cardiac lineage, suggesting that hPSC-derived cardiac progenitors and 
hiPSC-CMs rely less on amino acid catabolism for energy production than undifferentiated or 
mesoderm committed cells. 
Secretion of alanine and proline (at lower rates) was observed for all differentiating cell 
populations; alanine is a glycolytic product with a crucial role in nitrogen detoxification and proline 
is important in collagen synthesis (Phang et al., 2015). Both amino acids were produced at higher 
rates by the population enriched in mesoderm cells (day 1). Interestingly, overall amino acid 
production was higher in hiPSC-CMs (day 15) than in hiPSCs (day 0) (Figure 3.2D).  
Glutamate was highly produced until cardiac mesoderm specification (day 3) and from this 
timepoint onwards became barely consumed (Figure 3.2A). Glutamate is an intermediary in the 
degradation of many amino acids, thus a decrease in glutamate secretion also suggests a 
reduction in amino acid catabolism at later differentiation stages, when the differentiating 
population is mainly composed by cardiac committed cells. Glycine was produced until day 1 
(mesoderm phase), from day 3 to day 6 was slightly consumed, and by the end of the 
differentiation process, at day 15, was again produced.  
 
 




Overall these results indicate that the generated hiPSC-CMs remain highly glycolytic but show 
significant differences in amino acid metabolism relatively to hiPSCs, including increased 
production of some amino acids and decreased consumption of others. 
 
 
Figure 3.2. Metabolic profiling of hiPSC during CM differentiation in 2D monolayers. A)  Heatmap image 
of specific rates of metabolite production (red) and consumption (blue) (qMET, expressed in nmol/(10
6
cell.h)) 
at specific time points of the differentiation process: day 0 (hiPSC- DF19-9-11T.H line); day 1 (mesoderm); 
day 3 (cardiac mesoderm); day 6 (cardiac progenitors); day 15 (hiPSC-CMs). B)  Specific rates of glucose 
consumption and lactate production in hiPSC (day 0) and hiPSC-CMs (day 15). C) Ratio of specific rates of 
lactate production and glucose consumption (YLAC/GLC). D) Specific consumption and production rates of 
amino acids in hiPSC (day 0) and hiPSC-CMs (day 15). Data are represented as mean±SD. *p<0.05; ns, not 
significant. 
3.3. Impact of 3D aggregate culture of cardiac progenitors on cardiomyocyte enrichment 
and commitment   
We then assessed the impact of culturing hPSC-derived cardiac progenitors as 3D aggregates 
on CM differentiation and enrichment using a hiPSC line (DF19-9-11T.H). Briefly, cells were 
harvested from 2D monolayer cultures and seeded into AggreWell
TM
 plates at day 6 of 
differentiation, when cell population was enriched in cardiac progenitors, as evidenced by the high 






stirred conditions to ensure an appropriate diffusion of nutrients and oxygen throughout the entire 
aggregate and were maintained for additional 8 days (until day 15) in these culture conditions 
(Figure 3.3A).  
As cell aggregate size has been shown to impact cardiac induction and differentiation 
efficiency (Bauwens et al., 2008, 2011; Chen et al., 2015; Guo et al., 2009) we used the same cell 
seeding density as previously reported (Nguyen et al., 2014). The aggregates generated presented 
high cell viability and an average size of 184±45 μm (Figure 3.3B-C). By day 15 the expression of 
CM-specific markers in cells cultured as 3D aggregates (designated hereafter as hiPSC-CM-3D) 
was detected by immunofluorescence analysis (Figure 3.3D) and compared by flow cytometry 
analysis with the expression observed in 2D monolayer cultures (designated hereafter as hiPSC-
CM-2D; Figure 3.3E). Our results indicate no significant differences in the percentage of cells 
positive for cTnT and SIRPA, whereas the expression of VCAM-1 was significantly higher in 
hiPSC-CM-3D (95.6±1.5) than in hiPSC-CM-2D (72.8±4.5; Figure 3.3E). 
Whole-transcriptome analysis revealed some differences at the expression level of genes 
related with cardiac development and specification (Figure 3.3F). In particular, several mesoderm 
and cardiac mesoderm genes were down-regulated in hiPSC-CM-3D comparing with hiPSC-CM-
2D, suggesting that hiPSC-CM-3D are in a more advanced cardiac developmental state at day 15. 
Additionally, the expression of several genes associated with CM specification and maturation was 
higher in cells cultured as 3D aggregates, including genes related with sarcomeric structure and 
cardiac muscle contraction (MYL2, MYOZ2, TCAP, MYL3, MYOM2, MYLK3 and MYH7B). The 
expression of VCAM-1 (in accordance with flow cytometry analysis), ADRB1 (β-adrenergic receptor 
highly expressed in CMs), and PPARGC1A (coactivator of PPARs and other nuclear receptors and 
master regulator of mitochondrial biogenesis in heart (Ventura-Clapier et al., 2008)), were also 
higher in hiPSC-CM-3D than in hiPSC-CM-2D. 
Interestingly, hiPSC-CM-3D showed down-regulation of atrial-like CM markers, namely NPPA 
encoding atrial natriuretic peptide and SLN encoding sarcolipin, and up-regulation of ventricular-
like CM markers MLC2V and IRX4 in relation to hiPSC-CM-2D (Figure 3.3F). Additionally, the 
higher expression of marker genes of smooth muscle cells (e.g. MYH11, SMTNL2 and ACTA1) 
and fibroblasts (i.e. COL1A1, S100A4, PDGFRA, POSTN, VIM, THY1) in 2D monolayer cultures 
(Figure 3.3F) indicate that these cultures contain a higher fraction of non‐CM. These results 
suggest that the aggregation of cardiac progenitors improves CM enrichment as well as CM 
differentiation and commitment into the ventricular CM subtype. 
 
 





Figure 3.3. Effect of 3D aggregate culture of cardiac progenitors on CM enrichment and commitment. 
A) Schematic representation of the two strategies used to culture cardiac progenitors. At day 6, cells were 
dissociated and replated either in 2D static tissue culture plates or in AggreWell
TM
 plates to force cell 
aggregation. Generated aggregates were cultured in shake flasks until day 15. B) Aggregate size of hiPSC-
CMs at day 15. C) Cell viability of hiPSC-CM aggregates assessed, at day 15, by fluorescein diacetate (FDA, 
live cells; green) and propidium iodide (PI, dead cells; red) dye. Scale bar:200 µm. D) Immunofluorescence 
analysis of hiPSC-CMs (from plated 3D aggregates) for Troponin T (cTnT, red). Nuclei were counterstained 
with Hoechst (blue). Scale bar:30 µm. E) Percentage of cells positive for the cardiac specific markers: SIRPA, 
VCAM-1 and cTnT determined at day 15 by flow cytometry, in 2D monolayer (hiPSC-CM-2D, dark blue) and 
3D aggregate (hiPSC-CM-3D, light blue) cultures. *p<0.05; ns, not significant. F) Heatmap depicting fold 
changes in the expression of genes associated with mesoderm, cardiac mesoderm, cardiomyocytes, smooth 
muscle cells and fibroblasts in hiPSC-CM-3D versus hiPSC-CM-2D at day 15. Descreased gene expression 
changes is represented in green while increased expression in red. 
3.4. Impact of 3D aggregate culture approach on hiPSC-CM functionality 
Fucntionality of both hiPSC-CM-2D and hiPSC-CM-3D was compared in terms of calcium 
signaling, contractility kinetics and beating rate (Figure 3.4). The results showed that hiPSC-CM-3D 
present calcium peaks with lower amplitude (Figure 3.4A-B), reduced time to peak and time to 50% 
decay (Figure 3.4C) and slower upstroke and decay velocities (Figure 3.4D) in comparison with 
hiPSC-CM-2D. However, the lower amplitude and velocity detected in hiPSC-CM-3D may be 
related with a less efficient diffusion of the dye throughout the entire plated aggregate and not 






generated hiPSC-CMs with well-defined and synchronous intracellular calcium transients with a 
shape and duration resembling those of fetal like CMs (Louch et al., 2015).  
Concerning cell contractility, no significant differences in fractional shortening were observed 
between conditions (Figure 3.4E-F), however hiPSC-CM-3D showed a 4-fold higher shortening 
velocity and a 3-fold higher relengthening velocity compared to hiPSC-CM-2D (Figure 3.4G), 
revealing that hiPSC-CM-3D present a faster contractility kinetics, consistent with the increased 
expression of genes encoding cardiac contractile proteins (Figure 3.3F). 
Spontaneous contractility was observed for nearly 100% of the hiPSC-CM aggregates. The 
beating rate was significantly lower in hiPSC-CM-3D (57.9±1.8 beats/min) than in hiPSC-CM-2D 
(69.5±3.3 beats/min) (Figure 3.4H), values within the range previously reported for hPSC-CMs (21–
84 beats/min) (Feric and Radisic, 2016). It has been reported that during heart development the 
spontaneous activity of CMs at  early embryonic stages is replaced by a quiescent cell phenotype 
(Feric and Radisic, 2016). The significant decrease in beating rate may suggest that hiPSC-CM-3D 
are in a more advanced developmental state than hiPSC-CM-2D, as suggested above. 
 
 
Figure 3.4. Impact of 3D aggregate culture of cardiac progenitors on hPSC-CM functionality. A)  hiPSC-
CM were analyzed in terms of calcium transients (A-D) and contractile performance (E-H) at the end of the 
differentiation process (d15) in hiPSC-CM-2D (dark blue) and hiPSC-CM-3D (light blue). Calcium transient 
kinetics (A-D) evaluated with the intracellular calcium indicator Fluo-4 AM: A) Representative calcium 
transient; B) Calcium transient amplitude (F/F0); C) Time to peak and time to 50% decay; D) Average 
upstroke and decay velocities. n=28-35 cells/aggregates per condition. E) Representative contraction curves, 
reflecting changes in the percentage of cell length. F) Percentage of shortening; G) Maximum shortening and 
relengthening velocities. n=20-35 cells/aggregates per condition. H) Boxplot depicting the beating rate of 
hiPSC-CMs. Whiskers: 10-90 percentile. Outliers are plotted as individual points. Data are represented as 








3.5. Impact of 3D culture approach on transcriptome profile of hiPSC-CMs 
Next, we compared global gene expression changes in hiPSC-CM-3D and hiPSC-CM-2D. 
Scatter plot analysis revealed that both hiPSC-CM-3D and hiPSC-CM-2D present a high degree of 
similarity in gene expression profiles (Figure 3.5A). A total of 928 genes were identified as 
differentially expressed (FC>|1.3| and p-value<0.05), in hiPSC-CM-3D compared to hiPSC-CM-2D, 
518 of which were down-regulated and 410 were up-regulated (Figure 3.5B). KEGG pathways 
enrichment analysis indicated that these genes were significantly enriched in pathways related 
with: i) metabolism or involved in metabolism regulation (i.e. HIF-1 signaling pathway, 
glycolysis/gluconeogenesis, PI3K-Akt signaling, carbon metabolism and biosynthesis of amino 
acids) and ii) cell-ECM interactions and cell adhesion (i.e. ECM-receptor interactions and focal 
adhesion pathways) (Figure 3.5C).  
Upstream regulator analysis of differentially expressed genes was also performed to identify 
possible regulators responsible for the observed changes in gene expression. This analysis 
identified among others, HIF1A, TGFB1, ERBB2, SYVN1, SMARCA4 and ERK as upstream 
transcriptional regulators in hiPSC-CM-3D (Figure 3.5D). The network showing the predicted 
interactions between regulators and their targets as well as the regulation direction (i.e. “activation” 
or “inhibition”) is illustrated in Figure 3.5D.  
Pathways and functions related with focal adhesion, extracellular matrix (ECM) remodeling 
and actin cytoskeleton reorganization were significantly enriched in hiPSC-CM-3D compared to 
hiPSC-CM-2D (Figure 3.5C) probably as a consequence of cell adaptation to a 3D culture. 
Specifically, IPA predicted inactivation of actin cytoskeleton signaling, regulation of actin-based 
motility by RhoA and Tec Kinase signaling, in hiPSC-CM-3D compared with hiPSC-CM-2D, and 
consequently inactivation of functions related with cell movement/adhesion/migration (Figure 3.5E-
F). Also, several genes encoding ECM proteins (e.g. collagen types I, IV, V, VI, XIII, laminin, 
lumican, decorin, fibulin), metallopeptidase (Timp1) and integrins (ITGB1BP1 and ITGA1) were 
down-regulated in hiPSC-CM-3D. This correlates with the reduced amount of fibroblasts in these 
cultures (supported by the reduced expression of fibroblast markers (Figure 3.3F), as fibroblasts 
and related myofibroblasts are the main producers of ECM and ECM-regulatory proteins (MMPs 
and TIMPs) in the heart (Fan et al., 2012; Ivey and Tallquist, 2016; Krenning et al., 2010). In 
accordance, both PDGF and TGFβ factors, known to induce the production of ECM proteins, 
MMPs and TIMPs by fibroblasts (Krenning et al., 2010; Souders et al., 2009; Takeda and Manabe, 
2011), were down-regulated in hiPSC-CM-3D when compared with hiPSC-CM-2D (Figure 3.3F and 
3.5D). The expression of integrins (ITGB1BP1 and ITGA1), cell surface receptors that mediate cell-
ECM interaction and adhesion, was also significantly lower in hiPSC-CM-3D when compared with 
hiPSC-CM-2D (Figure 3.5G). 









Figure 3.5. Comparison of the transcriptional profile of hiPSC-CMs obtained in both 2D monolayer and 
3D aggregate cultures. A) Scatter plot depicting differences in gene expression in hiPSC-CM-2D and hiPSC-
CM-3D. B) Volcano plot of gene expression changes. Genes up-regulated (FC≥1.3 and p-value<0.05) are 
highlighted in red and genes down-regulated (FC≤-1.3 and p-value<0.05) in green. The number of regulated 
genes according to these criteria is shown on the top of the graphic. C) KEGG pathways significantly enriched 
in up and down regulated genes. The modified Fisher Exact p-value determined for each pathway is shown. 
D) Upstream regulator analysis of differentially expressed genes. Validated gene targets of each 
transcriptional regulator and their direction of change are also shown. The regulators are colored by their 
predicted activation state: activated (orange) or inhibited (blue). Darker colors indicate higher absolute 
 
 




regulation Z-scores. The edges connecting the nodes are colored orange when leading to activation of the 
downstream node and blue when leading to its inhibition. E-F) Heatmaps highlighting the activation status of 
biological functions (E) and canonical pathways (F) predicted by IPA. Functions/pathways were considered 
significantly activated (or inhibited) with an overlap p-value ≤ 0.05 and an IPA activation Z-score ≥ |2.0|. Blue 
indicates negative Z-score (inhibited function). G) Heat map depicting the significant differentially expressed 
genes (fold change ≥ 1.3 and p-value < 0.05) encoding ECM proteins, metallopeptidases and integrins in 
hiPSC-CM-3D in relation to hiPSC-CM-2D.  
 
The down-regulation of fibulin family in hiPSC-CM-3D may be related with the fact that these 
proteins mainly contribute to the formation of distinct ECM during early developmental stages in 
several tissues, including cardiac ventricular morphogenesis, and in adult tissue is mainly 
expressed in the heart valves (Zhang et al., 1996). Lumican and decorin, the other ECM proteins 
less expressed in hiPSC-CM-3D, were previously reported to be increased in various inflammatory-
like conditions, presenting a role in heart failure development by modulating ECM rearrangement 
and collagen assembly (Engebretsen et al., 2013; Jahanyar et al., 2007). In agreement, several 
upstream regulators that were inhibited in hiPSC-CM-3D are involved in pro-survival and 
hypertrophic responses during cardiac diseases and heart failure: Syvn1, an important modulator 
of ischemic damage in heart is up-regulated by endoplasmic reticulum stress; SMARCA4, a 
chromatin-remodeling protein that in embryos, promotes CM proliferation and in adults is turned off 
or reactivated in hypertrophic cardiomyopathy (Hang et al., 2010); ERBB2, that promotes CM 
dedifferentiation and proliferation during heart regeneration (D’Uva et al., 2015); ERK1, that is 
activated by hypertrophic stimuli (Kehat and Molkentin, 2010); and TGFB-1, an important mediator 
of the hypertrophic growth response of the heart (Dobaczewski et al., 2011; Takeda and Manabe, 
2011).  
Hypoxia-inducible factor-1 alpha (HIF-1α), a member of HIF-1 signaling pathway, was 
predicted as an “inhibited” up-stream regulator in hiPSC-CM-3D, consequently resulting in the 
inhibition of several genes, including genes related with glycolysis and glucose metabolism (e.g. 
GAPDH and PKM; Figure 3.5D). HIF1α is a central transcriptional regulator, whose activation is 
prompted by hypoxic conditions (Prigione et al., 2014). Specifically, HIF1α promotes cellular 
adaptation to reduced oxygen availability by increasing glucose uptake and glycolysis, improving 
angiogenesis or enhancing cell proliferation and survival (Guimarães-Camboa et al., 2015). Down-
regulation of HIF1α in hiPSC-CM-3D in relation to hiPSC-CM-2D, may suggest that agitated 3D 
cultures systems ensures more uniform cell exposure to oxygen tension possibly favoring an 
increase of oxidative metabolism. 
3.6. Impact of 3D culture approach on hiPSC-CM metabolism 
We then sought to assess whether the 3D culture approach would affect the metabolic profile 
of the generated hiPSC-CMs.  
To compare the central carbon metabolism of hPSC-CMs obtained in both conditions we 
performed 
13
C-based metabolic flux analysis (
13
C-MFA). Intracellular fluxes were determined by 
integrating transmembrane fluxes with 
13
C labeling profiles of intracellular metabolites from [1,2-
13






fits were obtained for both conditions (Figure A-3.2 and Figure A-3.3, Page 97); estimated fluxes 
and intervals are providaded in Table A-3.1 (Page 98). The fluxome and metabolic transcriptome 
profiles of hiPSC-CM-3D and hiPSC-CM-2D were compared aiming to reveal the main differences 
in metabolic fluxes and to correlate them with the expression of metabolic enzymes (Figure 3.6 and 
3.7A).   
The flux maps clearly show that both hPSC-CM cultures exhibit high glycolytic fluxes, diverting 
most of the cytosolic pyruvate to lactate secretion (Figure 3.6), which is consistent with the 
measured extracellular rates (Figure A-3.4, Page 99). Although hiPSC-CM-3D showed relatively 
lower glycolytic fluxes, including a 10-15% reduction in glucose uptake and lactate production, 
when compared with hiPSC-CM-2D, no significant differences were determined (Figure 3.7B). The 
fluxes through pentose phosphate pathway (PPP) were higher in hiPSC-CM-3D, achieving values 
of 5.2 nmol/(10
6
cells.h), whereas in hiPSC-CM-2D these fluxes were negligible (Figure 3.6). 
Additionally, in hiPSC-CM-3D a higher amount of cytosolic pyruvate was transported to the 
mitochondria (22.5 vs 7.3 nmol/(10
6
cells.h) in hiPSC-CM-2D), and entered the TCA cycle, 
reflecting a slightly higher coupling of glycolysis and TCA cycle. Oxidative decarboxylation of 
pyruvate to acetyl-CoA increased by 45% and TCA cycle fluxes were significantly higher 
(approximately 54%, Figure 3.7C) in hiPSC-CM-3D comparatively to hiPSC-CM-2D, which again 
points towards increased glucose oxidation in hiPSC-CM-3D. In accordance, the expression of 
several glycolysis-annotated genes (i.e. ENO1; PGK1; GAPDH; PGAM1/4; PKM) significantly 
decreased while the expression of genes related with oxidative phosphorylation (e.g. ATP5, COX 
and NDUF family of genes) increased in hiPSC-CM-3D (Figure 3.7A). 
Remarkably, in both conditions the citrate produced in TCA cycle was mainly (45-47%) 
transported to the cytosol, generating Acetyl-CoA precursors that are typically used for lipid 
biosynthesis. Additionally, in both culture conditions the consumption of glutamine was very low 
emphasizing the neglected role of glutamine anaplerosis. A net flux of alpha-ketoglutarate towards 
glutamate was estimated, contributing to an increased carbon loss from TCA cycle. To compensate 
the absence of glutamine anaplerosis and high withdrawal of citrate, hiPSC-CM-3D cells used 
other sources to fuel the TCA cycle, namely the anaplerotic pyruvate carboxylation (PC) reaction 
and the catabolism of alternative amino acids, such as leucine, lysine, threonine, isoleucine and 
valine (all significantly lower in hiPSC-CM-2D, (Figure 3.6, Figure 3.7 D,E)). The symmetric 
entrance of pyruvate into the TCA cycle, by the activities of pyruvate dehydrogenase (PDH) 
producing Acetyl-CoA (10.2 nmol/(10
6
cells.h) and PC producing oxaloacetate (12.3 
nmol/(10
6
cells.h)) (Figure 3.6), and the activity through malic enzyme (ME) highlights the 
importance of pyruvate cycling in maintaining the balance of TCA cycle activity in hiPSC-CM-3D. 
Also, transcriptome profile revealed up-regulation of several genes related with amino acid 
metabolism (e.g. GOT1 and GPT) in hiPSC-CM-3D compared with hiPSC-CM-2D (Figure 3.7A) 
corroborating the idea that amino acid metabolism was more active in hiPSC-CM-3D.  
In hiPSC-CM-2D, pyruvate cycling through ME and PC was rather inactive (Figure 3.6) and 
the most relevant anaplerotic reaction detected was a net flux of malate formation from cytosolic 
oxaloacetate (Figure 3.6).  
 
 





Fig. 3.6. Metabolic flux map of the central carbon metabolism of both hiPSC-CM-2D and hiPSC-CM-3D 
at day 15. Fluxes estimated by non-stationary 
13
C-metabolic flux analysis (MFA) are shown for hiPSC-CM-2D 




ATP production was calculated taking into account the estimated fluxes and the number of 
ATP molecules produced during anaerobic glycolysis and complete oxidation of glucose in the TCA 
cycle (Boyle, 2005). The results show that ATP production was slightly higher in hiPSC-CM-3D 
(456 nmol/h) than in hiPSC-CM-2D (428 nmol/h) (Figure 3.7F) but in both cultures, anaerobic 
glycolysis assured most of the energetic requirements contributing to 68% and 78% of total 
produced ATP in hiPSC-CM-3D and hiPSC-CM-2D, respectively (Figure 3.7F). Nonetheless, the 
amount of ATP produced through glucose oxidation was 54% higher in hiPSC-CM-3D than in 
hiPSC-CM-2D, originating 32% of the total ATP produced in hiPS-CM-3D and just 22% in hiPSC-






Also, hiPSC-CM-3D showed up-regulation of both creatine kinase (CK) and adenylate kinase 
(AK) genes comparatively to hiPSC-CM-2D (Figure 3.7A). These enzymes perform several 
functions in cellular energy metabolism, including maintenance of ATP homeostasis and OXPHOS 
regulation (Schlattner et al., 2006). Impairment or ablation of CK has shown to lead to contractile 
dysfunction, decreased energy reserve and ultimately cardiomyopathy and/or hypertrophy 
(Nahrendorf et al., 2005; Spindler et al., 2003). Thus, this result also suggests that hiPSC-CM-3D 
cultures present improved energetics than hiPSC-CM-2D cultures. 
 
 
Figure 3.7. Comparison of central carbon metabolism and metabolic transcriptional profile in both 2D 
monolayers and 3D aggregates of hiPSC-CM. A) Heat map of differentially expressed genes associated 
with metabolic processes/pathways in hiPSC-CM-3D compared to hiPSC-CM-2D. Genes were considered 
enriched based on a p-value < 0.05 and a FC ≥ |1.3|. Up-regulated and down-regulated genes are demarked 
in red and green, respectively. B-E) Mean fluxes and respective SD estimated for the following metabolic 
pathways: glycolysis (C); TCA cycle (D); amino acid consumption (E) and amino acid metabolism involved in 
TCA cycle anaplerosis (F). Data are represented as mean±SD. **p<0.01; ***p<0.001; ns, not significant. F) 
Total amount of ATP produced in hiPSC-CM-2D and hiPSC-CM-3D taking into account estimated fluxes and 
the reference amount of ATP produced per glucose molecule in anaerobic glycolysis and glucose oxidation. 
The contribution of both metabolic pathways for the estimated ATP production is indicated. 
 
4. Discussion 
In this study we applied a directed cardiac differentiation protocol adapted from previous 
reports (Kattman et al., 2011; Lanier et al., 2012; Lian et al., 2013) that allows the production of 
pure populations of hPSC-CMs as standard 2D monolayers and as 3D aggregates when promoting 
the aggregation of cardiac progenitor cells, and we compared the transcriptome and fluxome of 
hiPSC-CMs obtained in both culture systems. Specifically, we demonstrated that the aggregation 
of hPSC-derived cardiac progenitors induces: i) CM enrichment and commitment; ii) significant 
alterations in the expression of genes related with cell-ECM interactions, cell adhesion, cell 
metabolism and metabolism regulation; iii) changes in central carbon metabolism, including 
 
 




reduction of glucose consumption, increased oxidative decarboxylation of pyruvate, TCA cycle 
activity and amino acid metabolism when compared with hiPSC-CM-2D. 
Even though the differentiation in standard 2D conditions robustly generated monolayers of 
hPSC-CMs that presented typical CM markers and functionality, promoting aggregation of hPSC-
derived cardiac committed cells further improved CM differentiation, CM commitment towards 
ventricular-like subtype, and functionality as proved by: i) down-regulation of genes expressed in 
mesoderm, cardiac mesoderm, atrial-like CMs, smooth muscle and fibroblasts, ii) up-regulation of 
CM-specific genes, including genes encoding contractile proteins and proteins restricted to (IRX4) 
(Nelson et al., 2014, 2016) or strongly expressed in the ventricular myocardium (MLC2v) (O’Brien 
et al., 1993), and iii) faster contractility kinetics, when compared with 2D monolayer cultures. 
Previous studies have shown that addition of IWR-1 enhances differentiation of cardiac progenitors 
into ventricular-like CMs (Karakikes et al., 2014). Our results suggest that aggregation of cardiac 
progenitors and further differentiation as 3D aggregates may also favour CM specification into 
ventricular-like CM subtype. Further electrophysiological studies should be performed to validate 
this hypothesis. 
Although several efforts have been made towards moving cardiac differentiation protocols 
from 2D monolayer to 3D aggregate cultures to facilitate large-scale CM production (Chen et al., 
2012, 2015; Dahlmann et al., 2013; Kempf et al., 2014, 2015), adherent cultures typically yield 
higher differentiation efficiency (i.e. CM purity) and reproducibility (Kempf et al., 2016; Zhang et al., 
2015). Most likely because several critical process parameters need to be thoroughly optimized to 
successfully establish an effective 3D aggregate-based differentiation protocol, including cell 
aggregate size, agitation rate, small molecule concentrations and induction timing (Chen et al., 
2015). Also, the extensive cell death inherent to directed differentiation processes may result in 
aggregate disintegration or in accumulation of apoptotic/necrotic cells in the aggregate core, which 
may affect the development of neighbouring cells. Here, we overcome these issues by promoting 
cell aggregation when the differentiating population is mainly composed by cardiac committed 
cells. 
In the last decade, cell aggregation has been used as a tool to select specific subpopulations 
of differentiated cells to create homotypic spheroids (Bauwens et al., 2008; Dahlmann et al., 2013; 
Nguyen et al., 2014; Niebruegge et al., 2008; Ungrin et al., 2008). This enrichment may be justified 
because aggregation of specific cell types is directly related to the cells’ adhesion protein profile 
mediated by the collective ensemble of specific cell surface receptors. Based on this principle, cells 
with analogous surface proteins will adhere easier and faster (Hookway et al., 2015). Nguyen and 
colleagues confirmed this hypothesis by demonstrating that forced aggregation and 3D suspension 
culture is capable of enriching hPSC-CMs from heterogeneous differentiated cultures containing 
only 10%–40% hPSC-CMs (Nguyen et al., 2014). Also, this and other studies using primary CM 
cultures (Akins et al., 2010; Soares et al., 2012) showed that 3D aggregate cultures, due to their 
ability to better mimicking the in vivo environment, enhance structural and functional maturation of 
CMs compared with parallel 2D cultures. Herein, we showed the benefits of a 3D culture 






cultures into CM committed cells ameliorates differentiation and commitment and possibly CM 
maturation, contributing to reduced differentiation/maturation time. In further investigations, it will 
be interesting to increase culture time to more accurately evaluate the impact of 3D aggregate 
strategy on the induction of maturation features in hPSC-CMs. 
Jha and colleagues reported that combining a 3D culture of cardiac progenitors (obtained at 
day 4/5 differentiation) with a 3-day culture period of simulated microgravity using a random 
positioning machine results in the production of highly enriched CM cultures with high viability and 
typical functional properties after 20 days (Jha et al., 2016). In this study, we report similar results 
without a period of simulated microgravity and explored much further the impact of a 3D culture on 
the phenotype of the produced hPSC-CMs by providing a comprehensive and quantitative 
molecular and metabolic comparison between these cells and those generated in parallel 2D 
monolayer cultures. 
Integrated -omics analysis revealed that cell culture configuration induces considerable 
alterations in cell’s transcriptome and fluxome. The most significant differences at the 
transcriptome level in hiPSC-CM-3D in relation to hiPSC-CM-2D are the down-regulation of 
canonical pathways involved in cell adhesion, biological functions related with cell movement and 
chemotaxis, and expression of genes encoding for ECM proteins and integrins. The decreased 
expression of genes that encode ECM proteins may also reflect an increased CM purity in hiPSC-
CM-3D, since cardiac fibroblasts are the cell type that produce and secret the majority of the ECM 
that supports the myocardium (Krenning et al., 2010). Other studies performed with cancer cell 
lines also support these observations showing that 3D cultures often display different gene 
expression profiles, especially genes that play a role in proliferation, angiogenesis, migration, 
invasion and chemosensitivity, when comparing with 2D cultures (reviewed in (Edmondson et al., 
2014)). Recently, Fridley and colleagues showed that hydrodynamic forces that cells are exposed 
to in 3D cultures can alter the expression patterns of both ECM and GFs of differentiating PSC in 
multicellular aggregates (Fridley et al., 2014).  
Additionally, we showed that cell metabolism is slightly altered in 3D aggregate cultures. 
Upstream regulator analysis predicted that HIF-1α constitutes an inhibited transcriptional regulator 
in hiPSC-CM-3D, leading to down-regulation of a cascade of genes, including glycolytic genes. In 
later stages of cardiac development, HIF-1α has been shown to act as an inhibitor in the transition 
from fetal to adult CM phenotype (Ahuja et al., 2007), thus the HIF-1α repression observed in 
hiPSC-CM-3D may again indicate that this culture is in an advanced stage of development. 
Several studies have reported changes in energy metabolism during hPSC differentiation (la 
et al., 2011). Specifically, cell differentiation has been associated with increased mitochondrial 
content and activity and with a transition from a predominant glycolysis-based metabolism in PSCs 
towards an increased OXPHOS-based metabolism in differentiated cells (Wanet et al., 2015). 
Here, we clearly show that hiPSC-CMs obtained in both 2D monolayers and 3D aggregates remain 
highly glycolytic, presenting a metabolic phenotype largely driven by high glucose consumption and 
lactate production at near stoichiometric levels. This scenario suggests that hiPSC differentiation 
towards CMs proceeds without a metabolic shift from glycolytic to oxidative state. This lead us to 
 
 




speculate that such metabolic shift could be important in a late developmental state, probably to 
promote the transition from fetal to mature hPSC-CMs. Nonetheless, it should be noted that hiPSC-
CM-3D showed down-regulation of several glycolytic genes, up-regulation of OXPHOS genes, 
increased oxidative decarboxylation of pyruvate to acetyl-CoA and TCA-cycle activity, and higher 
ATP production through glucose oxidation, when compared with hiPSC-CM-2D. These results 
indicate a slightly improved oxidative metabolism in aggregate cultures.  
Importantly, we showed that amino acid metabolism significantly decreased throughout the 
differentiation process, suggesting that hPSC-derived cardiac progenitors and CMs rely less on 
amino acid catabolism for energy production than undifferentiated or mesoderm committed cells. It 
has been widely reported that hiPSCs are highly dependent on amino acid metabolism (Lopaschuk 
and Jaswal, 2010), either to feed TCA cycle or to modulate epigenetic processes that are critical to 
maintain pluripotency and/or induce differentiation (Harvey et al., 2016). Methionine metabolism, 
for example, is crucial for the production of S-adenosylmethionine that is the methyl donor for 
histone and DNA methylation and is required for maintenance of hPSCs self-renewal and 
undifferentiated state (Shiraki et al., 2014). Methionine, leucine and lysine were shown to be 
necessary for hPSC proliferation and their absence from the culture medium has been shown to 
induce G1 cell cycle arrest and eventually apoptosis (Kilberg et al., 2016). 
hiPSC-CM-3D showed higher amino acid metabolism that contributed to TCA cycle 
anaplerosis than hiPSC-CM-2D. Surprisingly, fluxome analysis revealed that in both hiPSC-CM-2D 
and hiPSC-CM-3D, glutamine consumption was very low and was mainly channelled to proline 
formation, probably to contribute for collagen synthesis (Phang et al., 2015) instead of supporting 
TCA cycle anaplerosis. Also, in both culture conditions a considerable outflow of citrate from TCA 
cycle to cytoplasm for fatty acid biosynthesis was observed. In hiPSC-CM-3D, this loss of carbon 
from TCA cycle was compensated by an increased catabolism of amino acids, producing Acetyl-
CoA and relevant TCA cycle intermediates, and by pyruvate cycling via the activity of ME and PC. 
These anaplerotic reactions contributed to increase TCA cycle activity in hiPSC-CM-3D. 
Recently, lipid deficiency in culture medium has been shown to induce the increase of PPP 
and fatty acid synthesis whereas lipid supplementation mitigates these metabolic pathways and 
increases oxidative metabolism (Zhang, 2016). In fact, the concentration of fatty acids present in 
the culture medium used in this study (RPMI+B27) is in the μM range, which might partly justify the 
high fluxes through PPP and fatty acid biosynthesis.  
Fatty acid β-oxidation is the major source of energy in adult CMs in vivo (Lopaschuk and 
Jaswal, 2010) and the average concentration of free fatty acids in human plasma is within the 
range of 0.2–0.4 mM (Lopaschuk and Jaswal, 2010), much higher than the concentration of fatty 
acids in RPMI+B27 medium. Additionally, the concentration of glucose in RPMI+B27 (11 mM) 
exceeds the concentration of glucose in blood of healthy adults (approximately 5.5 mM) (Ceriello et 
al., 2008). Thus, improvements in hPSC-CM differentiation and maturation protocols in the future 
will probably pass by medium design strategies to optimize the concentrations of glucose, fatty 
acids and amino acids in culture medium to better mimic the in vivo carbon substrate usage in fetal 






Overall the cardiac differentiation strategy reported herein provides novel insights for scaling 
up the production of hPSC-CMs. Specifically it enabled the efficient generation of pure 3D 
aggregates of hPSC-CMs suitable to use directly in high-throughput in vitro assays for drug 
discovery or in in vivo cell therapy applications, overcoming the challenges of low rates of cell 
retention following transplantation of single cells (Günter et al., 2016). Using an integrated 
experimental and computational systems biology approach, this study provides a more 
comprehensive picture of CM differentiation as 2D monolayers and 3D aggregates as well as a 
useful baseline for investigating and assessing hPSC-CM metabolism during differentiation 







Figure A-3.1. Comparison of CM purity obtained after directed differentiation of 2D monolayers of 
hiPSC and hESCs. Percentage of cells positive for the cardiac specific markers: SIRPA and VCAM 
determined by flow cytometry, at day 15, in 2D monolayer of hiPSC-CM (dark blue) and hESC-CM (grey) 











Figure A-3.2. Experimental and simulated intracellular 
13
C-labelling dynamics in hiPSC-CM-2D using 
[1,2-
13
C]GLC. Circle markers correspond to GC-MS measurements corrected for natural isotope abundance. 
Lines correspond to fitted MIDs from nonstationary 
13
C-MFA flux estimation of labelling experiments. 
 
 
Figure A-3.3. Experimental and simulated intracellular 
13
C-labelling dynamics in hiPSC-CM-3D using 
[1,2-
13
C]GLC. Circle markers correspond to GC-MS measurements corrected for natural isotope abundance. 
Lines correspond to fitted MIDs from nonstationary 
13






Table A-3.1. Metabolic network reactions and simulated fluxes determined by nonstationary 
13
C-MFA. 
Estimated flux values are shown in units of nmol/(10
6
cell.h). Negative flux values indicate that net direction is 
reverse to the direction indicated.  
  hiPSC-CM-2D hiPSC-CM-3D 
v1 G6P <-> F6P 166.63 144.61 
v2 F6P -> FBP 166.63 154.92 
v3 FBP <-> DHAP + GAP 166.63 154.92 
v4 DHAP <-> GAP 166.63 154.92 
v5 GAP <-> 3PG 333.27 315.00 
v6 3PG <-> PEP 321.60 314.15 
v7 PEP -> Pyr.c 321.60 314.15 
v8 Pyr.c <-> Pyr.m 7.30 22.51 
v9 G6P -> P5P + CO2 0.00 15.47 
v10 P5P + P5P <-> GAP + S7P 0.00 5.16 
v11 S7P + GAP <-> E4P + F6P 0.00 5.16 
v12 E4P + P5P <-> GAP + F6P 0.00 5.16 
v13 Pyr.c <-> Lac 318.06 292.18 
v14 Pyr.c <-> Ala 8.18 8.23 
v15 Pyr.m -> AcCoA.m + CO2 7.00 10.21 
v16 OAA.m + AcCoA.m -> Cit.m 9.49 16.33 
v17 Cit.m <-> AKG + CO2 5.18 8.68 
v18 AKG -> SucCoA + CO2 4.73 8.09 
v19 SucCoA <-> Suc 4.73 8.09 
v20 Suc <-> Fum.m 4.73 10.35 
v21 Fum.m <-> Mal.m 4.76 10.35 
v22 Mal.m <-> OAA.m 9.18 4.03 
v23 Mal.c -> Pyr.c + CO2 0.10 6.32 
v24 Pyr.m + CO2 -> OAA.m 0.30 12.30 
v25 Gln <-> Glu 0.00 0.37 
v26 AKG <-> Glu 0.45 0.59 
v27 Asn <-> Asp 0.09 0.79 
v28 3PG -> Ser 11.66 0.84 
v29 Ser -> Pyr.c 11.84 2.45 
v30 Ser <-> Gly + C1 -0.01 -0.15 
v31 Glu <-> Pro 1.64 1.45 
v32 Val + CO2 -> Suc + CO2 + CO2 0.00 0.62 
v33 Ile + CO2 -> Suc + AcCoA.m + CO2 0.00 1.58 
v34 Leu + CO2 -> AcCoA.m + AcCoA.m + AcCoA.m + CO2 0.80 0.24 
v35 Thr -> AcCoA.m + Gly 0.00 2.72 
v36 Phe -> Tyr 0.03 0.00 
v37 Tyr -> Fum.m + AcCoA.m + AcCoA.m + CO2 0.03 0.00 
v38 Met + Ser + CO2 -> Suc + Cys.snk + CO2 + C1 0.00 0.06 
v39 Lys -> CO2 + CO2 + AcCoA.m + AcCoA.m 0.01 0.56 
v40 His -> Glu + C1 0.01 0.09 
v41 Arg -> Glu + Urea.snk 1.15 0.00 
v42 Glu + CO2 -> Arg 0.03 0.00 
v43 Glc.ext -> G6P 166.63 160.08 
v44 Lac.ext <-> Lac -318.06 -292.18 
v45 Ala.ext <-> Ala -8.18 -8.23 
v46 Gln.ext -> Gln 0.00 0.37 
v47 Glu.ext <-> Glu 0.06 0.40 
v48 Ser.ext <-> Ser 0.17 1.52 
v49 Gly.ext <-> Gly 0.01 -2.57 
v50 Pro.ext <-> Pro -1.64 -1.45 
v51 Val.ext -> Val 0.00 0.62 
v52 Ile.ext -> Ile 0.00 1.58 
v53 Leu.ext -> Leu 0.80 0.24 
v54 Thr.ext -> Thr 0.00 2.72 
v55 Phe.ext -> Phe 0.03 0.00 
v56 Tyr.ext -> Tyr 0.00 0.00 
v57 Met.ext -> Met 0.00 0.06 
v58 Lys.ext -> Lys 0.01 0.56 
v59 His.ext -> His 0.01 0.09 
v60 Arg.ext <-> Arg 1.11 0.00 
v61 Asp <-> OAA.c 0.22 -7.66 
v62 Cit.c -> OAA.c + AcCoA.c 4.31 7.66 
 
 




v63 CO2.ext <-> CO2 -16.71 -38.19 
v64 AcCoA.c -> FA.ext 4.31 7.66 
v65 Cit.c -> Cit.snk 0.00 0.00 
v66 Mal.m <-> Mal.c -4.43 6.32 
v67 0*Mal.c -> Mal.s 0.00 0.00 
v68 0*Mal.m -> Mal.s 100.00 100.00 
v69 Mal.s -> Sink 100.00 100.00 
v70 0*Fum.c -> Fum.s 45.60 0.00 
v71 0*Fum.m -> Fum.s 54.40 100.00 
v72 Fum.s -> Sink 100.00 100.00 
v73 Mal.c <-> Fum.c 0.00 0.00 
v74 OAA.c <-> Mal.c 4.52 0.00 
v75 Asp.ext <-> Asp 0.13 -8.44 
v76 0*Cit.c -> Cit.s 0.00 100.00 
v77 0*Cit.m -> Cit.s 100.00 0.00 
v78 Cit.s -> Sink 100.00 100.00 
v79 Cit.c <-> Cit.m -4.31 -7.66 
v80 Asn.ext -> Asn 0.09 0.79 
 
 
Figure A-3.4. Metabolic profiling of hiPSC-CMs in both 2D monolayers and 3D aggregates. A)  Heatmap 
image of specific rates of metabolite production (red) and consumption (blue) (qMET, expressed in 
nmol/(10
6
cell.h)) at day 15 in 2D monolayers and 3D aggregates of hiPSC-CMs, respectively designated by 
hiPSC-CM-2D (dark blue) and hiPSC-CM-3D (light blue). B)  Specific rates of glucose consumption and 
lactate production. C) Ratio of specific rates of lactate production and glucose consumption (YLAC/GLC). 
Data are represented as mean±SD. ns, not significant. 
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The immature phenotype of human pluripotent stem cell derived cardiomyocytes (hPSC-CMs) 
constrains their potential in cell therapy and drug testing. In this study, we assessed if mimicking 
substrate usage during in vivo cardiac development induces in vitro hPSC-CM maturation. We 
report that shifting hPSC-CMs from glucose-containing to galactose- and fatty acid- containing 
medium promotes their fast maturation into adult-like CMs with higher oxidative metabolism, 
transcriptional signatures closer to those of adult ventricular tissue, and higher myofibril density and 
alignment. Comprehensive physiological characterization further demonstrated improved calcium 
handling, enhanced contractility, and more physiological action potential kinetics within 20 days in 
galactose- and fatty acid-containing medium. Integrated “-omics” analyses showed that addition of 
galactose to culture medium improves total oxidative capacity of the cells, ameliorates fatty acid 
oxidation avoiding the lipotoxicity that results from cell exposure to high fatty acid levels. This study 
provides an important link between substrate utilization and functional maturation of hPSC-CMs 
and facilitates the application of this promising cell type to clinical and preclinical applications. 
 




In the last decade remarkable progress has been made towards the establishment of 
protocols to direct the differentiation of human pluripotent stem cells (hPSC, including hiPSC and 
hESC) into cardiomyocytes (hPSC-CMs) (Denning et al., 2015). However, hPSC-CMs are often 
immature, showing metabolic, structural and functional characteristics that more closely resemble 
fetal CMs rather than adult CMs (Feric and Radisic, 2016). hPSC-CMs commonly display 
disarrayed sarcomeres, irregular shapes, underdeveloped mitochondria and use glucose (Glc) as 
major energy source, contrasting with adult CMs which present organized sarcomere structures, 
rod-shaped morphologies, well-developed mitochondria with mature lamellar cristae and rely on 
fatty acid (FA) β-oxidation for energy production (Feric and Radisic, 2016; Yang et al., 2014a). 
Although some efforts have been made recently towards the development of methods for 
enhancing hPSC-CM maturity (by increasing time in culture (Lundy et al., 2013), applying 
mechanical and electrical stimulation (Chan et al., 2013; Mihic et al., 2014; Ruan et al., 2016), 
adding chemicals or small molecules (Yang et al., 2014b), adjusting substrate stiffness (Hazeltine 
et al., 2012) or using genetic approaches (Lieu et al., 2013; Liu et al., 2009)) the outcomes have 
been variable. The use of distinct sets of analyses for CM maturation profile characterization has 
also limited the direct comparison between different studies.  
CM maturation in vivo has been associated with a transition from an embryonic-like glycolytic 
to an adult-like oxidative metabolism (Lopaschuk and Jaswal, 2010). In a normal heart, 70% of 
ATP generation comes from FA oxidation, whereas Glc, Lactate (Lac) and pyruvate (Pyr) provide 
only 30% of the energy produced (Lionetti et al., 2011). It has been shown that hPSC-CMs that are 
metabolically dependent on FA β-oxidation, in vitro, recapitulate cellular activities of more mature 
CMs, constituting a reliable model to study late onset disorders (Drawnel et al., 2014). Wen and 
colleagues were able to unveil the pathological phenotype associated with arrhythmogenic right 
ventricular dysplasia after inducing metabolic maturation in hiPSC-CMs (Wen et al., 2015). The 
authors used a combination of insulin, dexamethasone and 3-isobutyl-1-methil-xanthine to increase 
FA synthesis and trigger the activation of PPARα, which led to enhanced mitochondrial oxidative 
phosphorylation. Although the use of medium additives was proved to induce hiPSC-CM 
bioenergetics switching, the impact of key medium substrates on modulating hPSC-CM metabolism 
and maturation profile still need to be investigated.  
In this study, we hypothesised that manipulating the composition of the hiPSC-CM culture 
medium to mimic the metabolic substrate usage by human adult CMs in vivo would promote 
hiPSC-CM maturation in vitro. We selected multiple conditions based on the fact that during 
cardiac development CMs start to use first Lac and then FA as major sources of energy 
(Lopaschuk and Jaswal, 2010). Specifically, we tested to culture hiPSC-CMs for 20 days in Glc 
depleted medium supplemented either with: i) FA (FAM), ii) Galactose (Gal) and FA (GFAM) or iii) 
Lac during the first 10 days and then with Gal and FA for the remaining period (LACM&GFAM), 
using standard Glc-rich hiPSC-CM maintenance medium (GLCM) as reference (Figure 4.1A). 
GFAM revealed to be the best feeding strategy to culture hiPSC-CMs, significantly improving 
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several structural and functional maturation markers. By integrating transcriptome, metabolome 
and fluxome profiling, we provide a comprehensive molecular basis and a quantitative dissection of 
hiPSC-CM phenotypes observed during culture in different media.  
 
2. Methods 
2.1. hiPSC maintenance and differentiation to CMs   
In this study the hiPSC line DF19-9-11T.H from WiCell was used. hiPSCs were cultured on 
Matrigel® (Corning) or on fully defined Synthemax II-SC (Corning) coated plates in mTESR1 
medium (STEMCELL Technologies) until reaching 80%-90% confluency. Differentiation to CM  was 
performed as described previously (Correia et al., 2016). Briefly, we used a directed differentiation 
protocol that involves the use of RPMI+B27 medium and serial application of Activin A, 
CHIR99021, Ascorbic Acid and IWR1 in 2D monolayer culture conditions. After 15 days of 
differentiation, cell preparations containing >80% cardiac troponin T-positive CM (confirmed by flow 
cytometry) were obtained. 
2.2. hiPSC-CM culture 
After differentiation, hiPSC-CMs were cultured for 20 days in four different culture media as 
indicated in Figure 4.1A: GLCM: standard hiPSC-CM medium (RPMI+B27); FAM: RPMI without 
Glc supplemented with B27, 1mM glutamine (Gln), 100µM oleic acid (OA), 50µM palmitic acid 
(PA); GFAM: RPMI without Glc supplemented with B27, 1mM Gln, 10mM galactose (Gal), 100µM 
OA and 50µM PA; and LACM&GFAM: 10 days in RPMI without Glc supplemented with B27, 1mM 
Gln and 4mM sodium L-Lactate (Sigma-Aldrich) and 10 days in GFAM. At days 10 (d10) and 20 
(d20), hiPSC-CMs were harvested for metabolic, transcriptomic, structural and functional analysis. 
2.3. Metabolic and fluxomic analysis 
2.3.1. Metabolite analysis 
Glutamine (Gln), glutamate (Glu), glucose (Glc) and lactate (Lac) concentrations from cell 
culture supernatants were measured using YSI 7100MBS (YSI Incorporated, USA).  Ammonia was 
quantified with an enzymatic assay kit (NZYTech, Portugal). Amino acid concentration was 
determined by HPLC using the Waters AcQ.Tag Amino Acid Analysis Method (Waters, Milford, 
MA), as described elsewhere (Carinhas et al., 2010). The specific metabolic rates (qMet, 
expressed in nmol/(10
6
cell.h)) were calculated using the equation: qMet = ΔMet/(Δt  Xv), where 
ΔMet (mol/L) is the variation of metabolite concentration during the time period Δt (h), and Xv 
(cell/L) the average of cell concentration during the same time period. 
2.3.2. Measurement of Oxygen Consumption Rate and Extracellular Acidification Rate  
OXPHOS and glycolysis in hiPSC-CMs were estimated by measuring oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) in real-time using an XF-96 Extracellular 
Flux Analyzer (Seahorse Biosciences) according to the manufacturer’s protocols.  
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2.3.3. Isotopic tracer experiments and GC-MS analysis 













C]Palmitic Acid (from Sigma-Aldrich). Only one isotopic 
tracer was used at a time to allow monitoring of the incorporation of each tracer. Label 
incorporation was characterized 24 and 48h after label addition. Metabolic quenching, metabolite 
extraction and derivatization protocols were performed as described in the literature (Carinhas et 
al., 2016, 2017). 
Metabolites were analyzed in a QP2010 mass spectrometer (Shimadzu, Japan) in the EI 
mode (70eV) with a HP-5 MS column (Agilent Technologies). The obtained spectra were analyzed 
and integrated using GC-MS Solution software version 2.50 SU1 (Shimadzu, Japan). Mass 
Isotopomer Distributions (MID) were calculated after spectra integration and corrected for natural 
isotope abundance. The percentage of incorporation of each substrate in the TCA cycle was 
determined as the percentage of incorporation of each labelled substrate in TCA metabolites 
(citrate, fumarate and malate) normalized by the total incorporation provided by the main 
substrates present in the media in the same metabolites. 
2.3.4. Metabolic network and nonstationary 13C-MFA 
Nonstationary 
13
C-MFA of parallel labelling experiments was performed using the software 
package INCA (Young, 2014), which automatically generates and simulates material balance 
equations from a user-defined metabolic network structure and experimental datasets. At least 10 
restarts with random initial values for the parameters (intracellular fluxes and pools) were 
performed to find a global optimum. At convergence, the goodness-of-fit of the obtained solution 
was evaluated with a qui-square statistical test. The parameter continuation method
 
was used to 
calculate 95% confidence intervals of the estimated fluxes (Antoniewicz et al., 2006). 
2.3.5. ATP production 
ATP production was estimated using the reference value of ATP generated in glycolysis, TCA 




2.4. Transcriptomic analysis 
2.4.1. RNA Extraction, Amplification, Labeling, and BeadChip Hybridization of RNA Samples 
Total RNA from hiPSC-CMs was extracted using the RNeasy Mini Kit (Qiagen). RNA quality 
was characterized by the quotient of the 28S to 18S ribosomal RNA electropherogram peak using 
an Agilent 2100 bioanalyzer and the RNA Nano Chip (Agilent). Transcriptional profiling was 
assessed using Illumina HumanHT-12 v4 Expression BeadChip microarray technology (Illumina) 
and data were processed and normalized as described in (Silva et al., 2015). Genes differentially 
expressed/enriched were identified using Student’s t test (p value <0.01) and fold change FC≥|1.3|. 
2D-Principal component analysis (2D-PCA), Pearson correlation matrixes and density plots were 
generated using R version 3.3.2. Kolmogorov-Smirnov test was used to calculate pvalues. Pathway 
analysis was performed using Ingenuity Pathway Analysis (Ingenuity Systems; Qiagen). For GO 
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term analysis, GO term database (http://geneontology.org/) was used. Human left and right 
ventricular RNA samples, from a commercial supplier (Biocat #R1234138‐50‐BC and #R1234139‐
50‐BC, respectively), were included in the analysis as positive control. 
2.5. Characterization of hiPSC-CMs   
2.5.1. Cell concentration and viability 
Cell concentration and viability were determined by cell counting in a Fuchs–Rosenthal 
haemocytometer (Brand, Wertheim, Germany) using the trypan blue (Sigma-Aldrich) exclusion 
method (0.1% (v/v) in DPBS). 
2.5.2. Transmission electron microscopy (TEM) 
Monolayers of human hiPSC-CMs were fixed in 2% (v/v) glutaraldehyde in 0.1 M HEPES 
buffer (pH 7.4) for 20 min, washed in DPBS and stored in 1% (v/v) glutaraldehyde in DPBS until 
analyses. Samples were washed, contrasted, dehydrated, infiltrated, embedded, cured, dissected 
into small blocks and mounted on epon dummy blocks, as previously described (Correia et al., 
2016). Ultrathin sections of cell monolayers were cut on a Leica UC6 ultramicrotome using a 
diamond knife. Sections were collected on formvar-coated slot grids, stained with lead citrate and 
uranyl acetate as described in the literature (Venable and Coggeshall, 1965), and analyzed on a 
FEI Morgagni 268 at 80 kV. Images were taken with an Olympus MegaView III using the iTEM 
software. 
2.5.3. Sarcomere Alignment 
Sarcomere alignment was determined as previously described (Ruan et al., 2016). Briefly, 
alignment is defined by the inverse of the magnitude of angle dispersion (the standard deviation of 
angles of sarcomere edges measured in ImageJ software (National Institutes of Health)). Low 
angle dispersion indicates high degree of alignment. Rose plot was generated using Mathematica 
(Wolfram Research Inc.). 
2.5.4. Immunofluorescence microscopy 
Cells were washed with DPBS and fixed in 4% (w/v) Paraformaldehyde (PFA) in DPBS 
solution for 15 min. After being permeabilized and blocked with 5% (v/v) FBS, 1% (w/v) BSA, 0.3% 
(v/v) Triton X-100 in DPBS for 1h, at room temperature (20-25°C), cells were incubated with 
primary antibodies diluted in 1% (w/v) BSA, 0.1% (w/v) TX-100 in PBS overnight at 4°C. The 
following primary antibodies were used: α-sarcomeric actinin (1:200, Sigma-Aldrich), titin (1:100, 
Santa Cruz Biotechnology) and troponin I (1:100, Millipore). Afterwards, cells were washed in 
DPBS and incubated with secondary antibody, Alexa Fluor 594 goat anti-mouse IgG (1:500, 
Invitrogen), in the dark for 1h at room temperature (20-25°C). Cell nuclei were counterstained with 
Hoechst 33342 nucleic acid dye (1:1000, Thermo Scientific). Representative images were taken 
using an inverted fluorescence microscope (DMI 6000, Leica).  
2.5.5. Cell morphology 
Cell area, circularity index and aspect ratio were determined in ImageJ software using 
standard analysis plugins. For each condition, at least 70 cells were analyzed. 
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2.5.6. Measurement of mitochondrial membrane potential  
Differences in membrane potential, were assessed using MitoView™ 633 (Biotium, Inc., 
California, USA) following manufacturer's instructions. Briefly, after incubation with the dye for 1h, 
fluorescence was measured in a microwell plate fluorescence reader, Infinite 200 PRO NanoQuant 
(TECAN).  
2.5.7. Lipid droplets content 
Lipid droplet content was assessed using the Lipid Droplets Fluorescence Assay Kit (Cayman, 
USA), according to the manufacturer’s instructions. Fluorescence was quantified in a microwell 
plate reader, Infinite 200 PRO NanoQuant (TECAN). Representative images were taken using an 
inverted fluorescence microscope (DMI 6000, Leica).  
2.6. Assessment of hiPSC-CM functionality 
2.6.1. Dissociation and Plating 
hiPSC-CMs were dissociated into single-cell suspensions by incubation with TrypLETMSelect 
for 5min. Single hiPSC-CM were seeded on Matrigel-coated Fluorodishes at 2,000—6,000 
cells/cm2. Single contracting hiPSC-CM and CM clusters (<10 cells) growing on PDMS substrates 
for 3-5 days were chosen for image acquisition.  
2.6.2. Confocal Imaging and Drug Treatment  
hiPSC-CMs were imaged in the different culture media inside a climate control chamber at 
37ºC with 5% CO2 (Pathology Devices) using a Nikon A1R confocal microscope with DIC 
microscopy using a 488- or 647-nm laser and an anti-vibration table (TMC). Movies were acquired 
with at least 100 fps. Movies of CMs displaying at least five contraction cycles were recorded at 
baseline and then 5 min after each treatment. Movies were acquired without and with field-
stimulated with 10 V at 1 Hz using the RC- 37WS perfusion insert with electrodes (Warner 
Instruments) connected to a C-Pace EP stimulator (Ion Optix).  
2.6.3. Calcium and Action Potential imaging 
For calcium imaging, 0.5 mM of Fluo-4 AM (Life Technologies) was added to the CM culture 
medium 10 min prior to image acquisition. For action potential imaging, FluoVolt membrane 
potential kit (Life Technologies) was used at a dilution of 1:1000 according to the manufacturer’s 
protocol. Both fluorescence and DIC channels were recorded concurrently for multiple contraction 
cycles. 
2.6.4. Data Analysis and Display  
The Nikon Elements software package and Fiji were used for movie file conversions 
(Schindelin et al., 2012). Movies were cropped using Fiji to isolate the contracting CM from 
neighboring cells and cellular debris. Contractile kinetics and force generation by the CMs  were 
analyzed using the method developed by Kijlstra et al (Kijlstra et al., 2015). Specifically, movies 
were loaded into Visible™ software (Reify) to generate a similarity matrix of n rows by n columns, 
where n is the number of frames in the movie. Analysis of the similarity matrix was performed in 
Excel (Microsoft). For analysis of contraction curves, at least five contraction curves from a single 
video were averaged by matching the start of the contractions. Curve-fitting was applied to this 
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averaged curve to obtain accurate measurements of maximum shortening and relengthening 
velocities.  
2.6.5. Contractile Force Determination 
Contractile forces generated by shortening CMs were calculated in MATLAB based on the 
contractility curve generated with BASiC (Kijlstra et al., 2015), the dimensions of the CMs, and the 
mechanical properties of the PDMS substrate (Palchesko et al., 2012). Variable input for the 
MATLAB script is the width of the cell in centimeters, the length of the cell (in the direction of 
contraction) in centimeters, and the amount of cell shortening in centimeters. The Young’s modulus 
of PDMS substrates was 5 kPa for all experiments.  
2.7. Statistical analysis 
Statistical analysis was performed using GraphPad Prism Software version 5. Values are 
represented as mean±SD or as mean±SEM of independent measurements or assays (at least n=3 
replicates were considered). Statistical significance was evaluated using either Student's t test or 
one-way analysis of variance (ANOVA). Values of P<0.05 were considered statistically significant.  
 
3. Results 
3.1. hiPSC-CMs shift their metabolism from glycolysis to OXPHOS in the absence of glucose 
Beating CMs differentiated from hiPSC exhibit a typical fetal-like glycolytic metabolism, as 
confirmed by a high Lac production (Figure 4.1B), high qLac/qGlc ratio (Figure 4.1C), and a high 
fraction of Lac (90%) derived from [1,2-13C]Glc upon 48h incubation (Figure 4.1D). These 
metabolic indicators as well as the fraction of intracellular TCA cycle pools derived from [1,2-
13C]Glc and [U-13C]Gln, do not change significantly when keeping hiPSC-CMs in Glc rich medium 
(GLCM) during 20 days (Figure 4.1D-E), reflecting no improvements in the oxidative capacity of the 
cells when cultured in GLCM. This metabolic picture changes when removing Glc from the medium 
and adding FA alone (FAM) or together with galactose (GFAM), or Lac in the first 10 days followed 
by GFAM (LACM&GFAM) (Figure 4.1B). hiPSC-CMs were able to consume all new substrates and 
stop Lac secretion (Figure 4.1B) showing remarkable metabolic plasticity. In both GFAM and 
LACM&GFAM, hiPSC-CMs displayed a significantly higher oxygen consumption rate (OCR, Figure 
4.1F), lower extracellular acidification rate (ECAR, Figure 4.1G) and consequently higher 
OCR/ECAR ratio (Figure 4.1H), reflecting the higher contribution of OXPHOS comparatively to 
glycolysis for energy generation in these conditions.  
To further investigate the changes in central carbon metabolism, we cultured hiPSC-CMs in 
the conditions described above using uniformly 13C-labelled versions of the corresponding 
nutrients and analysed the incorporation of 13C into TCA cycle intermediates (citrate, fumarate and 
malate). In FAM, at day 0, 18% of the labelled fraction of these metabolites came from [U-13C]PA 
and [U-13C]OA and the remaining 82% from [U-13C]Gln (Figure 4.1I), suggesting that in FAM 
glutaminolysis is an important pathway to support TCA cycle anaplerosis when compared with 
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GLCM, where just a small portion of the TCA cycle pools incorporates carbon from [U-13C]Gln 
(Figure 4.1E). In the presence of Gal (GFAM), the incorporation of Gln decreased to 38%, whereas 
[U-13C]Gal accounted for approximately 40% of the label in TCA cycle (Figure 4.1J). Notably, after 
10 days in FAM the contribution from FA to TCA cycle label increased to 35% (Figure 4.1I). A 
similar adaptation of hiPSC-CMs to FA consumption was observed in GFAM, in which FA 
contribution to labelled TCA cycle pools increased from 19% (day 0) to 36% (day 20) (Figure 4.1J). 
For hiPSC-CMs cultured in LACM&GFAM, the incorporation of FA in TCA intermediates was 
similar at days 10 and 20 (approximately 30%, Figure 4.1K), suggesting that initial reliance in Lac 
oxidation may precondition hiPSC-CMs, allowing for a better adaptation to FA metabolization upon 
initial exposure to this substrate. Also, like in GFAM, there is a decrease in Gln contribution 
concomitant with increased incorporation of Gal (Figure 4.1J-K). These results highlight the 
increased role of FA and Gal as fuel of TCA cycle during culture in GFAM in detriment of Gln. 
 
Figure 4.1. Effect of culture medium composition on central carbon metabolism of hiPSC-CMs. A) 
Representative scheme illustrating the experimental set-up. The metabolome of hiPSC-CMs was evaluated 
before (d0) and after 10 (d10) and 20 days (d20) of culture in different media: GLCM (black), FAM (Orange), 
GFAM (Red) and LACM&GFAM (Grey). B) Heatmap image of metabolome data illustrating specific 
consumption (blue) and production (red) rates of metabolites (qMET; nmol/(10
6
cell.h)). C) Ratio of Lac 
production to Glc consumption (YLac/Glc) in GLCM through culture time. D) Percentage of labelled M2 
isotopomers from [1,2-
13
C]Glc in Lac and in TCA intermediates (Cit, Fum, Mal). E) Percentage of labelled M4 
isotopomers from [U-
13




C]Gln, respectively. F) Basal oxygen consumption rate (OCR). G) Extracellular acidification 
rate (ECAR). H) OCR/ECAR ratio reflecting the relative contribution of OXPHOS over glycolysis for energy 
generation. I-K) Pie charts indicating the contribution of the main substrates of each media, for TCA cycle 
pools. The percentages were determined based on the incorporation of each labelled substrate in Cit, Fum 
and Mal. OA: Oleic Acid and PA: Palmitic acid. Data are represented as mean±SD of 12-24 wells, n≥2 
separate experiments. *p<0.05; ***p<0.001; ns, not significant. 
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3.2. Culture of hiPSC-CMs in fatty acid medium lacking sugar source induces lipotoxicity  
Our results show that when cultured in FAM, hiPSC-CMs exhibited: i) a drastic decrease in 
cell concentration from day 10 onwards, reaching about 10% of the initial cell concentration at day 
20 (Figure 4.2A) and ii) a significant 4-fold increase in lipid droplet content when compared with 
hiPSC-CMs cultured in other media (Figure 4.2B). These results suggest that FA supply has 
surpassed the cellular oxidative capacity, leading to the intracellular accumulation of FA that has 
probably caused cellular damage and toxicity (Borradaile and Schaffer, 2005). Several studies 
have shown that cell exposure to high FA levels can affect multiple cellular processes such as 
reactive oxygen species (ROS) production, causing mitochondria, endoplasmic reticulum and 
lysosomal dysfunction and ultimately apoptosis (Drosatos and Schulze, 2013). Whole-genome 
transcriptome analysis revealed that FAM induced up-regulation of apoptosis-related genes and 
genes that encode for mediators of oxidative stress resistance and heat shock proteins (Figure 
4.2C). The activation of these genes reflects an adaptive mechanism of the cells to hamper cardiac 
damage associated with high FA exposure. To further characterize the global changes in central 
carbon metabolism of hiPSC-CMs cultured in FAM when compared to other feeding strategies,  
uptake and production rates were integrated with the 
13
C labelling profiles of intracellular 
metabolites from multiple tracers in a metabolic network model using non-stationary metabolic flux 
analysis (MFA) (Woo Suk and Antoniewicz, 2013). Reasonable fits were obtained (Figure A-4.1-A-
4.3, Pages 132-134) and the estimated fluxes and associated 95% confidence intervals are 
provided in Table A-4.1 (Page 140). The flux map of hiPSC-CMs cultured in FAM at day 10, 
confirms that most of the consumed FA (74%) is channelled to internal stores (lipid droplets) 
instead of entering β-oxidation (Figure 4.2D). Moreover, the majority of the citrate (Cit) produced in 
TCA is transported to the cytosol generating cytosolic Acetyl–CoA (AcCoA).  
To compensate this high mitochondrial Cit withdrawal, TCA cycle activity is mainly fuelled i) by 
amino acid carbon sources, primarily glutamate (Glu), and ii) Pyruvate (Pyr) cycling through malic 
enzyme (ME) and pyruvate carboxylase (PC). Therefore, even though FA are the main substrate of 
the adult heart(Lopaschuk and Jaswal, 2010), culture of hiPSC-CMs in FA-rich medium lacking 
sugar source lead to FA accumulation and alterations in the central carbon metabolism  which 
could justify the decrease in cell viability. 
 
 




Figure 4.2.  In the absence of a sugar source, fatty acid rich medium induces lipotoxicity in hiPSC-CMs 
A) Percentage of cell concentration, in all conditions tested, in relation to day 0 (d0), assessed using the 
Trypan Blue Exclusion Method. B) Analysis of lipid droplet content using a lipid droplet-specific fluorescent 
dye (Nile Red) of hiPSC-CMs at day 15. Fluorescence values were normalized for the values obtained in cells 
cultivated in GLCM. Data are represented as mean±SD. *p<0.05; ***p<0.001; ns, not significant. C) Heat map 
of differentially expressed genes closely related with apoptosis, unfolded protein and oxidative stress 
responses in hiPSC-CMs cultivated in different culture media. Genes were considered up- or down-regulated 
based on a fold change in expression FC≥|1.3| compared to d0. D) Metabolic flux map of the central carbon 
metabolism of hiPSC-CMs cultivated for 10 days in FAM. The flux map was determined using non-stationary 
13
C-MFA. Arrow thickness reflects flux values (see Table A-4.1 for exact flux values). 
3.3. Galactose prevents lipotoxicity in hiPSC-CMs cultured in fatty acid medium and 
improves cellular oxidative capacity  
When cultured in GFAM, hiPSC-CMs showed unaltered cell concentration throughout culture 
time (Figure 4.2A) and a significant lower intracellular FA accumulation than in FAM (Figure 4.2B), 
suggesting that combining FA with Gal supplementation constitutes a better approach to culture 
hiPSC-CM avoiding lipotoxicity. A comparison of the flux maps of hiPSC-CMs in GLCM and GFAM 
at day 20, reveals that hiPSC-CMs maintained in GFAM exhibited higher oxidative metabolism as 
indicated by a lower flux through glycolysis (around 10-fold) and higher flux through TCA cycle 
(over 6-fold) (Figure 4.3A-B). Most of the cytosolic Pyr was transported to the mitochondria and 
converted to AcCoA through pyruvate dehydrogenase (PDH) activity (72.4 in GFAM vs 5.6 
nmol/(10
6
cells.h) in GLCM), whereas in GLCM most of the cytosolic Pyr was diverted to Lac 
secretion (491.4 in GLCM vs 0.0 nmol/(10
6
cells.h) in GFAM), consistent with the measured 
extracellular rates (Figure 4.1B). A pronounced effect of GFAM on hiPSC-CM central carbon 
metabolism was the up-regulation of the β-oxidation pathway, achieving fluxes of 11 
nmol/(10
6
cells.h) whereas in GLCM these fluxes were negligible, underscoring the increased FA 
oxidation in GFAM (Figure 4.3A-B). Importantly, hiPSC-CMs cultured in LACM&GFAM and GFAM 
showed similar fluxomes (data not shown).  
 





Figure 4.3.  Effect of culture media composition on the fluxome and metabolic transcriptome of hiPSC-
CMs. Metabolic flux maps highlighting central carbon metabolism of hiPSC-CMs cultured in GLCM (A) and 
GFAM (B). The contribution of each metabolic pathway for ATP production is specified in the pie chart and the 
total amount of ATP produced is indicated above the pie chart. Up-regulated and down-regulated genes 
encoding metabolic enzymes are demarked in red and green, respectively. C) Heat map of differentially 
expressed genes associated with metabolic processes/pathways. D–E) Density plots generated with fold 
change expression of genes from the four metabolic processes showed in (C), for hiPSC-CMs in GLCM (D) 
and GFAM (E) at day 20. X axis indicates log2 fold change in gene expression. Black line indicates expression 
of all genes. Coloured lines toward the left and right side of the black line indicate down-regulation and up-
regulation of pathways, respectively. Kolmogorov-Smirnov test was used to calculate p-values. F) Pairwise 
Pearson correlation coefficients using expression data for the metabolic processes showed in (C). The highest 
and the lowest coefficients are coloured in a red to blue gradient. G) 2D principal component analysis using 
expression data for the metabolic processes showed in (C).  
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The estimated changes in metabolic fluxes correlate with alterations in the metabolic 
transcriptome. Specifically, we observed a significant down-regulation of glycolytic genes and a 
significant up-regulation of most genes related to TCA cycle, OXPHOS and FA metabolism (Figure 
4.3C-E, Figure A-4.4A, Page 135) in GFAM and LACM&GFAM cultures, a trend similar to that seen 
in human adult ventricular (HAV) tissue (Figure 4.3C, Figure A-4.4B, Page 135). Using gene 
expression data from these four metabolic pathways, we carried out a Pearson correlation analysis 
and a 2D principal component analysis (2D-PCA) comparing hiPSC-CMs at day 0 and after 20 
days of culture in GLCM, GFAM, and LACM&GFAM with HAV tissue. The correlation coefficients 
between HAV and GFAM (0.53) and LACM&GFAM (0.52) cultures are higher than with GLCM 
cultures (0.24, Figure 4.3F). Additionally, 2D-PCA analysis clustered together hiPSC-CMs in GLCM 
at day 0 and at day 20, separating these samples from HAV in principal component 1 (PC1, 
60.88% variance, Figure 4.3G), while hiPSC-CMs cultured in GFAM and LACM&GFAM at day 20 
were placed in the middle of PC1 and closer to HAV tissue (Figure 4.3G). Together, these data re-
enforce the idea that hiPSC-CMs cultured in GFAM and LACM&GFAM show a metabolic 
transcriptome more similar to HAV tissue.  
We noticed a faster down-regulation of glycolysis related genes (such as ALDOC; GAPDH; 
PGK1) in LACM&GFAM than in GFAM (Figure 4.3C). This indicates that the first 10 days of culture 
in LACM contributes for a sharp inactivation of the glycolytic pathway whereas the presence of Gal 
in GFAM lead to a more gradual decrease in the expression of glycolytic genes. Of particular 
interest is the up-regulation of enzymes glucose-6-phosphate isomerase (GPI) from glycolysis and 
transaldolase (TALDO1) from the non-oxidative branch of pentose phosphate pathway (PPP) in 
GFAM (Figure 4.3B-C). Gal is converted into G6P inside the cells, and the G6P formed can enter 
either the glycolytic pathway or the PPP. Thus, the increased expression of GPI and TALDO1 may 
reflect an adaptive response of the cells to enhance Gal metabolization. Interestingly, the PPP flux 
was similar in GFAM and GLCM, but in GFAM represented approximately 87% of the respective 
glycolytic fluxes and in GLCM just 13% (Figure 4.3A-B). 
The increased expression of genes related with FA metabolism, namely: CD36 that regulates 
the uptake of FA across the plasma membrane; CPT1B and SLC25A20 both necessary to shuttle 
long-chain FA from the cytosol into the intramitochondrial space; and HADHA/B involved in β-
oxidation (Figure 4.3C) suggests that hiPSC-CMs in GFAM and in LACM&GFAM adapt also at the 
transcriptional level to more efficiently consume FA. Also, the higher expression of OXPHOS 
related genes (specifically, ATP5, COX and NDUF family of genes) (Figure 4.3C, Figure A-4.5, 
Page 136), re-enforces the idea that mitochondrial oxidative metabolism is enhanced in both 
media. In accordance, the estimated ATP production increased 2.7-fold in GFAM (1843 nmol/h) 
comparing with GLCM (687 nmol/h) (Figure 4.3A-B). Taking into account the estimated fluxes and 
the reference amount of ATP produced per each substrate molecule (Boyle, 2005), glycolysis 
accounts for 71% of the total produced ATP in GLCM, whereas in GFAM, glycolysis originates just 
2% of the total ATP. In GFAM the majority of the ATP (98%) is produced through oxidation of Gal 
(64%) and FA (34%) (Figure 4.3A-B, pie charts).  
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The lower Gln consumption rates in GLCM and GFAM (1.0 and 2.6 nmol/(10
6
cells.h), 




C-MFA and transcriptome analysis confirmed that in GLCM the majority of Glc is 
metabolized by glycolysis originating Lac, whereas in GFAM, FA and Gal are both oxidatively 
metabolized via TCA cycle and OXPHOS for ATP generation, providing additional evidence that 
hiPSC-CMs switch their metabolism from a fetal-like glycolytic metabolism to a more energetically 
efficient adult-like oxidative metabolism when cultured in GFAM (and LACM&GFAM). 
3.4. Adaptation to LACM induces higher cell death than GFAM 
The up-regulation of some genes related with unfolded protein response in both LACM and 
GFAM at day 10 (Figure 4.2C), suggests that Glc depletion per se induced a stress for the cells 
resulting in the activation of survival signalling cascades. Nonetheless, the cell death (Figure 4.2A 
and Figure A-4.6A, Page 137) and the up-regulation of apoptotic genes (Figure 4.2C) were higher 
in hiPSC-CMs cultured in LACM, suggesting that the metabolic adaptation to Lac consumption is 
more harmful for the cells than the adaptation to Gal and FA consumption. It should be highlighted 
that the hiPSC-CMs used in this study were already non-proliferative, as verified by the absence of 
ki-67 expression at day 0 (Figure A-4.6B, Page 137). The lack of significant enrichment in cell cycle 
related pathways, from day 0 to day 20, in all culture media (Figure A-4.6C, Page 137), also 
suggest that culture in different media did not affect hiPSC-CM proliferative capacity.   
3.5. hiPSC-CMs cultured in GFAM or LACM&GFAM present transcriptional signatures closer 
to human ventricular CMs 
Whole transcriptome analysis showed that global gene expression patterns of hiPSC-CMs 
change gradually and differently along culture time in distinct media. 2D-PCA of all differently 
expressed genes (p-value<0.01 between the analysed sample groups) clearly separated HAV the 
farthest from hiPSC-CMs at day 0 in PC1, that accounted for most of the data variance (40.48%; 
Figure 4.4A). GLCM, GFAM and LACM&GFAM cultures were placed in the middle of the PC1 axis, 
but GFAM and LACM&GFAM were positioned closer to HAV and GLCM closer to day 0 in PC1 
(Figure 4.4A). In accordance, gene expression of hiPSC-CMs maintained in GFAM and 
LACM&GFAM for 20 days showed higher correlation coefficients with HAV (0.88 and 0.89, 
respectively) than hiPSC-CMs in GLCM (0.84) (Figure 4.4B). In agreement, Venn diagrams 
showed that both GFAM and LACM&GFAM present more overlapping of significantly enriched 
genes with HAV tissue than GLCM (Figure 4.4C). Comparison of gene expression in all conditions 
at day 20 with the initial time point (day 0) using volcano plots, indicated that the total number of 
genes significantly up- and down-regulated (FC≥|1.3| and p-value<0.01) is higher in GFAM and 
LACM&GFAM than in GLCM (Figure 4.4D). This result reflects, as expected, a reduced variability 
in gene expression when hiPSC-CMs are maintained in GLCM for 20 days. 
Overall, these results suggest that transcriptional signatures of hiPSC-CMs cultured in GFAM 
and LACM&GFAM were more similar to that of HAV tissue used as reference of mature CMs. 
 





Figure 4.4. Effect of culture medium composition on hiPSC-CM transcriptional profiling. A) 2D principal 
component analysis of all genes significantly enriched (p<0.01) in hiPSC-CM cultures at day 0, after 20 days 
of culture in GLCM, GFAM and LACM&GFAM and HAV tissue samples. B) Pairwise Pearson correlation 
coefficients using expression data of all enriched genes (p<0.01). C) Venn diagrams of overlapping 
differentially-expressed genes (p<0.01 and FC≥|1.3|) among GLCM, GFAM, LACM&GFAM cultures at day 20 
and HAV tissue. D) Volcano plots of gene expression changes in relation to day 0. Genes significantly up-
regulated (FC≥1.3 and p<0.01) are red and genes significantly down-regulated (FC≤-1.3 and p<0.01) are 
green. The number of regulated genes according to these criteria is shown on the top of the graphic. E) 
Heatmap depicting changes in the expression of genes involved in biological processes/pathways closely 
associated with CM development and function. F-G) Density plots generated with fold change expression of 
genes from the four cardiac-related categories shown in (E), for day 20 cultures (GLCM, GFAM and 
LACM&GFAM). Black line indicates expression of all genes. Colored lines toward the left and right side of the 
black line indicate down-regulation and up-regulation of pathways, respectively. Kolmogorov-Smirnov test was 
used to calculate p-values. H) Heatmaps highlighting the activation status of canonical pathways (upper panel) 
and biological functions (lower panel) predicted by IPA. Functions/pathways were considered significantly 
activated (or inhibited) with an overlap p-value≤0.05 and an IPA activation Z-score≥|2.0|. Red indicates 
positive Z-score (activated function) and blue indicates negative Z-score (inhibited function).  
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3.6. GFAM and LACM&GFAM enhance the expression of cardiac markers 
When compared with hiPSC-CMs at day 0, hiPSC-CMs maintained in GFAM and 
LACM&GFAM for 20 days, exhibit enhanced expression of cardiac genes related with i) contractile 
function and sarcomere structure (e.g. MYL3, TNNC1, TNNI3), ii) calcium cycling (e.g. ATP2A2 
and RYR2), and iii) electrophysiological properties (e.g. KCNJ2) (Figure 4.4E). Of particular interest 
is the 2-fold up-regulation of KCNJ2, gene that suffices to render the electrophysiological 
phenotype indistinguishable from the adult counterparts (Lieu et al., 2013). 
The expression of genes typically enhanced in fetal-like CMs and repressed in adult 
ventricular CMs (e.g. NPPB and ACTA1) (Feric and Radisic, 2016), decreased in hiPSC-CMs 
cultured in GFAM and LACM&GFAM. In hiPSC-CMs cultured in GLCM, the expression of NPPB 
and ACT1, was reactivated and kept similar to those of the immature hiPSC-CMs (day0), 
respectively.  Although ACTA1 is part of the fetal gene program in CMs, this gene is also 
expressed by other cardiac cell types, including smooth muscle cells, which may justify its up-
regulation in HAV tissue. Notably, expression of the TNNI3 gene that encodes for the adult cardiac 
troponin I (cTnI), a key hallmark of human CM maturation in vivo (Bedada et al., 2014), was up-
regulated in all culture conditions tested, however this increase was higher in GFAM (Figure 4.4E). 
It should be noted that up-regulation of genes related with contractile function, calcium signaling 
and electrophysiology was observed already at day 10 in GFAM whereas in GLCM, only minor 
improvements were observed at day 20 (Figure 4.4E). Additionally, a more in-depth evaluation of 
the data using density plots revealed that in GFAM cultures the expression of these genes follows 
a distribution more similar to that observed in HAV tissue (Figure 4.4F-G).  
Examination of the transcript levels of all genes in the abovementioned samples, using IPA 
revealed the enrichment of several canonical pathways known to be critical in in vivo heart 
development. Inhibition of PI3K/AKT/insulin signalling and activation of PPAR signalling were 
consistently predicted by IPA and density plots in both LACM&GFAM and GFAM, whereas the 
opposite trend was observed in GLCM (Figure 4.4F-G). PPARα is a major transcriptional regulator 
abundantly expressed in heart (Lopaschuk et al., 2010). Specifically, PPARα regulates the 
expression of genes involved in FA uptake, cytosolic FA binding and esterification, FA β-oxidation, 
and Glc oxidation (Evans, 2004; Lopaschuk et al., 2010). PPARs activation have been related with 
the up-regulation of FA metabolism and with down-regulation of PI3/AKT/insulin pathway, which is 
involved in Glc metabolism regulation (Simons et al., 2012). Of note is the up-regulation of 
PPARGC1A, observed in GFAM and LACM&GFAM at day 10 (Figure 4.4E), that encodes for PGC-
1, a transcriptional coactivator highly expressed in cardiac tissue (Uosaki et al., 2015). Up-
regulation of PGC-1α results in increased mitochondrial biogenesis, FA β-oxidation and OXPHOS 
(Lehman et al., 2000; Ventura-Clapier et al., 2008), features already described as increased in 
GFAM and LACM&GFAM (Figure 4.1,3). The inverse relationship between FA metabolism/PPARα 
signalling and PI3K/AKT/insulin signalling observed in GFAM and LACM&GFAM cultures is 
consistent with the metabolic switch detected in these cultures and is in agreement with the pattern 
reported for 1-year matured hESC-CM (Kuppusamy et al., 2015).  
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Of note is that both IPA and density plots revealed that the cardiac hypertrophy pathway is 
significantly up-regulated in GLCM cultures. Specifically, the main canonical pathways and 
biological functions, predicted by IPA, as activated in GLCM and inactivated in GFAM and 
LACM&GFAM were cardiac hypertrophy and related pathways, including JAK/Stat, mTOR, 
Endothelin-1, VEGF, TGF-B, RhoA, Rac, Phospholipase C, Cdc42, HMGB1, actin cytoskeleton 
and integrin signaling (Frey et al., 2004; Heineke and Molkentin, 2006; Ruwhof and van der, 2000) 
(Figure 4.4H). On the other hand, PTEN pathway, identified as inactive in GLCM and active in the 
other media (Figure 4.4H) has been shown to attenuate CM hypertrophy (Oudit et al., 2008). At the 
cellular level, hypertrophy is associated with the reorganization and increase of actin filaments in 
the absence of cytokinesis, extracellular matrix (ECM) remodeling, increase of ROS formation, 
promotion of angiogenesis and fibrogenesis (Abel and Doenst, 2011; Carreño et al., 2006), 
biological functions also predicted as activated in GLCM (Figure 4.4H). The expression of genes 
related with ECM and cell surface markers dynamically changed through culture time in all media 
however, GLCM cultures seem to display a profile distinct from GFAM and LACM&GFAM cultures 
and from HAV tissue (Figure A-4.7, Page 137). For example, genes that encode for collagen 
(COL1A1, COL3A1, COL5A1, COL4A2, COL11A1) and vimentin (VIM) were highly up-regulated in 
GLCM but down-regulated or non-altered, relatively to day 0, in GFAM, LACM&GFAM and HAV 
(Figure A-4.7, Page 137), suggesting that in GLCM, cells suffer a high ECM remodeling, including 
collagen deposition, which might justify the activation of biological functions related with cell 
migration and spreading in GLCM (Figure 4.4H). Interestingly, we observed increased expression 
of some fibroblast markers from day 0 to day 20 in hiPSC-CMs cultured in GLCM together with the 
appearance of small niches of fibroblast-like cells (Figure A-4.8, Page 138)  
3.7. GFAM improves the structure and ultrastructure of hiPSC-CMs  
Immunofluorescence and TEM analyses corroborated the gene expression data, confirming 
an improved structural maturation of hiPSC-CMs cultured in GFAM (and in LACM&GFAM) 
comparatively to other media. hiPSC-CMs cultured in GFAM exhibited: i) well defined cross-striated 
patterns of sarcomeric α-actinin and cTnT; ii) high density of aligned myofibrils composed by 
sarcomeres with organized Z-disks, A- and I-bands and a distinctive H-zone; iii) significant higher 
degree of sarcomere alignment; and iv) more mitochondria with prominent cristae close to the 
myofibrils (Figure 4.5A-E). On the other hand, hiPSC-CMs maintained in GLCM showed 
disorganized and diffuse cTnT staining (Figure 4.5A) and a poorly organized contractile machinery, 
characterized by low myofibril density and orientation and variable Z-disc alignment (Figure 4.5C-
E). In accordance, Mitoview fluorescence (inner mitochondrial membrane potential dye), was 












Figure 4.5. Structural and ultrastructural analyses of hiPSC-CMs after culture in different media. A) 
Representative images of hPSC-CMs immunostained for cardiac troponin-T (cTnT) and α-sarcomeric actinin. 
Nuclei (blue) were stained with Hoechst 33342. Scale bars=30μm. B) Fold increase in mitochondria potential 
assessed by the mitochondria specific dye Mitoview. Fluorescence values were normalized for the values 
obtained in cells cultivated in GLCM. (C-D) Sarcomere alignment in hiPSC-CMs cultured for 20 days in GLCM 
and GFAM: C) Inverse of the magnitude of sarcomere angle dispersion and D) Rose plot histogram of 
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sarcomere orientation. n>30 sarcomeres per condition. E) TEM images of hiPSC-CMs. Myofibrils (MF), Z-
disks (Z), sarcomeric bands: A- and I-bands with a H-zone, intercalated disks (ID) connecting adjacent CM 
and Mitochondria (M) are highlighted. Scale bars=500nm. F-H) Cell structure characterization in terms of cell 
area (F), circularity index (G), length-to-width ratio (H). n>70 cells per condition. Data are represented as 
mean±SD. *p<0.05; **p<0.01; ***p<0.001; ns, not significant. 
 
Moreover, significant changes in cell morphology were observed through time in all conditions 
(Figure 4.5F-H). When compared to GLCM, hiPSC-CMs cultured in GFAM or LACM&GFAM 
exhibited significantly lower cell area (Figure 4.5F) and circularity index (Figure 4.5G) and higher 
length/width ratio (Figure 4.5H). These numbers are similar to the values previously reported for 
adult human ventricular CMs (Feric and Radisic, 2016). For example, length/width ratios in the 
range of 5-9.5 have been reported for adult CMs (Denning et al., 2015) and we observed an 
average ratio of 6.4 in hiPSC-CMs cultured in GFAM.  
The significant increase in cell surface area and spherical morphology observed in hiPSC-
CMs maintained in GLCM (Figure 4.5F-H), reflects again the propensity of hiPSC-CMs to undergo 
hypertrophy.  
3.8. GFAM improves calcium transients, contractility and action potential kinetics of hiPSC-
CMs 
Despite showing similar transient amplitudes (Figure 4.6A-B), hiPSC-CMs cultured in GFAM 
and LACM&GFAM at day 20 presented significantly faster calcium-transient kinetics compared with 
hiPSC-CMs at days 0 and 20 in GLCM, as indicated by significantly shorter time to peak, time to 
50% decay and faster Ca
2+ 
transient upstroke and decay velocities (Figure 4.6C-D). The faster 
calcium kinetics observed in GFAM and LACM&GFAM is supported by the high expression of 
RYR2 and ATP2A2 that are responsible respectively for the release and uptake of Ca
2+ 
in the SR 
(Figure 4.4E).  
Additionally, compared to day 0 and to cells at day 20 in GLCM, hiPSC-CMs cultured in GFAM 
and LACM&GFAM exhibited improved contractility with greater fractional shortening (approximately 
8.4% of resting length in both LACM&GFAM and GFAM vs. 4.9 (day 0) and 5.9 (GLCM day 20); 
Figure 4.6E-F), faster contractile kinetics (higher shortening and relengthening velocities; Figure 
4.6G), and greater peak force (0.48±0.22 (LACM&GFAM), 0.37±0.06 mN/mm
2
 (GFAM) vs. 
0.21±0.04 (GLCM day 0) and 0.27±0.12 (GLCM day 20); Figure 4.6H). The significantly lower 
contractile force generated by the cells in GLCM correlates with the lower expression of contractile 
and cytoskeletal genes observed in this medium (Figure 4.4E). The values of contractile force 
obtained at day 20 in GFAM (Figure 4.6H) were similar to the ones reported after hiPSC-CM 
maturation with a commercial medium containing T3 hormone (0.43-0.51 mN/mm
2
) (Ribeiro et al., 
2015). 
Importantly, the major functional improvements observed in hiPSC-CMs cultured in GFAM 
were detected as early as d10 (Figure 4.6 vs. Figure A-4.9, Page 138) with no meaningful further 
improvement in calcium and contractile kinetics observed between 10 and 20 days. This result 
provides additional evidence that GFAM stimulates a rapid functional maturation of hiPSC-CMs. In 
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contrast, hiPSC-CMs cultured in LACM&GFAM continued to exhibit improvements in fractional 
shortening, force generation, calcium uptake and shortening velocities from d10 to d20 (Table A-
4.2, Page 142). These results suggest that GFAM is more efficient than LACM at promoting the 
rapid functional maturation of hiPSC-CMs.  
Additionally, no significant differences were observed in calcium and contractile kinetics 
between cells cultured in GFAM and FAM at d10 (Figure A-4.9, Page 138), suggesting that Gal is 
not required for the enhancement of hiPSC-CM maturation. 
 
 
Figure 4.6. Impact of metabolic manipulation on hiPSC-CM functionality. hiPSC-CMs were analysed in 
terms of calcium transients (A-D), contractile performance (E-H) and action potential (AP) kinetics (I-L), before 
(d0) and after 20 days (d20) of culture in different media. Calcium transient kinetics (A-D) evaluated with the 
intracellular calcium indicator Fluo-4 AM: A) Representative calcium transient; B) Calcium transient amplitude 
(F/F0); C) Time to peak and time to 50% decay; D) Average upstroke and decay velocities. n=28-35 cells per 
condition. E) Representative contraction curves, reflecting changes in the percentage of cell length. F) 
Percentage of shortening; G) Maximum shortening and relengthening velocities. n=20-35 cells per condition. 
H) Maximum contractile force generated by hiPSC-CMs in each culture condition. n=8-17 cells per condition. 
AP kinetics (I-L) were determined with a voltage-sensitive dye (FluoVolt). I) Changes in the fluorescence 
intensity of the FluoVolt AP indicator over time. J) AP duration at 50% (APD50) and 90% repolarization 
(APD90). K) APD50/APD90. L) AP upstroke velocity. n=24-26 cells per condition. Data are represented as 
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hiPSC-CM beating rates also varied throughout culture time in all conditions, with significantly 
lower rates at day 20 for all of them (Figure A-4.10A, Page 139). Although the decrease was more 
pronounced in GLCM (Figure A-4.10A, Page 139), all beating rates are within the range of reported 
values for hPSC-CMs after maturation in vitro (21–84 BPM) (Feric and Radisic, 2016). 
Interestingly, we observed that hiPSC-CMs cultured in GFAM and LACM&GFAM were more easily 
electrically paced at 1Hz than hiPSC-CMs at d0 and d20 in GLCM (Figure A-4.10B, Page 139). 
Action potential (AP) durations at 50% and 90% repolarizations (APD50 and APD90), 
APD50/APD90 and upstroke velocity were significantly higher in GFAM than in GLCM cultures 
(Figure 4.6I-L). These results are consistent with prior studies that report that adult CMs exhibit 
increased APD90, APD50/90 and maximum upstroke velocity than immature CMs (Kuppusamy et 
al., 2015; Ribeiro et al., 2015; Sartiani et al., 2007).  
Altogether these data demonstrated that GFAM and LACM&GFAM cultures result not only in 
metabolic, molecular and morphological changes indicative of CM maturation, but also that 




In this study, we applied a systems-level approach to provide new insights on how the use of 
different metabolic substrates impacts metabolic, structural and functional maturation of hiPSC-
CMs. Combining a set of “-omics” tools (metabolomics, fluxomics and transcriptomics) with 
structural, morphological and functional analyses we show that a glycolytic-to-oxidative metabolic 
shift is a cause, rather than a consequence, of the phenotypic alterations characteristic of the CM 
maturation process. We report for the first time that: i) hiPSC-CMs cultured in medium without Glc 
supplemented with FA and Gal (GFAM) display improved maturation markers in relation to hiPSC-
CMs cultured in standard Glc medium (GLCM; Figure 4.7); ii) Gal supplementation ameliorates the 
oxidative capacity of the cells improving FA oxidation while avoiding lipotoxicity; and iii) hiPSC-CMs 
cultured in GLCM maintain a fetal-like profile and show features that resemble pathogenic 









Figure 4.7. Summary of major findings in this study. The main differences in terms of cell phenotype and 
metabolism after 20 days of culture in GLCM and GFAM are highlighted. 
 
GFAM culture allows to obtain CMs with a more mature phenotype, characterized by a more 
energetically efficient oxidative metabolism, transcriptome signatures that more closely resemble 
adult ventricular CMs, elongated morphologies, organized sarcomeric structures, higher myofibril 
density and alignment, faster calcium-transient kinetics, higher percentage of shortening and 
contractile force, enhanced AP durations and higher upstroke velocities. Transcriptome analysis 
revealed that substrate selection induces significant alterations in the expression of key 
transcriptional regulators and pathways involved in cell metabolism and cardiac development. We 
showed that hiPSC-CMs have substrate plasticity, being able to immediately adapt to consume 
other substrates (FA, Gal, Lac, Gln), in the absence of Glc. Rana and colleagues also 
demonstrated that hiPSC-CMs are capable of utilizing anaerobic or aerobic respiration depending 
upon the available carbon substrate and showed that hiPSC-CMs rely on OXPHOS for ATP 
production when cultured in Glc-depleted medium supplemented with Pyr, Gln, Gal and FA (Rana 
et al., 2012). Nevertheless, to date, no studies have quantified the intracellular fluxome and 
simulated metabolic fluxes distribution of hiPSC-CMs cultured in distinct carbon sources neither 
have extensively elucidated how the utilization of major metabolic substrates modulate structural 
and functional maturation of hiPSC-CMs as we addressed here. Nonstationary 
13
C-MFA analysis 
allowed us to confirm quantitatively that hiPSC-CMs present increased metabolic fluxes through FA 
β-oxidation and TCA cycle and improved ATP production in GFAM, reflecting a highly active 
OXPHOS. 
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Even though FA are the main substrates used by adult CMs (Lopaschuk and Jaswal, 2010), 
Glc-depleted medium supplementated with FA (FAM) induced cell toxicity. Nonetheless, combining 
FA supplementation with Gal could overcome lipotoxicity by improving oxidative capacity of hiPSC-
CMs. Different types of cells (cancer cells, primary fibroblasts and muscle cells) growing in medium 
in which Glc was replaced by Gal showed enhanced aerobic metabolism (Aguer et al., 2011; 
Marroquin et al., 2007; Rossignol et al., 2004), due to the induction of an energy deprivation state. 
Gal is metabolized at a much slower specific rate than Glc due to: i) lower affinity of the 
transporters (GLUT1 and GLUT4) for Gal compared to Glc and, ii) lower activity of galactokinase, 
the rate-limiting step in Gal metabolism, comparing to hexokinase, the rate-limiting step in Glc 
oxidation (Dott et al., 2014; Wagner et al., 1991); forcing cells to start to use OXPHOS to rapidly 
get sufficient ATP. Even though we observed increased expression of GLUT1 in hiPSC-CMs 
cultured in GFAM, fluxomic analysis confirmed that the uptake rate of Gal was significantly lower 
than Glc (30.42 vs. 254.17 nmol/(10
6
cell.h)) when using similar concentrations of both substrates. 
We confirmed that the flux from Pyr to Lac is negligible and that the majority of Gal is oxidized in 
TCA cycle and OXPHOS. 
It has been described that accumulation of FA leads to augmented intracellular FA derivatives 
(e.g. fatty acyl CoA, diacylglycerol, and ceramide) that can directly modify cellular structures and 
activate downstream pathways leading to cellular damage and toxicity (Lopaschuk et al., 2010). 
Other studies have shown that saturated FA (palmitate) cause greater lipotoxicity than unsaturated 
FA (oleate )(Drosatos and Schulze, 2013; Nemcová-fürstová et al., 2011). Kase et al. showed that 
Gal increases FA oxidation and the formation of neutral lipids that avoid the generation of 
‘‘lipotoxic’’ FA derivatives (Kase et al., 2013). Additionally, we observed that in GFAM, PPP 
pathway is highly active while it is negligible in FAM. Since, PPP is one of the main antioxidant 
cellular defence systems in the cells (Riganti et al., 2012), we can speculate that Gal also 
contributes to prevent the detrimental effects of free radical toxicity promoted by OXPHOS. 
Whether the lipotoxicity observed in FAM derives exclusively from the medium composition itself or 
from an inadequate adaptation of the cells to oxidative metabolism, still needs to be investigated. In 
the future it would be interesting to see if a pre-treatment with GFAM before adding FAM would 
prevent lipotoxicity.  
We showed that hiPSC-CMs maintained in GLCM during 20 days display a fetal-like CM 
phenotype and present features of cardiac pathological hypertrophy, namely higher surface area, 
higher expression of fetal genes, dominant glycolytic energetics, reduced calcium dynamics and 
contractile force. In accordance, other studies have reported that exacerbated CM pathologies and 
arrhythmia frequently appear in immature iPSC-CM within 30 days of culture in non-physiological 
conditions (Wen et al., 2015). 
In order to mimic the temporal substrate preference during CM development in vivo, we also 
evaluated the impact of culturing hiPSC-CMs in LACM for 10 days before cultivation in GFAM. 
Metabolome and transcriptome profiles revealed that LACM improved cells’ oxidative capacity. 
However this strategy resulted in higher cell death and reduced structural and functional maturation 
comparatively to cells cultured for the same period in GFAM. Nonetheless, we showed that 
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combining the additional 10 days of culture in GFAM was sufficient to improve structural and 
functional maturation of hiPSC-CMs, leading to a phenotype indistinguishable from hiPSC-CMs 
maintained in GFAM for 20 days. Therefore, we report two valuable strategies to induce 
metabolism switching and to improve hiPSC-CM maturation, with similar outcomes. The choice of 
the strategy to use may be dependent on the initial purity state of hiPSC-CM cultures (Tohyama et 
al., 2013). 
During development in vivo, CM maturation is regulated by several cues including cell-cell 
interactions, ECM, soluble factors, mechanical signals and substrate stiffness (Denning et al., 
2015; Feric and Radisic, 2016). To further improve hiPSC-CM maturation in vitro, our strategy can 
be combined with other approaches described in literature, such as electrical/mechanical 
stimulation (Chan et al., 2013), co-culture with supporting cells (Kim et al., 2010), and medium 
supplementation (e.g. T3 hormone (Yang et al., 2014b)). Also, it can be adopted for 3D cell 
culturing approaches (Zhang et al., 2015), which in combination with the use of environmentally 
controlled bioreactors (Correia et al., 2014) constitute a promising strategy towards scalable 
production of mature hiPSC-CMs. 
Overall, by bringing a holistic and quantitative metabolic analysis into the stem cell field, this 
work not only provides novel insight into the interaction of metabolism and maturation but also 
establishes a robust method to improve hiPSC-CM maturation. This method holds technical and 
economic advantages over the existing protocols due to its simplicity (a simple medium-exchange 
procedure) and ease of application (does not require specific equipment or addition of expensive 
factors/chemicals). It is noteworthy that 10 days of culture in GFAM was sufficient to promote 
hiPSC-CM phenotypic and functional maturation comparable to what has been described in the 
literature after 80-100 days of culture (Lundy et al., 2013). Therefore GFAM treatment constitutes a 
great advance for the maturation of hiPSC-CMs in a timely efficient manner. This will strengthen 
the utility of hiPSC-CMs in cell therapy, drug discovery, toxicity testing and cardiac disease 
modeling. 
 





Figure A-4.1.  Experimental and simulated intracellular 13C-labelling dynamics in GLCM condition 
using [1,2-13C]GLC and [U-13C]GLN. Circle markers correspond to GC-MS measurements corrected for 
natural isotope abundance. Lines correspond to fitted MIDs from nonstationary 13C-MFA flux estimation of 
parallel labelling experiments.  
 




Figure A-4.2. Experimental and simulated intracellular 
13









C]Gln. Circle markers correspond to GC-MS measurements 
corrected for natural isotope abundance. Lines correspond to fitted MIDs from nonstationary 13C-MFA flux 
estimation of parallel labelling experiments.  
 





Figure A-4.3.  Experimental and simulated intracellular 
13







C]Gln. Circle markers correspond to GC-MS measurements corrected for 
natural isotope abundance. Lines correspond to fitted MIDs from nonstationary 13C-MFA flux estimation of 
parallel labelling experiments. 
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Figure A-4.4. Density Plots generated with fold change in expression of genes from representative 
metabolic categories. A) LACM&GFAM d20 and B) HAV. X axis indicates log2 fold change in gene 
expression. Black line indicates expression of all genes. Coloured lines toward the left and right side of the 
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Figure A-4.6. Impact of culture media composition on metabolic activity and proliferative capacity. A) 
Metabolic activity at day 0 and day 10 in all conditions was assessed with PrestoBlue. B) Representative 
image of immature hiPSC-CMs (at day 0) immunostained for cardiac troponin-T (cTnT) revealing the absence 
of Ki67+ cells (green). Nuclei (blue) were stained with Hoechst 33342. Scale bars=30 μm. C) Adjusted P-value 
determined by IPA reflecting non-statistically significant enrichment of cell-cycle related pathways in all culture 
condition.  
 
Figure A-4.7.  Impact of culture media composition and culture time on the expression of genes 
related with extracellular matrix composition in hiPSC-CMs cultivated in different culture media. Heat 
map of differentially expressed genes. Colour gradient indicates gene expression fold-change values of all 
culture conditions tested compared with d0. Green and red represent down- and up- regulation, respectively. 
 




Figure A-4.8. hiPSC-CM culture in GLCM showed up-regulation of fibroblastic markers. A) Phase 
contrast microscope photos. The arrows highlight the appearance of zones with fibroblast-like cells at day 10 
(left panel) and day 20 (right panel). Scale bars=100μm. B) Heatmap reflecting the up-regulation of fibroblast 




Figure A-4.9. Impact of metabolic manipulation in hiPSC-CM functionality. hiPSC-CMs were analysed in 
terms of calcium signalling profiles (A-D) and contractile performance (E-H), before (white) and after 10 days 
of culture in different culture medium (GLCM-black, LACM -grey, GFAM-red and FAM). Calcium transient 
kinetic was evaluated by loading the hiPSC-CMs with the intracellular calcium indicator Fluo-4 AM: A) 
Representative calcium transients. F/F0: change of fluorescence signal over background florescence; B) 
Calcium transient amplitude (F/F0); C) Time to peak. D) Average upstroke and decay velocities. n = 24-35 
cells per condition. Contractile kinetics for each culture condition is described in: E) Representative contraction 
curves for each culture condition, reflecting changes in the percentage of cell length. F) Percentage of 
shortening; G) Average shortening and relengthening velocities. n = 15-22 cells per condition. H) Maximum 
contractile force generated. n = 8-17 cells per condition. Data are represented as mean±SEM. *p<0.05; 
**p<0.01; ***p<0.001; ns, not significant. 
 
 




Figure A-4.10. Impact of metabolic manipulation in beating rate and paced capacity. A) Boxplot 
depicting the beating rate of hiPSC-CMs before (white) and after 20 days in culture in GLCM (black), 
LACM&GFAM (grey) and GFAM (red). Whiskers: 10-90 percentile. Outliers are plotted as individual points. B) 
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Table A-4.1. Metabolic network reactions and simulated fluxes determined by nonstationary 
13
C-MFA. 
Flux values are shown in units of nmol/(106cell.h). Negative flux values indicate that net direction is reverse to 
the direction indicated. LB – lower bound; UB – upper bound. 
    GLCM d20     FAM d10 GFAM d20 
















UB   
v1 G6P <-> F6P 220.5 [ 150 ; 347.1 ] 0 [ 0 ; 0 ] 3.9 [ 1.8 ; 5.4 ] 
v2 F6P -> FBP 242.9 [ 165 ; 326.2 ] 0 [ 0 ; 0 ] 21.6 [ 15.9 ; 22.3 ] 
v3 FBP <-> DHAP + GAP 242.9 [ 165 ; 326.2 ] 0 [ 0 ; 0 ] 21.6 [ 15.9 ; 22.3 ] 
v4 DHAP <-> GAP 242.9 [ 165 ; 326.2 ] 0 [ 0 ; 0 ] 21.6 [ 15.9 ; 22.3 ] 
v5 GAP <-> 3PG 497.1 [ 338.4 ; 660.4 ] 0 [ 0 ; 0 ] 52 [ 38.1 ; 54 ] 
v6 3PG <-> PEP 496.9 [ 334.3 ; 658.4 ] 0 [ 0 ; 0 ] 49.7 [ 36.8 ; 53.2 ] 
v7 PEP -> Pyr.c 496.9 [ 334.3 ; 658.4 ] 0 [ 0 ; 0 ] 49.7 [ 36.8 ; 53.2 ] 
v8 Pyr.c <-> Pyr.m 5.6 [ 1.4 ; 8.6 ] 109.2 [ 106.3 ; 109.3 ] 72.4 [ 56.3 ; 75.6 ] 
v9 G6P -> P5P + CO2 33.7 [ 0 ; 50.2 ] 0 [ 0 ; 0 ] 26.5 [ 18.8 ; 29.2 ] 
v10 P5P + P5P <-> GAP + S7P 11.2 [ 0 ; 16.7 ] 0 [ 0 ; 0 ] 8.8 [ 6.3 ; 9.7 ] 
v11 S7P + GAP <-> E4P + F6P 11.2 [ 0 ; 16.7 ] 0 [ 0 ; 0 ] 8.8 [ 6.3 ; 9.7 ] 
v12 E4P + P5P <-> GAP + F6P 11.2 [ 0 ; 16.7 ] 0 [ 0 ; 0 ] 8.8 [ 6.3 ; 9.7 ] 
v13 Pyr.c <-> Lac 491.4 [ 336.4 ; 651.4 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0 ] 
v14 Pyr.c <-> Ala 0 [ -7.8 ; 14 ] 0 [ 0 ; 0 ] -11 [ -12.3 ; -9.1 ] 
v15 Pyr.m -> AcCoA.m + CO2 5.6 [ 2.6 ; 8.6 ] 30.3 [ 30.2 ; 30.3 ] 72.4 [ 54.8 ; 75.3 ] 
v16 OAA.m + AcCoA.m -> Cit.m 14.1 [ 6.3 ; 21.6 ] 55.4 [ 55.3 ; 55.4 ] 88.5 [ 66.5 ; 92.2 ] 
v17 Cit.m <-> AKG + CO2 14.1 [ 6.4 ; 20.3 ] 22.1 [ 22.1 ; 22.2 ] 88.5 [ 66.7 ; 92.1 ] 
v18 AKG -> SucCoA + CO2 14.7 [ 6.9 ; 27.2 ] 43.3 [ 43.2 ; 43.4 ] 95.7 [ 71.1 ; 100.1 ] 
v19 SucCoA <-> Suc 14.7 [ 6.9 ; 27.2 ] 43.3 [ 43.2 ; 43.4 ] 95.7 [ 71.1 ; 100.1 ] 
v20 Suc <-> Fum.m 14.7 [ 6.8 ; 26.7 ] 45.7 [ 45.6 ; 45.9 ] 95.7 [ 72 ; 99.4 ] 
v21 Fum.m <-> Mal.m 14.7 [ 4 ; 22.8 ] 52.1 [ 52.0 ; 52.2 ] 95.7 [ 72.2 ; 99.3 ] 
v22 Mal.m <-> OAA.m 14.1 [ 6.3 ; 21.4 ] -23.5 [ -23.7 ; -23.4 ] 88.5 [ 66.4 ; 91.5 ] 
v23 Mal.c -> Pyr.c + CO2 0 [ 0 ; 4.2 ] 108.9 [ 108.7 ; 109.5 ] 7.2 [ 4.7 ; 8.3 ] 
v24 Pyr.m + CO2 -> OAA.m 0 [ 0 ; 0 ] 78.9 [ 78.4 ; 79.4 ] 0 [ 0 ; 0.5 ] 
v25 Gln <-> Glu 1 [ 0.4 ; 1.7 ] 3.8 [ 3.6 ; 3.9 ] 2.6 [ 1.9 ; 2.7 ] 
v26 AKG <-> Glu -0.6 [ -6.4 ; -0.3 ] -21.2 [ -22.8 ; -20.2 ] -7.2 [ -8.4 ; -4.8 ] 
v27 Asn <-> Asp 0 [ 0 ; 0 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0 ] 
v28 3PG -> Ser 0.2 [ 0 ; 13.2 ] 0 [ 0 ; 0 ] 2.3 [ 0.7 ; 3.8 ] 
v29 Ser -> Pyr.c 0 [ 0 ; 8.3 ] 0.3 [ 0.2 ; 0.3 ] 4.5 [ 1.1 ; 7 ] 
v30 Ser <-> Gly + C1 -1.8 [ -4.1 ; 0 ] -2.4 [ -2.4 ; -2.4 ] -0.3 [ -2 ; 0 ] 
v31 Glu <-> Pro 0 [ -4.4 ; 3.5 ] -10.5 [ -10.5 ; -10.5 ] -1.4 [ -4.1 ; 1.4 ] 
v32 Val + CO2 -> Suc + CO2 + CO2 0 [ 0 ; 0.1 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0.5 ] 
v33 Ile + CO2 -> Suc + AcCoA.m + CO2 0 [ 0 ; 0.1 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0.5 ] 
v34 
Leu + CO2 -> AcCoA.m + AcCoA.m + 
AcCoA.m + CO2 
2.2 [ 1.2 ; 3.3 ] 0 [ 0 ; 0 ] 1.6 [ 0.1 ; 2.6 ] 
v35 Thr -> AcCoA.m + Gly 0 [ 0 ; 1.6 ] 3.9 [ 3.9 ; 4.0 ] 0.3 [ 0.1 ; 0.6 ] 
v36 Phe -> Tyr 0 [ 0 ; 0.1 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0.4 ] 
v37 
Tyr -> Fum.m + AcCoA.m + AcCoA.m + 
CO2 
0 [ 0 ; 0.1 ] 6.4 [ 6.3 ; 6.4 ] 0 [ 0 ; 0.4 ] 
v38 
Met + Ser + CO2 -> Suc + Cys.snk + 
CO2 + C1 
0 [ 0 ; 0 ] 2.4 [ 2.4 ; 2.5 ] 0 [ 0 ; 0.4 ] 
v39 
Lys -> CO2 + CO2 + AcCoA.m + 
AcCoA.m 
0.9 [ 0 ; 1.8 ] 0 [ 0 ; 0 ] 0 [ 0 ; 1.5 ] 
v40 His -> Glu + C1 1.8 [ 0 ; 4.2 ] 0 [ 0 ; 0 ] 0.3 [ 0 ; 2 ] 
v41 Arg -> Glu + Urea.snk 59.8 [ 0 ; Inf ] 0 [ 0 ; 0 ] 3.6 [ 0 ; 4.1 ] 
v42 Glu + CO2 -> Arg 64 [ 0.7 ; Inf ] 0 [ 0 ; 0 ] 2.7 [ 0 ; 2.9 ] 
v43 Glc.ext -> G6P 254.2 [ 178 ; 326.1 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0.2 ] 
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v44 Lac.ext <-> Lac -491.4 [ -651.4 ; -336.4 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0 ] 
v45 Ala.ext <-> Ala 0 [ -14 ; 7.8 ] 0 [ 0 ; 0 ] 11 [ 9.1 ; 12.3 ] 
v46 Gln.ext -> Gln 1 [ 0.4 ; 1.7 ] 3.8 [ 3.8 ; 3.8 ] 2.6 [ 1.9 ; 2.7 ] 
v47 Glu.ext <-> Glu 2 [ -1.2 ; 5.8 ] 6.9 [ 6.9 ; 6.9 ] 2.1 [ -0.2 ; 4.4 ] 
v48 Ser.ext <-> Ser -1.9 [ -9.7 ; 0.8 ] 0.3 [ 0.2 ; 0.4 ] 1.9 [ 0.7 ; 3.0 ] 
v49 Gly.ext <-> Gly 1.8 [ -1.6 ; 4.1 ] -1.5 [ -1.6 ; -1.4 ] -0.1 [ -0.6 ; 1.6 ] 
v50 Pro.ext <-> Pro 0 [ -3.5 ; 4.4 ] 10.5 [ 10.5 ; 10.5 ] 1.4 [ -1.4 ; 4.1 ] 
v51 Val.ext -> Val 0 [ 0 ; 0.1 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0.5 ] 
v52 Ile.ext -> Ile 0 [ 0 ; 0.1 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0.5 ] 
v53 Leu.ext -> Leu 2.2 [ 1.2 ; 3.3 ] 0 [ 0 ; 0 ] 1.6 [ 0.1 ; 2.6 ] 
v54 Thr.ext -> Thr 0 [ 0 ; 1.6 ] 3.9 [ 3.9 ; 4 ] 0.3 [ 0.1 ; 0.6 ] 
v55 Phe.ext -> Phe 0 [ 0 ; 0.1 ] 0 [ 0 ; 0. ] 0 [ 0 ; 0.4 ] 
v56 Tyr.ext -> Tyr 0 [ 0 ; 0.1 ] 6.4 [ 6.3 ; 6.4 ] 0 [ 0 ; 0.3 ] 
v57 Met.ext -> Met 0 [ 0 ; 0 ] 2.4 [ 2.4 ; 2.5 ] 0 [ 0 ; 0.4 ] 
v58 Lys.ext -> Lys 0.9 [ 0 ; 1.8 ] 0 [ 0 ; 0 ] 0 [ 0 ; 1.5 ] 
v59 His.ext -> His 1.8 [ 0 ; 4.2 ] 0 [ 0 ; 0 ] 0.3 [ 0 ; 2 ] 
v60 Arg.ext <-> Arg -4.2 [ -7 ; -1.3 ] 0 [ 0 ; 0 ] 0.9 [ -2.4 ; 3.8 ] 
v61 Asp <-> OAA.c -0.6 [ -1.8 ; -0.3 ] 0 [ 0 ; 0 ] 0 [ -1 ; 0 ] 
v62 Cit.c -> OAA.c + AcCoA.c 0 [ 0 ; 0.1 ] 33.3 [ 33.2 ; 33.3 ] 0 [ 0 ; 1.8 ] 
v63 CO2.ext <-> CO2 -5.9 [ -90 ; Inf ] -132.1 [ -132.2 ; -132.1 ] -287.8 [ -303.4 ; -213.4 ] 
v64 AcCoA.c -> FA.ext 0 [ 0 ; 0.1 ] 33.3 [ 33.2 ; 33.3 ] 0 [ 0 ; 1.8 ] 
v65 AP.ext -> AP.c 0 [ 0 ; 0 ] 1.9 [ 1.9 ; 1.9 ] 0.7 [ 0.5 ; 0.7 ] 
v66 AP.m -> 8 x AcCoA.m  0 [ 0 ; 0 ] 8x0.6 [ 8x0.6 ; 8x0.7 ] 8x0.7 [ 8x0.5 ; 8x0.7 ] 
v67 AO.ext -> AO.c 0 [ 0 ; 0 ] 1.7 [ 1.7 ; 2.3 ] 0.6 [ 0.5 ; 0.7 ] 
v68 AO.m -> 9 x AcCoA.m  0 [ 0 ; 0 ] 9x0.4 [ 9x0.4 ; 9x1.5 ] 9x0.6 [ 9x0.5 ; 9x0.6 ] 
v69 Gal.ext -> G6P 0 [ 0 ; 0 ] 0 [ 0 ; 0 ] 30.4 [ 22 ; 32.1 ] 
v70 Cit.c -> Cit.snk 0 [ 0 ; 1.9 ] 0 [ 0 ; 0 ] 0 [ 0 ; 1.5 ] 
v71 Mal.m <-> Mal.c 0.6 [ 0.2 ; 4.4 ] 75.6 [ 75.3 ; 75.7 ] 7.2 [ 4.5 ; 8.3 ] 
v72 0*Mal.c -> Mal.s 3.9 [ 0 ; 100 ] 0 [ 0 ; 6.4 ] 0.5 [ 0 ; 100 ] 
v73 0*Mal.m -> Mal.s 96.1 [ 0 ; 100 ] 100 [ 93.6 ; 100 ] 99.5 [ 0 ; 100 ] 
v74 Mal.s -> Sink 100 [ 100 ; 100 ] 100 [ 100 ; 100 ] 100 [ 100 ; 100 ] 
v75 0*Fum.c -> Fum.s 14 [ 6.2 ; 21.6 ] 0 [ 0 ; 0.2 ] 32.2 [ 28.9 ; 36.3 ] 
v76 0*Fum.m -> Fum.s 86 [ 78.4 ; 93.8 ] 100 [ 99.8 ; 100 ] 67.8 [ 63.7 ; 71.1 ] 
v77 Fum.s -> Sink 100 [ 100 ; 100 ] 100 [ 100 ; 100 ] 100 [ 100 ; 100 ] 
v78 Mal.c <-> Fum.c 0 [ 0 ; 0 ] 0 [ 0 ; 0 ] 0 [ 0 ; 0 ] 
v79 OAA.c <-> Mal.c -0.6 [ -1.9 ; -0.2 ] 33.3 [ 33.3 ; 33.3 ] 0 [ -1 ; 0 ] 
v80 Asp.ext <-> Asp -0.6 [ -1.8 ; -0.3 ] 0 [ 0 ; 0 ] 0 [ -1 ; 0 ] 
v81 0*Cit.c -> Cit.s 0 [ 0 ; 100 ] 0 [ 0 ; 100 ] 83.5 [ 0 ; 100 ] 
v82 0*Cit.m -> Cit.s 100 [ 0 ; 100 ] 100 [ 0 ; 100 ] 16.5 [ 0 ; 100 ] 
v83 Cit.s -> Sink 100 [ 100 ; 100 ] 100 [ 100 ; 100 ] 100 [ 100 ; 100 ] 
v84 Cit.c <-> Cit.m 0 [ -2 ; 0 ] -33.3 [ -33.3 ; -33.2 ] 0 [ -1.6 ; 0 ] 
v85 AP.c -> AP.m 0 [ 0 ; 0 ] 0.6 [ 0.6 ; 0.7 ] 0.7 [ 0.5 ; 0.7 ] 
v86 AP.c -> AP.snk 0 [ 0 ; 0 ] 0.4 [ 0.4 ; 1.5 ] 0.6 [ 0.5 ; 0.6 ] 
v87 AO.c -> AO.m 0 [ 0 ; 0 ] 1.3 [ 1.2 ; 1.3 ] 0 [ 0 ; 0.1 ] 
v88 AO.c -> AO.snk 0 [ 0 ; 0 ] 1.3 [ 1.3 ; 3.5 ] 0 [ 0 ; 0.1 ] 
Abbreviations: G6P. glucose-6-phosphate; F6P. fructose-6-phosphate; FBP. fructose-1.6-bisphosphate; 
DHAP. Dihydroxyacetone phosphate; GAP. glyceraldehyde 3-phosphate;  3PG. 3-Phosphoglyceric acid; PEP. 
phosphoenolpyruvate; Pyr. pyruvate; P5P. pentose-5-phosphate; CO2. carbon dioxide; S7P. sedoheptulose-
7-phosphate; E4P. erythrose 4-phosphate; Lac. lactate; Ala. alanine; AcCoA. acetyl-CoA; OAA. oxaloacetate; 
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Cit. citrate;αKG. α-ketoglutarate; Suc. succinate; Fum. fumarate; Mal. malate; Glu. glutamate; Pro. proline; 
Val. valine; Ile. isoleucine; Leu. leucine; Thr. threonine; Phe. phenylalanine; Tyr. tyrosine. Met. methionine; 
Ser. serine; Cys. cyteine; lys. lysine; His. histidine; Arg; arginine; Gln. glutamine; Asp. aspartate; FA. fatty 
acid; PA. palmitic acid; AO. oleic acid; c. cytosolic; m. mitochondrial; s. sink. 
Fumarate and succinate were considered as symmetric molecules during flux estimation.  
Compartmentalization of Pyr, Fum, Mal, Cit, AcCoA, OAA, AO and AP pools were taken in account in the 
model. Sink pools were considered for metabolites that could not be balanced. 
Balanced metabolite pools: G6P, F6P, FBP, DHAP, GAP, 3PG, PEP, Pyr.c, Pyr.m, P5P, CO 2, S7P, 
E4P, Lac, Ala, AO.c, AO.m, AP.c, AP.m, AcCoA.c, AcCoA.m, OAA.c,OAA.m, Pyr.c, Pyr.m, Cit.c, Cit.m, AKG, 
SucCoA, Suc, Fum.c, Fum.m, Mal.c,Mal.m, Gln, Glu, Asn, Asp, Ser, Gly, C1, Pro, Val, Ile, Leu, Thr, Phe, Tyr, 
Met, Lys, His, Arg.  
Unbalanced metabolite pools: AO.ext, AP.ext, Ao.snk, Ap.snk, Cit.snk, FA.ext, CO 2.ext, Glc.ext, Gal.ext 
Lac.ext, Ala.ext, Gln.ext, Glu.ext, Asp.ext, Asn.ext, Ser.ext, Gly.ext, Pro.ext, Val.ext, Ile.ext, Leu.ext, Thr. ext, 
Phe.ext, Tyr.ext, Met.ext, Lys.ext, His.ext, Arg.ext, Cys.snk, Urea.snk. 
 
Table A-4.2. Comparison of contractility kinetics and contractile force generated by cells cultivated in 










) 0.28±0.10 0.48±0.22 * 
% Shortening 5.90±2.17 8.42±3.30 * 
Maximum shortening velocity 
(μm/ms) 
0.05±0.02 0.07±0.03 * 
Maximum relengthening 
velocity (μm/ms) 
0.03±0.01 0.05±0.02 ** 
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To fully explore the potential of human pluripotent stem cell-derived cardiomyocytes (hPSC-
CMs) efficient methods for storage and shipment of these cells are required. Here, we evaluated 
the feasibility to cold store monolayers and aggregates of functional CMs obtained from different 
PSC lines using a fully-defined clinical compatible preservation formulation, and investigated the 
time frame that hPSC-CMs could be subjected to hypothermic storage. 
We showed that 2D monolayers of hPSC-CMs can be efficiently stored at 4°C for 3 days 
without compromising cell viability. However, cell viability decreased when the cold storage interval 
was extended to 7 days. We demonstrated that hPSC-CMs are more resistant to prolonged 
hypothermic storage–induced cell injury in 3D aggregates than in 2D monolayers, showing high cell 
recoveries (>70%) after 7 days of storage. Importantly, hPSC-CMs maintained their typical 















The emerging potential of human pluripotent stem cell derived cardiomyocytes (hPSC-CM) in 
cell-based cardiac repair, patient-specific disease modelling and drug toxicity (Lundy et al., 2014; 
Sinnecker et al., 2014) is strongly pushing these cell-based products towards a global marketplace. 
Up to date, many efforts have been made in improving PSC expansion (Chen et al., 2014; Serra et 
al., 2010, 2012; Wang et al., 2014), CM-lineage differentiation and enrichment processes (Correia 
et al., 2014; Lundy et al., 2014; Mummery et al., 2012), however little attention has been given to 
methodologies and protocols to preserve and transport these cell products from the manufacturing 
site to the clinical setting, for immediate administration in patients, to research institutes or to 
biotechnology companies. The complexity is associated with the laborious and time-consuming 
differentiation protocols, as well as the inability of maintaining the differentiated non-replicative cells 
in culture for long periods of time, highlight the need for developing efficient strategies for 
preservation of PSC-CMs. The cryopreservation protocols are still highly inefficient, usually 
resulting in a substantial loss of cell viability and function (Abbasalizadeh and Baharvand, 2013; 
Healy et al., 2011). Additionally, the majority of these protocols use animal-derived components 
(e.g., proteins, serum…) and/or toxic cryoprotective agents (CPAs, e.g., DMSO) (Li and Ma, 2012) 
rendering them unsuitable for clinical applications. It has been demonstrated that serum residues in 
the therapeutic product can trigger adverse reactions in patients (Thirumala et al., 2009). Washing 
protocols are therefore required to remove CPAs, serum and cellular debris from therapeutic cells 
prior to patient administration (Li and Ma, 2012; Thirumala et al., 2009).  
Hypothermic preservation can be an alternative to cryopreservation in short-term storage 
situations (e.g. to perform a inter- or trans-continental transport of the cells). During hypothermic 
storage, cells are maintained at temperatures that range between 4 and 10°C. These lower 
temperatures affect cell physiology namely by reducing their metabolism, energy storage 
degradation and oxygen demand (Rubinsky, 2003). Effective hypothermic preservation requires the 
use of preservation solutions that: i) provide optimal concentrations of ions and impermeable 
molecules to maintain ionic and osmotic balance, ii) prevent the formation of free radicals, iii) 
maintain an oncotic balance, and iv) supply energy substitutes (Baust, 2005; Mathew et al., 2004). 
A variety of preservation solutions such as ViaSpan® (University of Wisconsin solution), Celsior®, 
HTK-Custodiol and, more recently, HypoThermosol® (HTS), were developed taking these factors 
into consideration (Mathew et al., 2004) and are commercially available today. These solutions 
showed to be effective for hypothermic storage of a large diversity of cells, tissues and organs 
(including neonatal rat ventricular cardiomyocytes (Snyder et al., 2005), renal cells (Mathew et al., 
2002), hepatocytes (Duret et al., 2015; Gramignoli et al., 2014), liver tissue (Bessems et al., 2004), 
synthetic human epidermis tissue (Cook et al., 1995), kidney (Hrabalová et al., 2003), pancreas 
(Squifflet et al., 2011), liver (Bessems et al., 2004) and heart (Minasian et al., 2014; Wakayama et 
al., 2012)). Importantly, some of these formulations can be directly administered into patients, 
avoiding additional post-storage culture manipulations/costs and washing steps. HTS for example 
has been used as a vehicle solution for different therapeutic cells in several clinical trials, such as 
 




in the treatment of autoimmune disorders including rheumatoid arthritis with allogeneic adipose-
derived stem cells (NCT01743222), advanced heart failure with myogenic cells (NCT00526253), 
and restrictive scars using allogeneic dermal fibroblasts (NCT01564407).  
The time interval that a cardiac graft can be efficiently cold-stored remains limited to 6h 
(Minasian et al., 2014). This finite time frame further limits donor heart supply, access and utility. 
The ability to efficiently cold preserve functional CMs for extended periods will provide an appealing 
off-the-shelf solution for the treatment of cardiac diseases. Several studies have evaluated the 
ability to preserve adult/neonatal rat/mouse CMs at hypothermic conditions (Abi-Gerges et al., 
2013; Lu et al., 2006; Orita et al., 1995; Snyder et al., 2005; Uchida et al., 2011). For example, 
Snyder and colleagues reported the successful hypothermic storage of neonatal rat ventricular CM 
monolayers for up to 72h in HTS. After this storage period, CMs retained their viability, metabolic 
activity (82% by day 1 post-storage) and spontaneous contractile activity (Snyder et al., 2005); 
nevertheless, the impact of hypothermic storage on CM structure, ultrastructure, action potential 
and drug responsiveness was not evaluated.  
To date, there are no studies reporting the efficient hypothermic storage of PSC-CMs. 
Therefore, in this study we aimed to develop efficient strategies for hypothermic storage of murine 
and human PSC-CMs. The CM differentiation protocols are conventionally performed in 2D 
monolayers, or more recently in 3D cell configurations, such as cell aggregates (Mummery et al., 
2012; Zhang et al., 2015). It is well known that cell-cell and cell-matrix interactions play a critical 
role in cell survival/recovery after thawing (Serra et al., 2011). Disruption of these interactions may 
result in dissociation-induced apoptosis (Wong et al., 2006). Consequently, we evaluated the 
feasibility to cold store CMs obtained from different PSC lines as 2D monolayers and 3D 
aggregates and assessed the impact of the hypothermic storage time on cell viability and metabolic 
activity recovery. Cell phenotype, including structure, ultrastructure, gene and protein expression, 
and functionality were assessed post-storage by quantitative RT-PCR, flow cytometry, fluorescent 




2.1. CM layers Differentiation of mPSCs 
A murine transgenic αPIG induced pluripotent stem cell (miPSC) line was used in this study. 
This cell line was genetically modified to integrate and stably express a transgene containing 
puromycin-N-acetyl transferase and eGFP (enhanced green fluorescent protein) genes, both under 
control of the cardiac-restricted promoter α-myosin heavy chain (α-MHC) (Halbach et al., 2013). 
miPSC were expanded and differentiated as aggregates in fully controlled bioreactors as previously 
described by our group (Correia et al., 2014). Briefly, iPSCs were inoculated in the Wave Cellbag
TM
 
(GE Healthcare) as single cells, at a concentration of 7x10
4 
cell/mL, and were cultivated under 





rocking angle: 4°; agitation rate: 10-26 rpm; working volume: 1 L) in differentiation medium 
(Iscove’s modified Dulbecco’s medium (IMDM) with GlutaMAX, supplemented with 20 % (v/v) fetal 
bovine serum (FBS), 1 % (v/v) non-essential amino acids (NEAA), 1 % (v/v) Pen/Strep, 50 μM β-
mercaptoethanol (all from Invitrogen)). At day 9, cell lineage selection was induced by addition of 
puromycin (8 μg/mL). At day 11, cell aggregates composed of more than 97% of iPSC-CMs were 
harvested from Wave bioreactor. These cell aggregates were either preserved (as described in 




, in 24-well plates coated with CELLstart CTS (Invitrogen)). Cells were cultivated at 37°C, in 
a humidified atmosphere of 5% CO2, until hypothermic storage studies were performed. 
2.2. CM layers Differentiation of hPSCs 
Two hPSC lines were used: hiPSC (DF19-9-11T.H from WiCell) and human embryonic stem 
cell (hESC) line (NKX2-5(eGFP/w) (Elliott et al., 2011), kindly provided by Dr. David Elliott from 
Murdoch Childrens Research Institute). HPSC were cultured on Synthemax® II – SC Substrate 
(Corning) coated plates in mTESR1 (STEMCELL Technologies) medium until reaching 80% 
confluence. Cardiac differentiation was induced as described by Lian et al (Lian et al., 2013). Using 
this protocol, 2D monolayer cultures composed by 50-70% of hPSC-CMs were obtained. To enrich 
the cell population into CMs, cells were cultured in CM enrichment medium (RPMI 1640 without 
glucose (Invitrogen) supplemented with B27 without insulin (Invitrogen) and 4 mM sodium L-lactate 
(Sigma-Aldrich)) for 10 days as described elsewhere [32]. After CM enrichment (more than 80% 
VCAM positive cells), monolayer cultures were dissociated into single cells by incubation with 
TrypLE
TM





Synthemax® II – SC Substrate (Corning) coated 24-well plates, and maintained for one week at 
37°C in a humidified atmosphere of 5% CO2, until hypothermic storage studies; and ii) aggregated 
as described in literature (Skelton et al., 2014). Briefly, 5x105 cells were inoculated per well of low-
adherent U bottom 96 well plates (Nunc), centrifuged at 500 g for 5 min, and cultured in 
differentiation media (RPMI 1640 (Invitrogen) supplemented with B27 without insulin) for one week 
until preservation tests. 
2.3. Hypothermic storage of PSC-CM 
2D Monolayer cultures and 3D aggregates of murine and human PSC-CMs were stored at 4°C 
in HypoThermosol®-FRS solution (HTS, BioLife Solutions) for 3, 5 and 7 days (designated as S3, 
S5 and S7, respectively). Immediately before hypothermic storage, culture medium was replaced 
by the following volumes of HTS solution: 2D monolayers - 300 µL/well in 24 well plate; 3D 
aggregates - 150 μL/well in 96 well plate (1 aggregate/ well) or 1 mL/cryovial (300 
Aggregates/cryovial). After the hypothermic storage interval, HTS solution was removed, murine 
and human PSC-CMs were washed once with the respective differentiation media (described in 
sections 2.1. and 2.2.) and cultivated in the same medium for 7 days. In the first 24 hours post-
storage, medium was supplemented with 10 μM of Rho-associated kinase inhibitor (ROCKi, Biogen 
Cientifica SL). Medium was totally exchanged at days 0, 1, 3 and 7 of culture. 
 




2.4. Assessment of PSC-CM viability and metabolic activity after storage 
Cell viability, metabolic activity, and metabolism were evaluated at days 0, 1, 3 and 7 of 
culture post-storage, using the methods described below.  
2.4.1. Fluorescein diacetate-propidium iodide staining.  
The qualitative assessment of the cell plasma membrane integrity was performed using the 
enzyme substrate fluorescein diacetate (FDA, Sigma-Aldrich), and the DNA-binding dye propidium 
iodide (PI, Sigma-Aldrich), as described in the literature (Jones and Senft, 1985). Briefly, cells were 
incubated with 20 μg/mL FDA and 10 μg/mL PI in Dulbecco’s Phosphate Buffered Saline (DPBS, 
Invitrogen) for 2-3 min and visualized by fluorescence microscopy (DMI 6000, Leica Microsystems 
GmbH).  
2.4.2. Lactate Dehydrogenase (LDH) activity in the supernatant.  
The release of intracellular LDH to the supernatant can be correlated with the extent of cell 
lysis as described by Decker et al (Decker and Lohmann-Matthes, 1988). LDH activity from the 
supernatant of centrifuged (300 g, 5 min) samples was determined spectrophotometrically following 
(at 340 nm) the rate of oxidation of NADH to NAD
+
 coupled with the reduction of pyruvate to lactate 
as described elsewhere (Serra et al., 2011).  
2.4.3. Trypan Blue exclusion method.  
Cells cultured as monolayers were dissociated as described in section 2.2. Cell concentration 
was estimated by counting cells using a Fuchs–Rosenthal haemocytometer (Brand). Viable cells 
were determined by using the trypan blue dye (0.1% (v/v) in DPBS) exclusion method. The 




 assay.  
Metabolic activity was determined using the metabolic indicator PrestoBlue (Invitrogen) 
reagent following manufacturer’s recommendation. Briefly, cells were incubated for 1-2 h with 
culture medium containing 10% (v/v) PrestoBlue reagent. Fluorescence was measured (excitation 
wavelength: 570 nm, emission wavelength: 585 nm) using a microwell plate fluorescence reader 
Infinite 200 PRO NanoQuant (TECAN). The active ingredient of PrestoBlue (resazurin) is a 
nontoxic, non-fluorescence indicator dye that is reduced to red-fluorescent resorufin by 
metabolically active cells. Fluorescence intensity is proportional to the number of live and metabolic 
active cells. Thus, PrestoBlue assay provides a quantitative measure of cell viability and metabolic 
activity. Fluorescence values were normalized to the values obtained with the same cells before 
cold storage, and are indicated as a percentage of metabolic activity recovery. 
2.4.5. NucView™ 488 and MitoView™ 633 Apoptosis Assay.  
A qualitative assessment of apoptosis was performed using the Apoptosis Assay Kit 
NucView™ 488 and MitoView™ 633 (Biotium, Inc., California, USA) following manufacturer's 
instructions. This kit contains the green fluorescent NucView 488 caspase-3 substrate and the far-
red fluorescent MitoView 633 mitochondrial dye for profiling caspase-3 activity and changes in 





for 1 h, cells were observed using fluorescence microscopy (DMI 6000, Leica) and representative 
images were taken. 
2.4.6. Quantification of caspase activity.  
A quantitative assessment of apoptosis was performed using the Caspase Family 
Fluorometric Substrate Kit II Plus (Abcam) following manufacturer's instructions. Briefly, the activity 
of caspases -3/7, -6, -8, -9 and -10 was determined by incubation with the respective AFC 
conjugated substrates. AFC-based substrates yield fluorescence upon protease cleavage 
(Ex/Em=400 nm/505 nm). The fold increase in caspase activity was determined by the ratio of the 
values of fluorescence obtained for the cells subject to cold storage to the values obtained by the 
cells immediately before storage. 
2.5. Metabolite analysis 
Glucose (GLC), glutamine (GLN) and lactate (LAC) concentrations in the culture medium were 





were calculated using the equation: qMet. = ΔMet/(Δt ΔXv), where ΔMet (mol/L) is the variation of 
metabolite concentration during the time period Δt (h), and ΔXv (cell/L) the average of cell 
concentration during the same time period. 
2.6. Assessment of PSC-CM structure and ultrastructure after hypothermic storage 
2.6.1. Scanning electron microscopy (SEM) and Transmission electron microscopy (TEM) 
Monolayers and aggregates of human PSC-CMs were fixed in 2% (v/v) glutaraldehyde in 0.1 
M HEPES buffer (pH 7.4) for 20 min, washed in DPBS and stored in 1% (v/v) glutaraldehyde in 
DPBS until analyses. For TEM analyses, cell aggregates were immersion fixed in a mixture of 2% 
glutaraldehyde and 2% paraformaldehyde in 50 mM HEPES. Subsequently, the samples were 
washed once in 100 mM HEPES, twice in DPBS, and twice in double-distilled water before 
postfixation with osmium tetroxide (1% (v/v) in water, 2 h on ice). After several washes in water, the 
samples were contrasted en-bloc with aqueous uranyl acetate (1% (w/v), 2 h on ice), washed 
several times in distilled water, dehydrated in a graded series of ethanol, infiltrated in epon 812 
(epon/ethanol mixtures: 1:3, 1:1, 3:1, 1 h each, pure epon overnight, pure epon 6 h), and 
embedded in flat embedding molds. Finally, the samples were cured at 65°C in the oven. 2D-
Monolayers were fixed with 2% (v/v) glutaraldehyde in 100 mM HEPES for 1 h, and washed in 100 
mM HEPES and distilled water. Postfixation, en-bloc contrasting, dehydration, epon infiltration and 
curing were performed as described above. After curing, the samples were dissected into small 
blocks and mounted on epon dummy blocks. Ultrathin sections of aggregates and monolayers 
were cut on a Leica UC6 ultramicrotome using a diamond knife. Sections were collected on 
formvar-coated slot grids, stained with lead citrate and uranyl acetate as described in the literature 
(Venable and Coggeshall, 1965), and analysed on a FEI Morgagni 268 at 80 kV. Images were 
taken with an Olympus MegaView III using the iTEM software. 
For SEM analyses cell aggregates were immersion fixed in 2% (v/v) glutaraldehyde with 2% 
(w/v) paraformaldehyde (PFA) in 50 mM HEPES, and washed once in 100 mM HEPES, twice in 
 




DPBS, and twice in double-distilled water before post-fixation with osmium tetroxide (1% in water, 2 
h on ice). After several washes in distilled water, the samples were dehydrated in a graded series 
of ethanol, critical-point dried using the Leica CPD 300, mounted to carbon tabs which were glued 
to 12 mm aluminum stubs, and sputter coated with gold using the Baltec SCD 050 sputter coater. 
Samples were imaged in a Jeol 7500F cold field emission SEM at 5kV acceleration voltage and 8 
mm working distance using the lower secondary electron detector. 
2.7. Measurement of aggregate size 
The aggregate size was determined using an inverted-microscope (DMI 6000, Leica) by 
measuring two perpendicular diameters of each aggregate. These measures were used to 
calculate the average diameter of each aggregate. 
2.8. Characterization of PSC-CMs after hypothermic storage  
2.8.1. Flow cytometry.  
After a 5 min dissociation with TypLE
TM
Select, human PSC-CMs were washed twice with 
DPBS and a total of 5x10
5
 cells were incubated with each of the antibodies VCAM-1 (CD106-PE, 
BD Biosciences), SIRPα/β (CD172a/b-PE, BioLegend) and isotype controls IgG1,κ-PE (BD 
Biosciences) for 1 h at 4°C. Cells were washed twice with DPBS, and analysed in a CyFlow® 
space (Partec GmbH) instrument, registering 10,000 events/sample. 
2.8.2. Immunofluorescence microscopy.  
Cells were washed with DPBS and fixed in 4% (w/v) PFA and 4% (w/v) sucrose in DPBS 
solution for 15 min. Afterwards, cells were permeabilized for 10 min in 0.5 M Ammonium chloride 
(Sigma-Aldrich), 0.25% (v/v) Triton X-100 in DPBS and blocked with 5% (v/v) FBS in DPBS for 1 h, 
at room temperature. Cells were subsequently incubated overnight at 4°C with primary antibodies 
diluted in 0.2% (w/v) Fish Skin Gelatin (FSG), 0.1% (w/v) TX-100 in DPBS. The following primary 
antibodies were used: α-sarcomeric actinin (1:200, Sigma-Aldrich), titin (1:100, Santa Cruz 
Biotechnology), troponin I (TnI, 1:100, Millipore), troponin T (Tnt, 1:100, Millipore), MYL2 (1:140, 
ABCAM), MYL7 (H-60, 1:50, Santa Cruz Biotechnology). Non reporter cell lines were also 
incubated with F-actin Alexa Fluors 488 dye (Life technologies). Cells were washed in DPBS and 
secondary antibodies were incubated for 60 min at room temperature in the dark. Secondary 
antibodies used were: AlexaFluor 594 goat anti-mouse IgG and AlexaFluor 594 goat anti-rabbit IgG 
(1:500 dilution in 0.2% (w/v) FSG, 0.1% (w/v) TX-100 in DPBS). Cell nuclei were counterstained 
with Hoechst 33342 nucleic acid dye. Cells were visualized using an inverted fluorescence 
microscope (DMI 6000, Leica).  
2.8.3. Quantitative RT-PCR. 
Total RNA was extracted using the High Pure RNA Isolation Kit (Roche), and reverse 
transcription was performed with High Fidelity cDNA Synthesis Kit (Roche), following 
manufacturer’s instructions. Relative quantification of gene expression was performed using 
LightCycler 480 Probes Master (Roche) in 20 μL reactions with 50 ng cDNA template and 20x 





480 Real-Time PCR System (Roche). Cycle threshold (Ct’s) were determined by LightCycler 480 
Software. All data was analyzed using the 2-ΔΔCt method for relative gene expression analysis. 
Changes in gene expression were normalized to the average of RFLP0 and GAPDH gene 
expression as internal control. The TaqMan probes used for human ISL1, KDR, GATA4, NKX2.5, 
TNNT2, VCAM1, MYH7, MYL2, MYL7, HCN4, CACNA1C, ACTC1, MYH6, MYH7, SCN5A, RFLP0 
and GAPDH genes were HS00158126_m1, HS00911699_m1, Hs00171403_m1, 
Hs00231763_m1, Hs00165960_m1, Hs01003372_m1, Hs01110632_m1, Hs00166405_m1, 
Hs00221909_m1, Hs00175760_m1, Hs00167681_m1, Hs00606316_m1, Hs01101425_m1, 
Hs01110632_m1, Hs00165693_m1, Hs99999902_m1 and Hs99999905_m1, respectively. 
2.9. Assessment of PSC-CM function after hypothermic storage 
2.9.1. Electrophysiological analyses of mIPSC-CMs. 
Single mPSC-CMs were plated on glass cover slips coated with 0.1% gelatin. The patch 
clamp experiments were performed as described previously (Kuzmenkin et al., 2009). Briefly, cover 
slips were placed into a recording chamber (37°C) and cells were continuously perfused with 
extracellular solution. Cell membrane capacitance was determined online using Pulse software 
(Heka Elektronik). Action potential (AP) recordings of spontaneously beating murine PSC-CMs 
were performed utilizing the whole-cell current-clamp technique with an EPC-9 amplifier (HEKA 
Elektronik), and operated through the Pulse acquisition software. Response to hormonal regulation 
was analyzed by administering 1 µM isoproterenol (Iso, Sigma-Aldrich). 
2.9.2. Electrophysiological analyses of hIPSC-CMs. 
Single hPSC-CMs were plated on 35 mm plastic petri dishes previously coated with 
Synthemax. These dishes were used as recording chambers mounted on the stage of an inverted 
microscope. A gravity based superfusion system was used for the exchange of extracellular 
solution (2–3 mL/min), which had the following composition: 135 mM NaCl, 5 mM KCl, 1.5 mM 
MgSO4, 0.33 mM NaH2PO4, 10 mM HEPES, 1 mM CaCl2, 15 mM D-glucose, adjusted to pH 7.35 
with 1 mM NaOH. Cells  were voltage-clamped using the whole cell patch-clamp configuration, as 
described previously (Vicente et al., 2010). Briefly, the patch pipettes (2–5 MΩ) were pulled from 
borosilicate glass capillaries (Science Products GmbH, GB150T-8P) and filled with an internal 
solution containing: 135 mM potassium gluconate, 5 mM KCl, 5 mM NaCl, 10 mM Na1/2HEPES, 1 
mM MgCl2, 0.1 mM EGTA, 2 mM Na2ATP, 0.4 mM NaGTP (pH 7.3 adjusted with 1 mM KOH; 
305±5 mOsm). The estimated junction potential for the filling and bathing solution combinations 
mentioned above is -8.9 mV (calculated with JPCalc 2.00, School of Physiology and Pharmacology 
University of New South Wales). Data were not corrected for the junction potential. Currents were 
recorded with an Axopatch 200B electrometer (Axon Instruments Inc., USA) and stored on a PC 
computer using pClamp 6.0.3 software (Axon Instruments Inc., USA) and an analogue digital 
interface (Digidata 1200; Axon Instruments, USA). Signals were acquired at a sampling rate of 5 
kHz and filtered at 2 kHz (-3 dB, four pole Bessel). Electrode and cell membrane capacitances 
were compensated whenever possible. Cells with significant leak currents were rejected. 
 




The holding potential (VH) was kept at -70mV.  Current-voltage relationships were 
investigated using a set of 10 mV (260 ms) command pulses from -130 to 0 mV. More depolarizing 
potentials, greater than 0 mV, were not used as in this protocol because patch seals tend to brake. 
Thus, to avoid depolarization-induced cells damage, we excluded the depolarizing steps above 0 
mV from the current-voltage relationships, focusing more on the evaluation of the inward currents. 
The K
+
 outward currents were observable only at potentials greater than ± 40mV (Figure 6.A).  
The Ca
2+
 dependence of the outward K
+
 currents was assessed using a two-pulse protocol, 
which consists of a triple set of double depolarizing pulses (Figure 6.B). A prepulse lasting 50 ms to 
-40, -10 or +20 mV was delivered to trigger Ca
2+
 influx through voltage-activated channels. The 
prepulse was immediately followed by a second depolarizing pulse to +40 mV for 750 ms to elicit 
the outward K
+
 current.  
2.9.3. Pharmacological responses of hPSC-CMs. 
Single hPSC-CMs were plated on 35 mm plastic petri dishes previously coated with 
Synthemax. These dishes were used as recording chambers mounted on the stage of an inverted 
microscope. A gravity based superfusion system was used for the exchange of extracellular 
solution (2–3 mL/min), which had the following composition: 135 mM NaCl, 5 mM KCl, 1.5 mM 
MgSO4, 0.33 mM NaH2PO4, 10 mM HEPES, 1 mM CaCl2, 15 mM D-glucose, adjusted to pH 7.35 
with 1 mM NaOH. Cells  were voltage-clamped using the whole cell patch-clamp configuration, as 
described previously (Vicente et al., 2010). Briefly, the patch pipettes (2–5 MΩ) were pulled from 
borosilicate glass capillaries (Science Products GmbH, GB150T-8P) and filled with an internal 
solution containing: 135 mM potassium gluconate, 5 mM KCl, 5 mM NaCl, 10 mM Na1/2HEPES, 1 
mM MgCl2, 0.1 mM EGTA, 2 mM Na2ATP, 0.4 mM NaGTP (pH 7.3 adjusted with 1 mM KOH; 
305±5 mOsm). The estimated junction potential for the filling and bathing solution combinations 
mentioned above is -8.9 mV (calculated with JPCalc 2.00, School of Physiology and Pharmacology 
University of New South Wales). Data were not corrected for the junction potential. Currents were 
recorded with an Axopatch 200B electrometer (Axon Instruments Inc., USA) and stored on a PC 
computer using pClamp 6.0.3 software (Axon Instruments Inc., USA) and an analogue digital 
interface (Digidata 1200; Axon Instruments, USA). Signals were acquired at a sampling rate of 5 
kHz and filtered at 2 kHz (-3 dB, four pole Bessel). Electrode and cell membrane capacitances 
were compensated whenever possible. Cells with significant leak currents were rejected. 
The holding potential (VH) was kept at -70mV.  Current-voltage relationships were 
investigated using a set of 10 mV (260 ms) command pulses from -130 to 0 mV. More depolarizing 
potentials, greater than 0 mV, were not used as in this protocol because patch seals tend to brake. 
Thus, to avoid depolarization-induced cells damage, we excluded the depolarizing steps above 0 
mV from the current-voltage relationships, focusing more on the evaluation of the inward currents. 
The K
+
 outward currents were observable only at p otentials greater than ± 40mV (Figure 5.6.A).  
The Ca
2+
 dependence of the outward K
+
 currents was assessed using a two-pulse protocol, 
which consists of a triple set of double depolarizing pulses (Figure 5.6.B). A prepulse lasting 50 ms 
to -40, -10 or +20 mV was delivered to trigger Ca
2+





prepulse was immediately followed by a second depolarizing pulse to +40 mV for 750 ms to elicit 
the outward K
+
 current.  
 
2.9.2. Pharmacological responses of hPSC-CMs. 
The effect of pharmacological treatment on the contractile activity of hPSC-CMs was analyzed 
by administering in the superfusion fluid: 300 pM Nimodipina; 30 mM KCL; 1 μM Verapamil; 0.5 
mM Adrenaline. hPSC-CMs were visualized using a Nikon Eclipse Ti-U inverted microscope at 
room temperature (± 25°C). Bright field video/images were recorded with a FASTCAM MC2 
camera (Photron Europe, Limited) controlled with PFV (Photron FASTCAM Viewer) software. A 
region of interest was drawn around the contracting structures filmed at 10 fps. Pixel density, used 
as indirect measurement of contraction, was digitized using ImageJ software (National Institutes of 
Health [NIH]). 
2.9.4. Detection of Ca
2+
 Transients.  
Ca
2+
 imaging was performed according to the standard protocol provided in Rhod-3- Calcium 
Imaging kit (Invitrogen). Aggregates of human PSC-CMs were plated onto eight-well culture plates 
coated with Synthemax and cultured for 1 week, to promote cell adherence and migration to the 
plate. Briefly, cells were labelled with Rhod-3 for 1 h at 37°C, washed twice in DPBS, incubated for 
1 h with a water-soluble reagent to reduce baseline signal and washed again in DPBS. Cells were 
imaged live using a spinning disk confocal microscope (Nikon Eclipse Ti-E; System: Andor 
Revolution XD; Confocal Scanner: Yokogawa CSU-x1) and calcium transients were determined 
using Micro-Manager 1.4 and ImageJ software. 
2.10. Statistical analysis 
All statistical analyses were performed using GraphPad Prism version 5 (GraphPad Software 
Inc.). Values are represented as mean±standard deviation of independent measurements or 
assays (at least n=3 replicates were considered). Statistical significance was evaluated using either 
Student's t test with Welch's correction or one-way analysis of variance (ANOVA). Values of 
P<0.05 were considered statistically significant. 
 
3. Results 
3.1. Impact of hypothermic storage on PSC-CM viability and metabolic activity 
In this study we aimed at developing a protocol for hypothermic storage of PSC-CMs, cultured 
either as 2D monolayers or 3D aggregates, to ensure efficient short-term preservation and/or 
shipping of PSC-CM suitable for clinical applications and toxicology testing. Murine and human 
PSC-CMs were preserved at hypothermic conditions (4°C) for 3, 5 and 7 days (designated 
hereafter as S3, S5 and S7, respectively), in HypoThermosol®-FRS (HTS) preservation solution. 
HTS was used since it is a xeno-free, cGMP and clinical compatible solution that has been 
 




successfully utilized for hypothermic preservation of multiple cell types including neonatal rat CMs 
(Snyder et al., 2005).  
Our results show that miPSC-CMs can be efficiently stored for 7 days in hypothermic 
conditions in HTS solution, without compromising cell viability or metabolic activity (Figure A-5.1, 
Page 172). Both 2D monolayers and 3D aggregates of iPSC-CMs remained highly viable after cold 
storage (Figure A-5.1A, Page 172) and maintained α-MHC driven eGFP expression (Figure A-5.1A, 
Page 172). By day 7 of culture post-storage, both 2D monolayers and 3D aggregates of mPSC-
CMs have nearly recovered their metabolic activity (>90%, as determined by the PrestoBlue assay 
- Figure A-5.1B, Page 172).  
hPSC-CMs were more sensitive to hypothermia induced stress than mPSC-CMs. Our results 
showed that high cell viabilities (80%) can be obtained when 2D monolayers of hPSC-CMs were 
preserved at hypothermic conditions for 3 days (S3 condition, Figure 5.1A-B). However, cell 
viability post-storage decreased with increased cold storage intervals (Figure 5.1, Table 5.1). 
Specifically, cell viabilities, determined by the Trypan Blue exclusion method (Figure 5.1A) and 
metabolic activity recoveries, evaluated using the PrestoBlue assay (Figure 5.1B, Table 5.1), of 
approximately 60% and 50% were estimated for S5 and S7 conditions, respectively. The marked PI 
and NucView
TM
 Caspase-3 substrate staining (Figure 5.1C) and the significantly higher cell lysis 
measured by the LDH activity in the supernatant (Figure 5.1D) at day 1 post-storage, confirmed 
that cell death was more pronounced in S7 condition. In agreement, we verified that the caspase 
activity of stored hiPSC-CMs (immediately and 24 hours after cold storage) in S7 condition 
increased in relation to the hiPSC-CMs before hypothermic storage (Figure 5.1E). More 
specifically, we observed a significant increase in the activity of apoptotic initiator caspases (-8, -9 
and -10) and apoptotic effector caspases (-3/7 and -6). The highest increase in caspase activity 
(~1.7 fold increase) was registered in caspase 3/7, 24 hours after cells were removed from 
hypothermic storage corroborating the pronounced NucView
TM
 Caspase-3 substrate staining 
observed in Figure 5.1C. All together these results allowed us also to perceive that cell death 
occurred mainly from day 0 to day 1 of culture post-storage by both necrosis and apoptosis. 
Nonetheless, after 7 days in culture post-storage, cells that recovered from hypothermia remained 
viable, adherent to culture dishes without meaningful PI/NucViewTM staining (Figure 5.1C). 
MitoViewTM staining also highlighted the presence of abundant and functional mitochondria, a 
typical CM feature (Figure 5.1C - lower panel). It is worth noting that after all cold storage intervals 
(S3, S5 and S7), cells restored their metabolism, as shown by similar values of specific glucose 
and glutamine consumption rates and lactate production rate when compared with the control, 
hiPSC-CMs not subjected to hypothermic storage i.e., maintained in culture during the storage 






Figure 5.1. Hypothermic storage of hiPSC-CM as 2D monolayers. hiPSC-CMs were stored for 3 (S3), 5 
(S5) and 7 (S7) days at 4°C, in HTS solution. Cell recovery was evaluated for 7 days post-storage. A) 
Evaluation of cell recovery after the storage interval and 7 days of culture post-storage using the Trypan Blue 
exclusion method. B) Assessment of metabolic activity recovery using the PrestoBlue test. The cell 
concentration (A) and the Fluorescence values of PrestoBlue (B) are presented as a % in relation to the 
values obtained in the cells immediately before cold storage. C - upper panel) Viability analysis of hiPSC-
CMs from S7 condition, assessed at days 1 and 7 post-storage, using the FDA (live cells, green) and PI (dead 
cells, red). C - lower panel) Detection of caspase-3 activity using NucView™ Caspase-3 Substrate (red) and 
the MitoView™ mitochondrial dye (cyan), at day 1 and day 7 post-storage in S7 cultures. Scale bars: 100μm. 
 




D) Cell lysis measured by the LDH activity in the culture supernatant. Values are normalized by the number of 
cells. E) Fold increase in the activity of caspases -3/7, -6, -8, -9 and -10 immediately and 24h after 
hypothermic storage in S7 condition in relation to the cells before storage. Data are presented as mean ± SD 
of three (A), four (E) and five (B, D) measurements. P<0.05 (*), P<0.01 (**), P<0.001 (***), Not-significant (ns), 
determined by one-way analysis of variance and unpaired t test.  
 
Similar profiles of cell recovery were obtained when CMs derived from a hESC line were 
preserved as 2D monolayers (Figure A-5.2, Page 173). Specifically, cell recoveries of 80% were 
obtained after 5 days of hypothermic storage (Figure A-5.2A, Page 173 - condition S5) but 
increased storage intervals (condition S7) led to a significant decrease in cell viability and 
metabolic activity recovery (42%, as determined by the PrestoBlue assay, Figure A-5.2A, Page 
173). After both storage intervals, cells that survived to hypothermic storage recovered their 
metabolism (Figure A-5.2B, Page 173).  
Hypothermic preservation of hiPSC-CMs cultured as 3D aggregates led to higher cell 
recoveries than when cultured as 2D monolayers. From 3 days in culture post-storage onwards, no 
significant differences in metabolic activity recovery were detected between S5 and S7 conditions 
(Figure 5.2B). By day 7 of culture post-storage, metabolic activity recoveries of 66% and 71% were 
determined by the PrestoBlue assay, in S5 and S7 conditions, respectively (Figure 5.2B, Table 
5.1). No necrotic centers were observed in aggregates from S5 and S7 and just a few PI-positive 
cells randomly distributed through the aggregate were detected at day 1 post-storage (Figure 
5.2A). Importantly, contrary to what was observed in 2D monolayer cultures (Figure 5.1E), after 
hypothermic storage of hiPSC-CM aggregates the activity of initiator and effector caspases did not 
change significantly, and was even lower for some stored samples in relation to hiPSC-CMs before 
hypothermic storage (Figure 5.2C). These data indicate that when hiPSC-CM are stored in this 
configuration cell death by apoptosis is not meaningful. In scanning electron microscopy (SEM) 
images it was possible to identify a higher amount of dead cells/cellular debris on the surface of the 
aggregates subjected to hypothermic storage comparatively to control aggregates (hiPSC-CM 
aggregates not subjected to cold storage; Figure 5.2D vs. 5.2E).  
 
Table 5.1. Evaluation of hiPSC-CM recovery after 3 (S3), 5 (S5) and 7 (S7) days of storage at 4°C in HTS 
preservation solution. Error bars denote the mean±SD of five (2D Monolayers) and fifteen (3D Aggregates) 
measurements. Significant differences in relation to the Control (cells not subjected to hypothermic storage 
cells, maintained under conventional culture conditions for 14 days (i.e. equivalent to 7 days of storage plus 7 
days of post-storage recovery))  were determined by unpaired t test with Welch's correction and are indicated 
by: P<0.01 (**), P<0.001 (***). NS:  Non-significant differences to the Control. Specific consumption rates of 








Figure 5.2. Hypothermic storage of hiPSC-CM as 3D aggregates. Aggregates were stored for 5 (S5) and 7 
days (S7) at 4°C in HTS solution. Cell recovery was evaluated for 7 days post-storage. A) Evaluation of 
metabolic activity recovery post-storage by PrestoBlue assay. The Fluorescence values are presented as a % 
in relation to the values obtained in the cells immediately before cold storage. B) Cell viability at day 1 post-
storage assessed using FDA (live cells, green) and PI (dead cells, red) dyes. C) Fold increase in the activity of 
caspases -3/7, -6, -8, -9 and -10 immediately and 24h after hypothermic storage in S7 condition in relation to 
the cells before storage. D-E) Scanning electron microscopy of hiPSC-CM aggregates from S7 condition after 
7 days in culture post-storage (D) and the control (hiPSC-CM aggregates not subjected to cold storage i.e., 
maintained in culture during the storage period, E). The boxed regions were magnified to show cell boundaries 
and cell-cell contacts (arrow). Scale bars: 200 μm (B), 10 μm (C-left and D), 1 μm (C-middle and C-right). 
Data are presented as mean ± SD of four (C) and fifteen (B) measurements. P<0.05 (*), P<0.01 (**), P<0.001 









These results were also confirmed by PrestoBlue assay as lower cell viabilities and metabolic 
activities post-storage were attained in S5 and S7 conditions comparatively to the control (Figure 
5.2B). Noteworthy, after 7 days of culture post-storage, aggregates from S7 condition maintained 
their structure, being almost indistinguishable from control aggregates (Figure 5.2D vs. 5.2E). In 
accordance, no significant differences (p>0.05) in aggregate size were detected between 
aggregates from S7 condition (269±17 µm, Figure 5.2D) and control aggregates (256±13 µm, 
Figure 5.2E). The metabolic profile, namely specific glucose and glutamine consumption rates and 
lactate production rate, was also not significantly different from control aggregates (Table 5.1). 
3.2. Effect of hypothermic storage on PSC-CM phenotype 
Hypothermic storage may affect not only cell viability and metabolic activity but also cell 
phenotype and function (Taylor, 2006). Although we showed that hPSC-CMs are more resistant to 
prolonged hypothermic storage–induced cell injury in 3D aggregates than in 2D monolayers, we 
intended to confirm also that viable cells recovered after hypothermic storage in 2D-monolayers, 
maintain their phenotype. Thus, we assessed the effect of hypothermic storage on the structure 
and functional features of hPSC-CMs storage as 2D monolayers and 3D aggregates. Our results 
showed that PSC-CMs, stored either as 2D monolayers or 3D aggregates, recovered from all 
hypothermic storage intervals (S3, S5 and S7), restored their metabolism (Table 5.1), retained the 
expression of cardiac markers (determined by flow cytometry, Figure 5.3A and 5.4A) and the 
contractile function  (Figure 5.3B and 5.4B). Therefore, cells subjected to a longer period of 
hypothermic storage (S7 condition) were selected and further characterized in terms of gene 
expression, cell structure, ultrastructure and function. 
 Quantitative RT-PCR analyses was performed for hiPSC-CMs stored as 2D monolayers. The 
results revealed that, after seven days in culture post-storage, all CM specific genes, with the 
exception of VCAM1, and the cardiac progenitor related genes, KDR and GATA4, were highly 
expressed in hPSC-CMs subjected to cold storage than in the control (i.e. non-stored cells that 
were maintained in culture for 14 days, which corresponds to the 7 days of hypothermic storage 
plus 7 days in culture post-storage) (Figure 5.3B). These data suggests a hypothetical role of 
hypothermia in CM enrichment (cardiac progenitor cells present in culture prior to hypothermia 







Figure 5.3. Characterization of hiPSC-CMs stored as 2D monolayers in hypothermic conditions for up 
to 7 days. A) Percentage of SIRPA and VCAM-positive cells determined by flow cytometry. B) The beating 
frequency (beats per minute) after all storage intervals (S3, S5, and S7) was monitored until day 4 of culture 
post-storage in hiPSC-CM cultured as 2D monolayers. The results were normalized to the beating frequency 
measured in the control cells not subjected to cold storage. C) Quantitative RT-PCR analysis showing the 
relative expression of cardiac-related transcription factors, cardiac-specific structural genes, calcium handling 
and membrane ion channels in S7 condition, after 7 days in culture post-storage (d7). Values were normalized 
to the control, cells not subjected to cold storage and maintained in culture for the same time period. Data are 
presented as mean ± SD of at least three measurements. P<0.05 (*), P<0.01 (**), P<0.001 (***), Not-
significant (ns) determined by unpaired t test. 
 
To access morphology and structure of hiPSC-CM stored as 3D aggregates, 
immunofluorescence microscopy analysis was carried out. Our results showed that hiPSC-CM, 
exhibited a typical      cardiac morphology with highly organized sarcomeric α-actinin, titin, troponin 
I and troponin T after 7 days of hypothermic storage (Figure 5.4C). Similar results were attained for 
miPSC-CM that also expressed Myl2, Myl7 and α-MHC (Figure A-5.3, Page 173), as well as for 
cells stored as 2D monolayers (not shown). 
   
 





Figure 5.4. Characterization of hiPSC-CMs stored as 3D aggregates in hypothermic conditions for up 
to 7 days. After hypothermic storage and one week in culture post-storage, cells were characterized by flow 
cytometry (A) and immunofluorescence staining (C) for cardiac specific markers. The regained of contractile 
activity was also assessed by phase contrast microscopy (B). A) Percentage of SIRPA, VCAM and cTNT-
positive cells determined by flow cytometry. B) The beating frequency (beats per minute) after all storage 
intervals (S3, S5, and S7) was monitored until day 4 of culture post-storage. The results were normalized to 
the beating frequency measured in the control cells not subjected to cold storage. C) Immunofluorescence 
analysis of hiPSC-CMs (from plated 3D aggregates), after hypothermic storage, for the CM-specific markers: 
sarcomeric α-actinin, Troponin C, Troponin I, Titin (red) antibodies. F-actin is stained with phalloidin (green). 
Nuclei were counterstained with Hoeschst (blue). Scale bars: 30 μm. 
  
Transmission electron microscopy (TEM) analysis revealed that after the storage interval and 
7 days in culture post-storage, hiPSC-CMs cultured either as 2D monolayers (Figure 5.5A) or 3D 
aggregates (Figure 5.5B) did not display signals of microstructural damage (such as damaged cell 
membranes and organelles) and showed ultrastructural features indistinguishable from the hiPSC-
CMs not subjected to hypothermic storage (control; Figure 5.5C). Myofilaments organized in 
myofibrils with a sarcomeric pattern were observed as well as abundant long and slender 
mitochondria. Z bands delimiting the sarcomeres and highly specialized cell-cell junctions 
(intercalated disks) were also identified in both culture configurations (Figure 5.5A and 5.5B). No 
other bands were visible in the sarcomere construct, in the cold stored hiPSC-CMs and control 
(Figure 5.5A-C). The aligned sarcomeres in stored hiPSC-CMs presented a mean length of 
1.40±0.06 μm, similar to the control (1.49±0.09 μm), and to sarcomere length reported in literature 






Figure 5.5. Ultrastructural characterization of hiPSC-CMs after hypothermic preservation. Transmission 
electron microscopy (TEM) images of hiPSC-CMs, stored at hypothermic conditions for 7 days (S7), as 2D 
monolayers (A) and as 3D aggregates (B). C) TEM images of the control 3D aggregates - hiPSC-CMs not 
subjected to hypothermic storage i.e., maintained in culture during the storage period (control). HiPSC-CMs 
presented a large nucleus (Nu)-to-cytoplasm ratio and contained many myofibrils (MF) aligned and organized 
in a sarcomeric pattern. Z-bands (Z) and neighbouring CMs (CM1, CM2) connected by intercalated disks (ID) 
were also observed. Scale bars: 1μm (A, B-right, C-right); 2 μm (B-left, C-left). 
  
 




3.3. Characterization of hiPSC-CM function after hypothermic storage 
We verified that after all storage intervals murine (not shown) and human iPSC-CMs stored as 
2D monolayers and 3D aggregates regained their normal beating frequency after 3-4 days in 
culture (Figure 5.3B, Figure A-5.4B, Page 174). The action potential (AP) characteristics of miPSC-
CMs cold stored as 2D monolayers were very similar to control miPSC-CMs, showing comparable 
maximum diastolic potential (MDP), beating frequency, velocity of diastolic depolarization (Vdd), 
AP upstroke velocity (Vmax), and AP duration (APD) (Figure A-5.4A, Page 174). Moreover, the 
response of cold stored and control miPSC-CMs to cardiostimulatory drugs was not significantly 
different. When the adrenergic agonist isoproterenol was administered, a similar increase of AP 
frequency was observed (Figure A-5.4B, Page 174). Positive chronotropic effects of isoproterenol 
were reversible upon washout (Figure A-5.4B, Page 174). 
Characterization of hiPSC-CM function after 7 days of hypothermic storage as 2D monolayers 
plus 7 days in culture was accessed by recording inward and outward whole-cell K
+
 conductances 
in voltage-clamp experiments using the whole-cell patch-clamp configuration. After obtaining 
‘whole-cell mode’, brief measurements of membrane potential (Vm, under Current-clamp) were 
conducted before shifting to voltage clamp. These recordings revealed that cell membranes were 
adequately polarized after 7 days of cold storage (Vm= -69.2± 0.6mV; n=8). To evaluate voltage 
dependence of transmembrane currents, a wide range of potentials were used to record currents 
following 10 mV steps (of 260 ms) from -130 to +0 mV, while keeping the holding potential at -70 
mV (Figure 5.6A left panel). The corresponding curves revealed three main components: i) a clear 
inward component from -130 to -60 mV (component that may correspond to the typical cardiac 
inward K rectifier – Ikr); ii) a inward ‘hump’ from -50 to -20 mV; and iii) a typical delayed outward K
+
 
current above -10 mV (Figure 5.6A right panel). To investigate the outward K
+
 current, a less 
abrasive single voltage step (to +40 mV) was performed (Figure 5.6B). This protocol consisted in a 
brief depolarization (50 ms) to -10 mV aiming at Ca
2+ 
influx through voltage-activated channels, 
which was immediately followed by a longer depolarizing step (750 ms) to +40 mV. 
 The inward current ‘hump’ detected in the current-voltage relationship between -50 and 0 mV 
(Figure 5.6A) suggests the activation of voltage-gated calcium channels allowing Ca
2+
 influx mainly 
through CaV1 (L-type) channels (Grant, 2009). Even though we did not perform experiments to 
directly evaluate calcium dynamics, it is likely that activation of voltage-activated calcium channels 
may account for the inward current ‘hump’ observed here. Thus, Ca
2+
 recruitment through voltage-





outward currents occur as described for CMs (Lu et al., 2007). 
Consistent with this, we showed that the outward K
+
 current (Figure 5.6B) was clearly voltage-
dependent with the maximal amplitude obtained when cells were depolarized with a prepulse 
reaching -10 mV, i.e. close to the maximum activation of CaV1 (L-type) currents. Indirect 
measurements of contractions obtained from video data analysis revealed that hiPSC-CMs 
subjected to 7 days of cold storage as 2D monolayers respond appropriately to different 






Figure 5.6. Functional characterization of hiPSC-CMs subjected to hypothermic storage for 7 days. 
After hypothermic storage for 7 days and one week in culture post-storage, cell functionality was evaluated by 
the detection of CM-specific action potentials (AP, A-B), typical CM response to drugs (C-H) and calcium 
transients (I-J). A) Whole-cell voltage-clamp recordings from hiPSC-CMs subjected to 7 days of hypothermic 
storage as 2D monolayers. A - left panel) Representative currents following a set of voltage pulses (260 ms), 
covering a wide range of potentials, with incremental depolarization steps (10 mV) from -130 to 0 mV (holding 
voltage -70 mV) (see inset). A - right panel) Corresponding current-voltage relationship showing 3 different 
components in terms of voltage dependence: a strong inward rectifier, an inward ‘hump’, and a delayed 
outward current. B) Representative current traces from a triple set of double depolarizing pulses: one first step 
to -40, -10 and +20 mV, lasting 50 ms, followed by a second pulse to +40 mV, lasting 750 ms (see inset). One 
can notice a larger outward current at +40 mV when preceded by a prepulse to -10mV, which suggest a Ca
2+
-
dependent current component. C-H) Effect of chronotropic drugs: 30 mM KCL C), 1 μM Verapamil D), 0.5 mM 
 




Adrenaline (E-F), and 300 pM Nimodipina (G-H), on contractile activity of hiPSC-CMs (cultured as 2D 
monolayers) subjected to 7 days of hypothermic storage, analysed by video recording in an inverted 
microscopy. I) Pseudo-color images showing minimal (Ca
2+
 min, left image) and maximal (Ca
2+
 max, right 
image) intensity of the calcium indicator dye Rhod-3. The six hiPSC-CMs analysed (from plated 3D 
aggregates) are highlighted. J) Graphical representation of calcium level cycling, during hiPSC-CMs 
contraction, determined by confocal imaging of the Rhod-3 dye, for the six different hiPSC-CMs. Data are 
presented as mean ± SD of twenty four (F, H) measurements. P<0.001 (***), Not-significant (ns) determined 
by unpaired t test. 
An increase in K
+
 concentration from 5 to 30 mM shifted the potential equilibrium of K
+
 
resulting in membrane potential depolarization and consequently in a strong and sustained 
contraction (Figure 5.6C). 
The addition of verapamil (1 μM), which specifically blocks L-type Ca
2+
 channels, reduced the 
beating frequency and ultimately arrested beating (Figure 5.6D). On the other hand the 
administration of 0.5 μM of Adrenaline, a β-receptor agonist, increased significantly the beating 
frequency of hiPSC-CMs but not the duration of the contraction events (Figure 5.6E-F). The 
treatment with nimodipine (300 pM), a L-type Ca
2+
 channel blocker, evoked subtle but meaningful 
effects on beating behaviour. Beating frequency remained constant whereas the duration of the 
contractions significantly decreased (Figure 5.6G-H). These data strongly suggested the existence 
of L-type voltage activated Ca
2+
 currents in hiPSC-CMs after hypothermic storage. 
Real-time intracellular calcium imaging, using the calcium indicator dye Rhod-3, revealed that 
2D monolayers (not shown) and 3D aggregates of hiPSC-CMs present synchronized oscillatory 
patterns of intracellular calcium concentrations (Figure 5.6I-J). 
Overall, these results clearly show that murine and human iPSC-CMs exhibit intact molecular, 
ultrastructural and functional properties after one week of hypothermic storage. 
4. Discussion 
Several studies have focused on the development of methods to preserve primary cultures of 
neonatal and adult CMs from rat and mouse origin (Ku et al., 1997; Orita et al., 1994; See et al., 
1992; Snyder et al., 2005; Vettel et al., 2014; Wheeler and Chien, 2012), but little has been done to 
optimize the short- and long- term storage of hPSC-CMs that more accurately reflect the 
physiology of human CMs. In this study we developed efficient strategies for the hypothermic 
storage of 2D monolayers and 3D aggregates of hPSC-CMs. We showed that both 2D cell 
monolayers and 3D cell aggregates of mPSC-CMs can be maintained for up to one week in 
hypothermic conditions without meaningful effects on cell viability (>90% of cell recovery), structure 
and functionality (including action potential and drug responsiveness). However, we verified that 
hPSC-CMs are more sensitive to hypothermia/rewarming-induced stress than mPSC-CMs. A 30% 
decrease in cell viability was observed in hPSC-CMs preserved as monolayers, when the storage 
interval was extended from 3 to 7 days. In fact, it is not surprising that murine and human PSC-
CMs present such a different tolerance to hypothermic storage as several studies have described 
significant differences in the transcriptional networks, global molecular signatures and signaling 
pathways in mouse and human PSC (Ernst et al., 2015; Schnerch et al., 2010). These differences 





observed in these cells (Schnerch et al., 2010). Mu and coworkers showed significant differences 
in the induction of differentiation of murine and human ESCs into CMs as well as in specific 
features of each CM derivative, including average beating frequency and response to 24h of 
hypoxia stimulation (Mu et al., 2014).  
In this work, we showed that hPSC-CM aggregates subjected to 5 and 7 days of hypothermic 
preservation present similar cell recoveries post-storage. After 7 days of hypothermic storage, cell 
recoveries were higher in PSC-CM aggregates (70%) than in PSC-CM monolayers (50%). These 
results suggest that a 3D architecture confers an additional protection to extended hypothermia-
induced stress, possibly due to the formation of vast and stable cell-to‐cell and cell-to-extracellular 
matrix (ECM) interactions. It has been reported that a tridimensional organization favors the 
establishment and maintenance of cellular junctions between cardiac cells (Soares et al., 2012). In 
the same study, the authors demonstrated that aggregates of cardiac cells exhibit a larger number 
of intercellular junctions and a higher amount of ECM connecting the cells comparatively to 2D-
cultures (Soares et al., 2012). Interestingly, it has been shown that in 3D conformations, cell 
extensions become entangled with ECM fibrils, resulting in integrin-independent mechanical 
interactions that strengthen cell anchorage (Jiang and Grinnell, 2005). All these findings support 
our supposition that spatial organization of PSC-CMs may affect their biological response to 
hypothermic storage. 
It has been reported that hypothermic storage may induce adverse effects on cells, including 
hypoxic stress, ischemia and reperfusion injury, disruptions in membrane potential (redox balance), 






 homeostasis), generation of reactive 
oxygen species (ROS), collapse of cytoskeleton and ultrastructural damage (Bishopric et al., 2001; 
Boutilier, 2001; Rauen and De Groot, 1998; Stefanovich et al., 1995; Taylor, 2006; Taylor et al., 
2005). These effects are more pronounced with increasing hypothermic storage interval, resulting 
in the activation of necrotic or apoptotic cell death pathways (Taylor, 2006; Taylor et al., 2005). 
Activation of the apoptotic cascade takes hours to days to be fully manifested after cells or tissues 
were removed from storage. Thus, to assess the efficiency of the preservation strategy, cell 
recovery should be assessed for an extended time period in culture post-storage and preferably 
using complementary characterization techniques. In this study we evaluated CM recovery during 7 
days of culture post-storage, through the analysis of cellular membrane integrity (FDA/PI staining, 
trypan blue exclusion test); metabolic activity (PrestoBlue assay) and detection of apoptosis 
activation and mitochondrial activity (Quantification of caspase activity and MitoView/NucView
TM
 
staining). As expected, extended hypothermic preservation intervals induced both necrosis and 
apoptosis of hPSC-CMs, particularly in 2D monolayer cultures. Nonetheless, hPSC-CMs that 
recovered from hypothermic storage, either in 3D aggregate or in 2D monolayer cultures, 
maintained their phenotype as reflected by a typical CM structure/ultrastructure and cardiac protein 
expression profile. The expression of typical CM genes (including transcription factors, specific 
structural genes and ionic channels) revealed to be significantly higher in stored hiPSC-CMs than 
in the control, suggesting that hypothermia state may enhance CM enrichment/maturation 
processes. A recent study reported that apoptotic stimuli, more specifically a sublethal caspase-
 




activation, up-regulates cardiac progenitor and CM differentiation, increasing the final yield of CMs 
(Bulatovic et al., 2015). As shown in our study and in others (Mahler et al., 2003; Snyder et al., 
2005; Taylor, 2006) the hypothermic state promotes caspase activation, consequently we could 
also speculate about an interference of cold preservation in cardiogenic pathways. Importantly, 
hiPSC-CMs subjected to 7 days of hypothermic storage maintained their functionality, exhibiting 





 currents) (Ma et al., 2011), ii) indirect ‘fingerprints’ of voltage 
activated L-type Ca2+ currents (Ma et al., 2011), and iii) appropriate contractile activity response to 
chronotropic agents (Dick et al., 2010). 
Commercially available hypothermic solutions, such as HTS, were carefully formulated to 
maintain the ionic and osmotic balances, inhibit acidosis and prevent cell swelling at low 
temperatures (Mathew et al., 2004; Taylor, 2006). These features facilitate preservation of cell 
homeostasis, not achievable when using just culture medium as a preservation formulation. For 
example, normal human epidermal keratinocytes can be maintained for periods exceeding one 
week at 4°C in HTS and only 24 hours in normal growth media at 4°C (Van Buskirk et al., 1996). 
Currently, the incorporation of protective agents, including antioxidants, ion chelators and 
membrane stabilizers in preservation media has been reported to markedly improve preservation 
efficacy. For example, fructose-1,6-bisphosphate (Wheeler and Chien, 2012; Wheeler et al., 2005), 
2,3-butanedione (Fagbemi and Northover, 1996; Wheeler and Chien, 2012), Myosin II ATPase 
inhibiting-agents (Abi-Gerges et al., 2013), dopamine and lipophilic derivatives (Vettel et al., 2014), 
and human neuregulin-1 peptide (Jabbour et al., 2011) proved to be efficient in improving the post-
storage viability in mouse/rat hearts and/or CMs. A recent study with preserved bioartifical livers 
showed that an improved protective effect can be obtained if distinct agents are added to the 
storage solution during the appropriate preservation stage (pre-incubation, hypothermia and 
rewarming) (Dai and Meng, 2011). Specific protective agents could also be combined with our cold 
storage preservation protocol to further enhance preservation efficacy after extended storage 
intervals.  
In summary, we established effective and clinical compatible strategies for cold storage of 2D 
monolayers and 3D aggregates of murine and human PSC-CMs and provided some evidences 
about the appropriate time interval to store PSC-CMs at hypothermic conditions without 
compromising their viability, phenotype and function. These preservation strategies can be 
integrated with the differentiation process, avoiding additional and possible harmful manipulation of 
cells, such as monolayer/aggregate dissociation. Moreover, these strategies enable cell products to 
be manufactured off-site in certified companies. Importantly, our approach for hypothermic storage 
of 2D monolayers of PSC-CM will facilitate the delivery of certified, validated, ready-to-use cell 
plates suitable for high-throughput cardiac drug testing and toxicity screening, whereas the one-
week storage strategy for PSC-CM aggregates will allow the distribution of not only off-the-shelf 
tissue like in vitro models for cardiac toxicity drug testing but also therapeutic cells that could be 
directly used in cardiac regenerative therapies. In fact, it has been demonstrated that the delivery 





cells in a murine model of cardiac injury (Bauer et al., 2012). The strategies for cold preservation of 
PSC-CM described herein contribute to overcome the hurdles and needs of the regenerative 
medicine market and scientific community, constituting a step forward towards improved worldwide 





Figure A-5.1. Hypothermic storage of murine iPSC-CMs. 2D monolayers and 3D aggregates of miPSC-
CMs were stored for 7 days at 4°C in HTS solution. Cell recovery post-storage was evaluated for 7 days. Cell 
viability was assessed by cell staining with FDA (live cells, green) and PI (dead cells, red) - A upper panel - 
and by evaluation of α-MHC-eGFP expression (green) - A lower level. Photos were taken at day 1 post-
storage. Scale bars: 200 μm. B) Evaluation of metabolic activity recovery during 7 days post-storage using the 
PrestoBlue assay. The fluorescence values of PrestoBlue are presented as a % in relation to the values 











Figure A-5.2. Hypothermic preservation of hESC-CM as 2D monolayers. Cells were stored for 5 (S5) and 
7 (S7) days at 4°C in HTS solution. Cell recovery was evaluated for 7 days post-storage. A-B) Metabolic 
performance of hESC-CMs post-storage. A) Evaluation of metabolic activity recovery using the PrestoBlue 
assay. B) Mean specific rates of glutamine (qGLN) and glucose (qGLC) consumption and lactate production 
(qLAC) during one week in culture post-storage. Control refers to cells not subjected to hypothermic storage. 
Data are presented as mean ± SD of five measurements. P<0.05 (*), P<0.001 (***), Not-significant (ns), 
determined by unpaired t test. C) Viability analysis of hESC-CMs stored for 5 days at 4°C, assessed at day 7 
post-storage, using the MitoView
TM
 (functional mitochondria, cyan) and NucView
TM
 (apoptotic cells, red) – 






Figure A-5.3. Immunofluorescence labelling of miPSC-CMs after hypothermic storage as 2D 
monolayers. Cells were stained using the CM-specific, sarcomeric α-actinin, titin, troponin I, Myl2 and Myl7, 
antibodies (red). Expression of eGFP driven by the cardiac promoter α-MHC (green) was also detected. 







Figure A-5.4. Functional characterization of miPSC-CMs subjected to hypothermic storage for 7 days. 
Cell functionality was evaluated in cells stored for 7 days (S7, blue bars) and non-stored miPSC-CMs (control, 
grey bars) cultured as 3D aggregates by the detection of CM-specific action potentials (AP, A) and typical CM 
response to drugs (B). A) Action potential properties of miPSC-CMs: Vdd, velocity of diastolic depolarization; 
Vmax, the maximum rate of rise of the action potential upstroke; APD90, action potential duration at 90% of 
repolarization; APD50, action potential duration at 50% of repolarization. B) Effect of 1 μM Isoproterenol (Iso) 
on beating frequency of miPSC-CMs. Data are presented as mean ± SD of six (A-B) measurements. Not-
significant (ns) determined by unpaired t test. 
6. Acknowledgments 
The authors acknowledge: Dr. David Elliott for providing the PSC lines used in this study and 
support on the cardiomyocyte differentiation protocol; Dr. Thomas Kurth for performing TEM/SEM 
analyses and helping with result interpretation. Pedro Sampaio and Susana Lopes (CEDOC) for 
the use and assistance of Image acquisition and analyses system. This work was supported by 
FP7 EU project CARE-MI (HEALTH-2009_242038) and the Fundação para a Ciência e Tecnologia 
(FCT) funded projects CARDIOSTEM (MITP-TB/ECE/0013/2013), CardioRegen (HMSP-
ICT/0039/2013) and CardioRecept (PTDC/BBB-BIO/1414) for financial support. iNOVA4Health - 
UID/Multi/04462/2013, a program financially supported by FCT / Ministério da Educação e Ciência, 
through national funds and co-funded by FEDER under the PT2020 Partnership Agreement is also 
acknowledged. CC acknowledges the FCT for her PhD grant (SFRH/BD/51573/2011). 
7. References 
Abbasalizadeh, S., and Baharvand, H. (2013). Technological progress and challenges towards 
cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic 
and autologous cell therapies. Biotechnol. Adv. 31, 1600–1623. 
Abi-Gerges, N., Pointon, A., Pullen, G.F., Morton, M.J., Oldman, K.L., Armstrong, D., Valentin, J.P., 
and Pollard, C.E. (2013). Preservation of cardiomyocytes from the adult heart. J. Mol. Cell. Cardiol. 
64, 108–119. 
Bauer, M., Kang, L., Qiu, Y., Wu, J., Peng, M., Chen, H.H., Camci-Unal, G., Bayomy, A.F., 
Sosnovik, D.E., Khademhosseini, A., et al. (2012). Adult cardiac progenitor cell aggregates exhibit 
survival benefit both in vitro and in vivo. PLoS One 7, e50491. 
Baust, J.M. (2005). Advances in Media for Cryopreservation and Hypothermic Storage. Bioprocess 
Biosyst Eng 46–56. 
Bessems, M., Doorschodt, B.M., van Vliet, A.K., and van Gulik, T.M. (2004). Preservation of rat 
livers by cold storage: a comparison between the University of Wisconsin solution and 
Hypothermosol. Ann. Transplant. 9, 35–37. 
 




Bishopric, N.H., Andreka, P., Slepak, T., and Webster, K.A. (2001). Molecular mechanisms of 
apoptosis in the cardiac myocyte. Curr. Opin. Pharmacol. 1, 141–150. 
Boutilier, R.G. (2001). Mechanisms of cell survival in hypoxia and hypothermia. J. Exp. Biol. 204, 
3171–3181. 
Bulatovic, I., Ibarra, C., Österholm, C., Wang, H., Beltrán-Rodríguez, A., Varas-Godoy, M., 
Månsson-Broberg, A., Uhlén, P., Simon, A., and Grinnemo, K.-H. (2015). Sublethal Caspase 
Activation Promotes Generation of Cardiomyocytes from Embryonic Stem Cells. PLoS One 10, 
e0120176. 
Van Buskirk, R.G., Rauch, J., Robert, S., Taylor, M.J., and Baust, J.G. (1996). Assessment of 
hypothermic storage of normal human epidermial keratinocytes (NHEK) using Alamar Blue. Vitr. 
Tox. 9, 297–303. 
Chen, K.G., Mallon, B.S., McKay, R.D.G., and Robey, P.G. (2014). Human pluripotent stem cell 
culture: considerations for maintenance, expansion, and therapeutics. Cell Stem Cell 14, 13–26. 
Cook, J.R., Eichelberger, H., Robert, S., Rauch, J., Baust, J.G., Taylor, M.J., and Buskirk, R.G. 
(1995). Cold-Storage of Synthetic Human Epidermis in HypoThermosol. Tissue Eng. 1, 361–377. 
Correia, C., Serra, M., Espinha, N., Sousa, M., Brito, C., Burkert, K., Zheng, Y., Hescheler, J., 
Carrondo, M.J.T., Sarić, T., et al. (2014). Combining Hypoxia and Bioreactor Hydrodynamics 
Boosts Induced Pluripotent Stem Cell Differentiation Towards Cardiomyocytes. Stem Cell Rev. 10, 
786–801. 
Dai, J., and Meng, Q. (2011). Differential function of protective agents at each stage of the 
hypothermic preservation of hepatocytes. J. Biochem. 149, 739–745. 
Decker, T., and Lohmann-Matthes, M.L. (1988). A quick and simple method for the quantitation of 
lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor 
(TNF) activity. J. Immunol. Methods 115, 61–69. 
Dick, E., Rajamohan, D., Ronksley, J., and Denning, C. (2010). Evaluating the utility of 
cardiomyocytes from human pluripotent stem cells for drug screening. Biochem. Soc. Trans. 38, 
1037–1045. 
Duret, C., Moreno, D., Anangi, B., and Roux, S. (2015). Cold-preservation of human adult 
hepatocytes for liver cell therapy. 
Elliott, D.A., Braam, S.R., Koutsis, K., Ng, E.S., Jenny, R., Lagerqvist, E.L., Biben, C., Hatzistavrou, 
T., Hirst, C.E., Yu, Q.C., et al. (2011). NKX2-5eGFP/w hESCs for isolation of human cardiac 
progenitors and cardiomyocytes. Nat. Methods 8, 1037–1040. 
Ernst, M., Dawud, R.A., Kurtz, A., Schotta, G., Taher, L., and Fuellen, G. (2015). Comparative 
computational analysis of pluripotency in human and mouse stem cells. Sci. Rep. 5, 7927. 
Fagbemi, O.S., and Northover, B.J. (1996). Effect of protein kinase C inhibitors and 2,3-
butanedione monoxime on the long-term hypothermic preservation of isolated rat hearts. Clin. Sci. 
(Lond). 91, 745–754. 
Gherghiceanu, M., Barad, L., Novak, A., Reiter, I., Itskovitz-Eldor, J., Binah, O., and Popescu, L.M. 
(2011). Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: 
Comparative ultrastructure. J. Cell. Mol. Med. 15, 2539–2551. 
Gramignoli, R., Dorko, K., Tahan, V., Skvorak, K.J., Ellis, E., Jorns, C., Ericzon, B.G., Fox, I.J., and 
Strom, S.C. (2014). Hypothermic storage of human hepatocytes for transplantation. Cell 
Transplant. 23, 1143–1151. 
Grant, A.O. (2009). Cardiac ion channels. Circ. Arrhythmia Electrophysiol. 2, 185–194. 
Halbach, M., Peinkofer, G., Baumgartner, S., Maass, M., Wiedey, M., Neef, K., Krausgrill, B., 
Ladage, D., Fatima, A., Saric, T., et al. (2013). Electrophysiological integration and action potential 
properties of transplanted cardiomyocytes derived from induced pluripotent stem cells. Cardiovasc. 
Res. 100, 432–440. 
Healy, L., Young, L., and Stacey, G.N. (2011). Stem cell banks: Preserving cell lines, maintaining 
genetic integrity, and advancing research. Methods Mol. Biol. 767, 15–27. 





(2003). Effect of various protective solutions on function after kidney transplantation. Biomed. Pap. 
Med. Fac. Univ. Palacký, Olomouc, Czechoslov. 147, 197–202. 
Jabbour, A., Gao, L., Kwan, J., Watson, A., Sun, L., Qiu, M.R., Liu, X., Zhou, M.D., Graham, R.M., 
Hicks, M., et al. (2011). A recombinant human neuregulin-1 peptide improves preservation of the 
rodent heart after prolonged hypothermic storage. Transplantation 91, 961–967. 
Jiang, H., and Grinnell, F. (2005). Cell-matrix entanglement and mechanical anchorage of 
fibroblasts in three-dimensional collagen matrices. Mol. Biol. Cell 16, 5070–5076. 
Jones, K.H., and Senft, J.A. (1985). An improved method to determine cell viability by simultaneous 
staining with fluorescein diacetate-propidium iodide. J. Histochem. Cytochem. 33, 77–79. 
Ku, K., Oku, H., Alam, M.S., Saitoh, Y., Nosaka, S., and Nakayama, K. (1997). Prolonged 
hypothermic cardiac storage with histidine-tryptophan-ketoglutarate solution: comparison with 
glucose-insulin-potassium and University of Wisconsin solutions. Transplantation 64, 971–975. 
Kuzmenkin, A., Liang, H., Xu, G., Pfannkuche, K., Eichhorn, H., Fatima, A., Luo, H., Saric, T., 
Wernig, M., Jaenisch, R., et al. (2009). Functional characterization of cardiomyocytes derived from 
murine induced pluripotent stem cells in vitro. FASEB J. 23, 4168–4180. 
Li, Y., and Ma, T. (2012). Bioprocessing of cryopreservation for large-scale banking of human 
pluripotent stem cells. Biores. Open Access 1, 205–214. 
Lian, X., Zhang, J., Azarin, S.M., Zhu, K., Hazeltine, L.B., Bao, X., Hsiao, C., Kamp, T.J., and 
Palecek, S.P. (2013). Directed cardiomyocyte differentiation from human pluripotent stem cells by 
modulating Wnt/β-catenin signaling under fully defined conditions. Nat. Protoc. 8, 162–175. 
Lu, J., Hou, R., Booth, C.J., Yang, S.-H., and Snyder, M. (2006). Defined culture conditions of 
human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 103, 5688–5693. 
Lu, L., Zhang, Q., Timofeyev, V., Zhang, Z., Young, J.N., Shin, H.-S., Knowlton, A.A., and 
Chiamvimonvat, N. (2007). Molecular coupling of a Ca2+-activated K+ channel to L-type Ca2+ 
channels via alpha-actinin2. Circ. Res. 100, 112–120. 
Lundy, S.D., Gantz, J.A., Pagan, C.M., Filice, D., and Laflamme, M.A. (2014). Pluripotent stem cell 
derived cardiomyocytes for cardiac repair. Curr. Treat. Options Cardiovasc. Med. 16, 319. 
Ma, J., Guo, L., Fiene, S.J., Anson, B.D., Thomson, J. a, Kamp, T.J., Kolaja, K.L., Swanson, B.J., 
and January, C.T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: 
electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. 
Physiol. 301, H2006-17. 
Mahler, S., Desille, M., Frémond, B., Chesné, C., Guillouzo, A., Campion, J.P., and Clément, B. 
(2003). Hypothermic storage and cryopreservation of hepatocytes: The protective effect of alginate 
gel against cell damages. Cell Transplant. 12, 579–592. 
Mathew, A.J., Van Buskirk, R.G., and Baust, J.G. (2002). Improved Hypothermic Preservation of 
Human Renal Cells Through Suppression of Both Apoptosis and Necrosis. Cell Preserv. Technol. 
1, 239–253. 
Mathew, A.J., Baust, J.M., Van Buskirk, R.G., and Baust, J.G. (2004). Cell preservation in 
reparative and regenerative medicine: evolution of individualized solution composition. Tissue Eng. 
10, 1662–1671. 
Minasian, S.M., Galagudza, M.M., Dmitriev, Y. V., Karpov,  a. a., and Vlasov, T.D. (2014). 
Preservation of the donor heart: from basic science to clinical studies. Interact. Cardiovasc. Thorac. 
Surg. 1–10. 
Mu, J., Li, X., Yuan, S., Zhang, J., and Bo, P. (2014). Comparative study of directional 
differentiation of human and mouse embryonic stem cells into cardiomyocytes. Cell Biol. Int. 38, 
1098–1105. 
Mummery, C.L., Zhang, J., Ng, E.S., Elliott, D. a, Elefanty, A.G., and Kamp, T.J. (2012). 
Differentiation of human embryonic stem cells and induced pluripotent stem cells to 
cardiomyocytes: a methods overview. Circ. Res. 111, 344–358. 
Orita, H., Fukasawa, M., Hirooka, S., Uchino, H., Fukui, K., Kohi, M., and Washio, M. (1994). 
Cardiac myocyte functional and biochemical changes after hypothermic preservation in vitro. 
 




Protective effects of storage solutions. J. Thorac. Cardiovasc. Surg. 107, 226–232. 
Orita, H., Fukasawa, M., Uchino, H., Uchida, T., Shiono, S., and Washio, M. (1995). Long-term 
hypothermic preservation of cardiac myocytes isolated from the neonatal rat ventricle: A 
comparison of various crystalloid solutions. Surg. Today 25, 251–256. 
Rauen, U., and De Groot, H. (1998). Cold-induced release of reactive oxygen species as a decisive 
mediator of hypothermia injury to cultured liver cells. Free Radic. Biol. Med. 24, 1316–1323. 
Rubinsky, B. (2003). Principles of low temperature cell preservation. Heart Fail. Rev. 8, 277–284. 
Schnerch, A., Cerdan, C., and Bhatia, M. (2010). Distinguishing between mouse and human 
pluripotent stem cell regulation: the best laid plans of mice and men. Stem Cells 28, 419–430. 
See, Y.P., Weisel, R.D., Mickle, D.A., Teoh, K.H., Wilson, G.J., Tumiati, L.C., Mohabeer, M.K., 
Madonik, M.M., Axford-Gatley, R.A., and Salter, D.R. (1992). Prolonged hypothermic cardiac 
storage for transplantation. The effects on myocardial metabolism and mitochondrial function. J. 
Thorac. Cardiovasc. Surg. 104, 817–824. 
Serra, M., Brito, C., Sousa, M.F.Q., Jensen, J., Tostões, R., Clemente, J., Strehl, R., Hyllner, J., 
Carrondo, M.J.T., and Alves, P.M. (2010). Improving expansion of pluripotent human embryonic 
stem cells in perfused bioreactors through oxygen control. J. Biotechnol. 148, 208–215. 
Serra, M., Correia, C., Malpique, R., Brito, C., Jensen, J., Bjorquist, P., Carrondo, M.J.T., and 
Alves, P.M. (2011). Microencapsulation Technology: A Powerful Tool for Integrating Expansion and 
Cryopreservation of Human Embryonic Stem Cells. PLoS One 6, 1–13. 
Serra, M., Brito, C., Correia, C., and Alves, P.M. (2012). Process engineering of human pluripotent 
stem cells for clinical application. Trends Biotechnol. 30, 1–10. 
Sinnecker, D., Laugwitz, K.-L., and Moretti, A. (2014). Induced pluripotent stem cell-derived 
cardiomyocytes for drug development and toxicity testing. Pharmacol. Ther. 143, 246–252. 
Skelton, R.J.P., Costa, M., Anderson, D.J., Bruveris, F., Finnin, B.W., Koutsis, K., Arasaratnam, D., 
White, A.J., Rafii, A., Ng, E.S., et al. (2014). SIRPA, VCAM1 and CD34 identify discrete lineages 
during early human cardiovascular development. Stem Cell Res. 13, 172–179. 
Snyder, K.K., Baust, J.M., Van Buskirk, R.G., and Baust, J.G. (2005). Enhanced Hypothermic 
Storage of Neonatal Cardiomyocytes. Cell Preserv. Technol. 3, 61–74. 
Soares, C.P., Midlej, V., de Oliveira, M.E.W., Benchimol, M., Costa, M.L., and Mermelstein, C. 
(2012). 2D and 3D-organized cardiac cells shows differences in cellular morphology, adhesion 
junctions, presence of myofibrils and protein expression. PLoS One 7, e38147. 
Squifflet, J.P., Ledinh, H., De Roover, A., and Meurisse, M. (2011). Pancreas preservation for 
pancreas and islet transplantation: A minireview. In Transplantation Proceedings, pp. 3398–3401. 
Stefanovich, P., Ezzell, R.M., Sheehan, S.J., Tompkins, R.G., Yarmush, M.L., and Toner, M. 
(1995). Effects of hypothermia on the function, membrane integrity, and cytoskeletal structure of 
hepatocytes. Cryobiology 32, 389–403. 
Taylor, M.J. (2006). Biology of Cell Survival in the Cold: The Basis for Biopreservation of Tissues 
and Organs. In Advances in Biopreservation, J. Baust, and J. Baust, eds. (Boca Raton, Fla: 
CRC/Taylor & Francis), pp. 15–62. 
Taylor, M.J., Rhee, P., Chen, Z., and Alam, H.B. (2005). Design of preservation solutions for 
universal tissue preservation in vivo: Demonstration of efficacy in preclinical models of profound 
hypothermic cardiac arrest. In Transplantation Proceedings, pp. 303–307. 
Thirumala, S., Goebel, W.S., and Woods, E.J. (2009). Clinical grade adult stem cell banking. 
Organogenesis 5, 143–154. 
Uchida, T., Nagayama, M., Taira, T., Shimizu, K., Sakai, M., and Gohara, K. (2011). Optimal 
temperature range for low-temperature preservation of dissociated neonatal rat cardiomyocytes. 
Cryobiology 63, 279–284. 
Venable, J.H., and Coggeshall, R. (1965). A Simplified Lead Citrate Stain for use in Electron 
Microscopy. J. Cell Biol. 25, 407–408. 





Hoeger, S., El-Armouche, A., Wieland, T., et al. (2014). Dopamine and lipophilic derivates protect 
cardiomyocytes against cold preservation injury. J. Pharmacol. Exp. Ther. 348, 77–85. 
Vicente, M.I., Costa, P.F., and Lima, P.A. (2010). Galantamine inhibits slowly inactivating K+ 
currents with a dual dose-response relationship in differentiated N1E-115 cells and in CA1 
neurones. Eur. J. Pharmacol. 634, 16–25. 
Wakayama, K., Fukai, M., Yamashita, K., Kimura, T., Hirokata, G., Shibasaki, S., Fukumori, D., 
Haga, S., Sugawara, M., Suzuki, T., et al. (2012). Successful transplantation of rat hearts subjected 
to extended cold preservation with a novel preservation solution. Transpl. Int. 25, 696–706. 
Wang, Y., Cheng, L., and Gerecht, S. (2014). Efficient and scalable expansion of human 
pluripotent stem cells under clinically compliant settings: A view in 2013. Ann. Biomed. Eng. 42, 
1357–1372. 
Wheeler, T.J., and Chien, S. (2012). Protection of rat cardiac myocytes by fructose-1,6-
bisphosphate and 2,3-butanedione. PLoS One 7, e35023. 
Wheeler, T.J., Wiegand, C.B., and Chien, S. (2005). Fructose-1,6-bisphosphate enhances 
hypothermic preservation of cardiac myocytes. J. Hear. Lung Transplant. 24, 1378–1384. 
Wong, R.C.B., Dottori, M., Koh, K.L.L., Nguyen, L.T. V, Pera, M.F., and Pébay, A. (2006). Gap 
junctions modulate apoptosis and colony growth of human embryonic stem cells maintained in a 
serum-free system. Biochem. Biophys. Res. Commun. 344, 181–188. 
Zhang, M., Schulte, J.S., Heinick, A., Piccini, I., Rao, J., Quaranta, R., Zeuschner, D., Malan, D., 
Kim, K.-P., Röpke, A., et al. (2015). Universal Cardiac Induction of Human Pluripotent Stem Cells 













































1. Discussion ...................................................................................................................... 181 
1.1. Modulating dissolved oxygen and bioreactor hydrodynamic to improve CM 
differentiation ..................................................................................................................... 183 
1.2. Using soluble molecules to guide the differentiation of hPSC towards CMs .............. 185 
1.3. Three dimensional cultures improve CM differentiation and confer resistance to 
prolonged hypothermic storage ......................................................................................... 186 
1.4. Unveiling the role of metabolic substrate availability on CM differentiation and 
maturation .......................................................................................................................... 187 
1.5. Assessment of hPSC-CM quality................................................................................ 189 
1.6. hPSC-CM maturation: achievements and biological relevance. ................................ 190 
1.7. Facilitating the widespread distribution of hPSC-CMs: Improvements in short-term 
storage and shipping of hPSC-CMs .................................................................................. 192 
2. Future perspectives ....................................................................................................... 193 
3. Conclusion ...................................................................................................................... 194 









Human pluripotent stem cells (hPSCs) have emerged as the most promising solution to 
overcome human cardiomyocyte (CM) scarcity. Due to their high proliferation capacity and 
differentiation potential, hPSCs can provide unlimited quantities of functional CMs for disease 
modeling, drug discovery, toxicity screening, mechanistic research and cell-based regenerative 
therapies (Denning et al., 2015). However, the high complexity of network signaling pathways, 
environmental factors and paracrine signaling involved in cardiac development in vivo, makes its in 
vitro recapitulation a tremendous challenge. Despite all the advances observed in this field, current 
protocols for hPSC differentiation towards CMs still generate limited numbers of metabolically, 
structurally and functionally immature CMs. Therefore, the production of hPSC derived CMs 
(hPSC-CMs) with improved maturation status, in sufficient quantity and with consistent quality (i.e. 
with the safety and standardization required in clinical-grade manufacturing processes or in 
pharmaceutical development) still remains as an unmet need. Moreover, the development of 
efficient, simple and safe methods for storage and worldwide shipment of these cells is another 
major requirement for the widespread use of hPSC-CMs.  
The work developed in this thesis focused at addressing these needs with the ultimate goal of 
developing robust, scalable and integrated platforms for the production, maturation and storage of 
hPSC-CMs. The main bottlenecks and the strategies used to address them as well as the major 
achievements obtained in each chapter of this thesis are summarized in Figure 6.1.  
The impact of several environmental and/or biological factors on CM differentiation, maturation 
and storage processes was studied (Figure 6.2). Briefly, in Chapter 2 the impact of dissolved 
oxygen and bioreactor hydrodynamics on CM differentiation was studied using a murine reporter 
iPSC line, as a model system for bioprocess development, and a simple spontaneous embryoid 
body differentiation protocol to clearly identify the impact of each culture condition tested. In 
Chapter 3 the effect of combining a directed differentiation protocol induced by a cocktail of soluble 
molecules (i.e. small molecules and growth factors) with forced aggregation of hPSC-derived 
cardiac committed cells on CM differentiation and enrichment was addressed. Chapter 4 explored 
the impact of carbon substrate source availability on hPSC-CM maturation. In Chapter 5 the 
feasibility to store 2D monolayers and 3D aggregates of hPSC-CMs at hypothermic conditions was 










































































Figure 6.2 - Microenvironmental features studied in this thesis. The manipulation of these 
features improved differentiation, maturation and hypothermic storage of CMs. 
 
1.1. Modulating dissolved oxygen and bioreactor hydrodynamics to improve CM 
differentiation 
In Chapter 2 we evaluated the effect of dissolved oxygen and compared the impact of 
different bioreactor hydrodynamics (in stirred tank and WAVE) on iPSC differentiation towards 
CMs. The results showed that combining an atmospheric hypoxia culture (4% O2 tension) with an 
intermittent agitation profile in stirred tank bioreactors improves 1000-fold the CM yields when 
compared to atmospheric normoxia (20% O2 tension) and continuously agitated cultures. 
Additionally, we show for the first time that wave-induced agitation further favours CM 
differentiation as demonstrated by faster kinetics, higher CM yields (60 CMs/input iPSC) and 
improved numbers of functional CMs (2.3×10
9






In particular, this study showed that: i) controlled dissolved oxygen (DO) of 4% O2 maximizes 
cell proliferation, and ii) intermittent stirring and wave induced agitation significantly improved CM 
differentiation efficiency (CM purity and yields). 
 The beneficial impact of lowering the dissolved oxygen tension from normoxic atmospheric 
(20% O2) to an atmospheric hypoxia level of 4% O2, that is within the range of physiological oxygen 
levels (2–5% O2), can be justified by the importance of this environmental condition during 
embryonic development. In fact, it is known that  the low-oxygen levels (7-20 mm Hg, 1-3% O2) 
(Patterson and Zhang, 2010) that the cells are exposed to, in the early developing embryo, induces 
the expression of genes, such as hypoxia inducible factor 1 (HIF-1) and vascular endothelial 
growth factor (VEGF), that modulate cell metabolism, proliferation, angiogenesis, vasculogenesis 
and foetal heart remodelling (Patterson and Zhang, 2010; Simon and Keith, 2008). Also, oxygen 
availability has been shown to affect directly the viability, proliferation and differentiation propensity 
of stem cells in vitro (Simon and Keith, 2008). In particular, several studies showed improved hPSC 
expansion at atmospheric hypoxia (Forsyth et al., 2006; Gibbons et al., 2006; Serra et al., 2010). 
Nonetheless, the conclusions regarding the direct impact of low-oxygen levels on CM 
differentiation are still misleading. Some studies have reported improved CM differentiation yields 
(Bauwens et al., 2005; Horton and Auguste, 2012; Niebruegge et al., 2009), others have shown 
best results when applying hypoxia only in specific intervals of the differentiation process (Burridge 
et al., 2011; Medley et al., 2013) and others have shown reduction in spontaneous differentiation in 
hypoxic (1-5% O2) conditions compared to normoxic (20% O2) conditions (Ezashi et al., 2005) and 
that EBs formed in 20% O2 generated CMs earlier and with the highest efficiency than EBs 
exposed 5% O2 for four days (Kurosawa et al., 2006). Kempf and colleagues recently published a 
novel efficient bioreactor protocol for hPSC differentiation towards CMs without controlling DO 
(Kempf et al., 2014, 2015). The different results reported in these studies may be related with 
differences in: culture approach (2D monolayer vs 3D aggregate or static vs agitated), dynamics of 
agitation (type and rate) and aggregate size since all these parameters affect the O2 levels 
experience at the cellular level. This highlights the importance of exploring the O2 profile that cells 
experience in different culture systems and bioreactor hydrodynamics as well as within the 
aggregates, to allow better comparison and interpretation of the results. Recently, Wu and 
colleagues developed a mathematical model to simulate the oxygen distribution within mouse and 
human ESC aggregates based on the O2 consumption rate and number of cells (Wu et al., 2014). 
This study may contribute to improve the understanding of the effects of O2 on the physiology of 
stem cells organized in 3D aggregates. 
Additionally, it should be noted that the oxygen levels slightly increase during embryonic 
development, reaching in the adult heart, 18 to 35 mmHg (2-5% O2) (Sanada et al., 2014). In fact, 
mature CMs are more sensitive to low oxygen levels than adult CMs since they rely essentially on 
oxidative metabolism for energy production. Therefore, atmospheric hypoxia may be beneficial in 
earlier phases of CM differentiation in vitro, contributing to improve proliferation of hPSCs and 
cardiac progenitors (and ultimately cell numbers at the end of the process) but in later stages of 







differentiation efficiencies and yields may be improved if an increased gradient of oxygen tension, 
that better mimics the slight increase in oxygen tension from the foetus to the adult heart, is 
provided to the cells throughout the differentiation process.  
The improved CM differentiation efficiency and yields observed in WAVE bioreactor cultures 
compared to stirred tank bioreactors can be justified by the distinct hydrodynamic environment 
imposed by each of these two bioreactor designs. Whereas stirred tank bioreactor uses an 
impeller, the WAVE system relies on the use of plastic bag placed on a horizontally shaken plate to 
generate a wave, to mix and homogenize the cell culture. Thus, these conceptually distinct 
systems provide different i) mixing, ii) mass and heat transfer dynamics and iii) hydrodynamic 
stress to the cells (Fridley et al., 2012; Placzek et al., 2009; Serra et al., 2012, 2014; Sieblist et al., 
2011) and all these parameters can hugely impact the culture outcome. In particular, it has been 
demonstrated that fluid shear stress may play a significant role in cardiomyogenesis (Stoppel et al., 
2016). Previous studies have shown that the shear-stress induced by laminar flow (Illi et al., 2005) 
and medium perfusion (Shachar et al., 2012) have potential to improve the efficiency of hPSCs 
differentiation into CMs. For example, perfusion can be applied cyclically, using a peristaltic pump, 
to promote a pulsatile flow frequency that mimics heart rate of humans (1 Hz = 60 beats per min 
(bpm)) or rodents (2 Hz or 3 Hz, 120 or 180 bpm). 
Although, we have not performed a comparative study of the hydrodynamic environment in 
both culture systems, we speculate that the improvements observed, in the temporal gene 
expression pattern and cardiac differentiation efficiency, in the WAVE compared to stirred tank 
bioreactor cultures, may be related to the frequency of mechanical loading applied in both systems. 
In stirred tank bioreactors, using an intermittent stirring, mechanical forces at frequencies close to 
0.033 Hz were generated, whereas with a wave-induced agitation higher frequencies were reached 
(0.82-0.86 Hz). Nonetheless, more detailed information about the impact of these mechanical 
forces (and the bioreactor hydrodynamics as whole), on physiological and molecular mechanisms 
is needed. For this a more physical-mathematical driven approach should be pursued to provide a 
comprehensive characterization of the hydrodynamic environment and quantification of the type 
and magnitude of the stresses generated in each culture strategy using for example computational 
fluid dynamics and/or laser doppler anemometry (Wang et al., 2013). This knowledge will 
contribute to explain the biological outcomes and to further optimize the bioreactor-based protocol 
by defining the culture conditions that promote more efficient mechanical stimulation to the cells.  
1.2. Using soluble molecules to guide the differentiation of hPSC towards CMs  
Cardiomyogenesis in vivo is orchestrated by spatiotemporal changes in soluble cues 
(including growth factors, small molecules, etc) that act as agonists and/or antagonists of signaling 
pathways that drive myocardial differentiation, specification and maturation. Nowadays the majority 
of the CM differentiation protocols rely on the temporal modulation of Wnt signaling, that induces 
mesoderm differentiation and cardiac lineage specification (Lian et al., 2012, 2013; Ueno et al., 
2007). However, the complexity of the human cardiomyogenesis process allied to the line-to-line 






generate high-quality hPSC-CM with consistent efficiency from multiple hPSC lines or 
differentiation batches. In Chapter 3 we applied a directed cardiac differentiation protocol adapted 
from others previously described in the literature (Kattman et al., 2011; Lanier et al., 2012; Lian et 
al., 2013) that relies on the sequential addition of a cocktail of growth factors and small molecules, 
including: Activin A, CHIR99021, and IWR1, known to modulate Activin and Wnt/β-catenin-
signalling pathways, which are involved in cardiac lineage development (Kattman et al., 2011; Kim 
et al., 2015; Lian et al., 2012); and Ascorbic Acid that promotes the proliferation of both mesoderm 
and cardiac mesoderm cells (Cao et al., 2012). We showed that this protocol could be applied to 
four different hPSC lines (including hESCs and hiPSC) and generate 2D monolayers of hPSC-CMs 
that present typical CM gene and protein expression profiles, structure, ultrastructure, calcium 
signalling and contractility kinetics, within 15 days of culture. 
1.3. Three dimensional cultures improve CM differentiation and confer resistance to 
prolonged hypothermic storage  
The impact of 3D aggregate culture on CM differentiation and hypothermic storage of hPSC-
CMs was assessed in Chapters 2 and 5, respectively.  
Since the transition of CM differentiation protocols from 2D to 3D cultures typically results in 
lower CM purities and reduced reproducibility when compared to 2D cultures, in Chapter 3 we 
devised a protocol for CM differentiation and enrichment that relies on two steps. First, cardiac 
differentiation is induced in 2D monolayers and when the majority of the cell population is cardiac 
committed (day 6), forced aggregation is promoted. We demonstrated that aggregation of cardiac 
progenitors improves CM enrichment and commitment, induces significant alterations in the 
extracellular matrix and metabolic transcriptomes, and a slight increase of TCA-cycle activity, 
amino acid metabolism and ATP production through glucose oxidation when compared with 
parallel 2D monolayer cultures. Also, we observed a slight improvement of contractile kinetics in 
3D aggregate cultures when compared to 2D monolayer cultures. Although forced aggregation 
may have contributed to enrich differentiating cultures into CMs, as demonstrated elsewhere 
(Nguyen et al., 2014), the 3D culture environment may have also contributed to enhance CM 
differentiation, commitment and functionality. Several studies have demonstrated that 3D culture 
strategies improve maturation of primary CMs (Akins et al., 2010; Soares et al., 2012) and hPSC-
CM (Chan et al., 2013; Mihic et al., 2014; Nunes et al., 2013; Ruan et al., 2016; Zhang et al., 
2013). Nonetheless, the majority of these studies did not provide a direct comparison with 2D 
cultures, as we performed in Chapter 3, and often combine other strategies that also affect CM 
maturation, such as mechanical stretch or electrical stimulation, making the results ambiguous. In 
Chapter 3, we observed slight improvements in hPSC-CM functionality with just 9 days of culture 
as 3D aggregates, thus we may speculate that prolonging the culture time would further improve 
CM functionality and ultimately CM maturation. 
In Chapter 5 we showed that 3D conformation confers an additional protection to extended 
hypothermia-induced stress. We demonstrated that cell viability and recovery in 2D monolayers of 







whereas 3D aggregates of hPSC-CMs show high cell viabilities after 7 days of cold storage and 
maintained their metabolic activity, (ultra)structure, phenotype and function. This work highlights 
that 3D aggregate cultures are more resistant to prolonged hypothermic storage intervals, probably 
by promoting the formation of more abundant and strong cell-cell interactions. 
1.4. Unveiling the role of metabolic substrate availability on CM differentiation and 
maturation 
CMs undergo several metabolic changes, during development to meet the increased energetic 
demands imposed by the continuous heart beating. While in early cardiac development, glycolysis 
is the major source of energy, as CMs mature and become terminally differentiated, mitochondrial 
oxidative capacity increases, and fatty acid oxidation becomes the major fuel source of energy 
(Lopaschuk and Jaswal, 2010). This correlation between the changes in cellular metabolic status 
and in vivo development encouraged our interest in exploring cell metabolism during hPSC 
differentiation towards CMs, in vitro. A systematic metabolic characterization during differentiation 
and maturation processes was performed in Chapters 3 and 4, respectively. In Chapter 3 it was 
demonstrated that cells remain highly glycolytic throughout all the differentiation process, and that 
the hPSC-CMs generated in both 2D and 3D cultures present a metabolic phenotype largely driven 
by high glucose consumption and lactate production at near stoichiometric levels. In addition, in 
Chapter 4 it was demonstrated that when hPSC-CMs were cultured in the standard glucose rich 
medium formulation for additional 20 days, cells maintain their glycolytic metabolism and a fetal-
like phenotype. These results motivated us to speculate that inducing a metabolic shift from 
glycolytic to an oxidative state, by replacing glucose in culture medium with other carbon sources 
preferably used by CMs (Lopaschuk and Jaswal, 2010), could improve the maturation status of 
hPSC-CMs in vitro, in a faster way than just prolonging the culture time, as previously 
demonstrated (Lundy et al., 2013).  
Even though we demonstrated that culturing hPSC-CMs in glucose depleted medium 
supplemented with fatty acids, the major substrate used by adult CMs (Lopaschuk and Jaswal, 
2010) improved CM structure and functionality, we also showed that this culture condition lead to a 
drastic cell death after 10 days of culture. Probably hPSC-CMs still present a poor oxidative 
capacity after the differentiation process (day 15 after induction of differentiation) that limits an 
efficient fatty acid metabolization. We showed that fatty acid uptake superseded fatty acid 
metabolization trough β-oxidation and TCA cycle, leading to the intracellular accumulation of fatty 
acid. Excess accumulation of lipids and overactivation of lipid signalling pathways typically trigger 
cellular dysfunction and ultimately apoptotic cell death or lipoapoptosis (D’Souza et al., 2016).  
Nonetheless, we demonstrated that supplementation of fatty acid medium with galactose, 
commonly used to improve the oxidative capacity in different cell types including cancer cells, 
primary fibroblasts and muscle cells (Aguer et al., 2011; Kase et al., 2013), circumvented the 
lipotoxicity issue, contributing to improve fatty acid oxidation. We found out that after 20 days of 






metabolism and improved molecular, structural and functional maturation when compared with 
hPSC-CMs cultured in glucose rich medium (GLCM). 
In order to mimic the temporal substrate preference during in vivo CM development, we also 
evaluated the impact of culturing hiPSC-CMs in glucose depleted medium supplemented with 
lactate for 10 days before cultivation in GFAM. Although the culture in lactate rich medium has 
contributed to improve cellular oxidative capacity, this approach resulted in lower structural and 
functional maturation comparatively to GFAM cultures. Of note is that, we showed that combining 
10 days in GFAM after 10 days of culture in lactate rich medium is sufficient to improve structural 
and functional maturation of hPSC-CMs, leading to a phenotype indistinguishable from hPSC-CMs 
maintained in GFAM for the entire 20 days. This combined approach is better suited to cultures 
with reduced hPSC-CM purity, since it enables a fast and efficient purification of CMs. In glucose 
depleted- and lactate-abundant conditions hPSCs and other proliferating cells that depend mainly 
on glycolysis do not survive in contrast to hPSC-CMs that can use lactate as an alternative energy 
source (Tohyama et al., 2013).  
In pathological conditions such as heart failure, cardiac energy metabolism, specifically fatty 
acid and glucose metabolism, is altered and has been implicated as a contributing factor to 
impaired heart efficiency and function (Fillmore et al., 2014; Sankaralingam and Lopaschuk, 2015). 
Studies using rodent models of cardiac diseases have provided emerging evidences that correcting 
these changes in energy metabolism by modulating mitochondrial oxidative metabolism may help 
in the treatment of heart failure (Fillmore and Lopaschuk, 2013). Nonetheless, due to substantial 
species differences in cardiac physiology, animal models cannot accurately recapitulate many 
aspects of human cardiac syndromes/pathologies. In this regard, the use of hPSC-CMs to study 
cardiac metabolism or to recapitulate key pathophysiological phenotypes is more appealing 
however it is still hampered by the poor hPSC-CM metabolic maturation observed in vitro. In few 
studies, hPSC-CMs were cultured with complex adipogenic cocktails (Kim et al., 2013; Wen et al., 
2015) to enhance metabolic maturation and specifically fatty acid β-oxidation. Herein, we used 
GFAM to improve the metabolic maturation of hPSC-CMs. This simple and cost-effective approach 
may contribute to streamline the manufacturing of more mature hPSC-CMs. Additionally, this thesis 
contributed to improve the knowledge in cardiac metabolism field, providing new evidences that a 
glycolytic-to-oxidative metabolic shift can be a cause, rather than a consequence of CM 
maturation. The comprehensive metabolic characterization performed throughout this thesis also 
provided novel insights for the identification/characterization of the differentiated population based 
on its metabolic signature. Importantly, it was demonstrated that manipulation of culture medium 
composition induces metabolic, molecular and phenotypic alterations that resemble physiological 
but also pathophysiological conditions such as cardiac hypertrophy and lipotoxicity. The metabolic 
models described in this thesis can be used to study scenarios of cardiac lipotoxicity and 
hypertrophy. These metabolic disorders can be triggered by several etiologies including obesity, 
diabetes mellitus, myocardial ischemia reperfusion/infarction and aging (D’Souza et al., 2016), thus 







This thesis as well as other previous studies showed that metabolic manipulation can dictate 
cell fate decisions in vitro (Shyh-Chang et al., 2013). However, it remains to be determined whether 
modulating metabolic processes directly in vivo could serve as instructive regulatory signals for 
resident cells to enhance tissue repair. This may open the way for the development of novel 
pharmacological therapies for tissue regeneration based on the manipulation of cell metabolism in 
vivo. For example, drugs that target specific metabolic enzymes involved in the balance between 
glycolysis, mitochondrial oxidative phosphorylation and oxidative stress could be applied locally to 
potentiate cell proliferation/differentiation/maturation. Advanced metabolomics technologies that 
allow tracking real-time changes in cellular metabolism in vivo, with high sensitivity, will be useful in 
the future to evaluate the feasibility and efficiency of these therapies. 
1.5. Assessment of hPSC-CM quality 
One major requirement for the manufacturing of stem cell derivatives is to ensure that the final 
product fulfils the desired quality requisites for biomedical applications. Throughout this thesis an 
extensive characterization of the generated PSC-CMs was performed, including phenotypic, 
metabolic and functional interrogation. Using several analytical methods ranging from quantitative 
reverse-transcription polymerase chain reaction (RT-PCR), flow cytometry, fluorescent microscopy, 
scanning and transmission electron microscopy, to patch clamp analysis we were able to confirm 
that the produced hPSC-CMs present typical cardiac gene and protein expression profiles, 
(ultra)structure, electrophysiology, drug responsiveness and rhythmic intracellular calcium 
transients. “Omics” tools, specifically, transcriptomics, metabolomics and fluxomics were also 
explored in this thesis. Integration of all the layers of information provided by these powerful tools 
pushed this study to new levels of understanding: Chapter 3 provides valuable molecular insights 
on the influence of culture system configuration on CM differentiation and Chapter 4 provides a 




Carbon-Metabolic Flux Analysis (
13
C-MFA) constituted a valuable resource in 
this thesis, enabling the quantitative description of central carbon metabolism (glycolysis, TCA 
cycle, FA oxidation and amino acid metabolism) and the estimation of energetic output (ATP 
synthesis) in hPSC-CM cultured in distinct carbon sources. As introduced in Chapter 1, in 
13
C-
MFA, isotopic labelling data are fitted to a predefined metabolic network model to estimate 
intracellular metabolic fluxes. In our work, we used a simplified metabolic network of central carbon 
metabolism, adapted from the literature (Woo Suk and Antoniewicz, 2013). To facilitate the 
accurate estimation of the fluxes, the complexity and redundancy of the metabolic network is 
typically simplified (Calheiros Gomes and Simoes, 2012; Zamboni, 2011). Therefore, improving 
model network complexity, for example to include data from more comprehensive lipidomics 
analysis, will be very useful in the future to better describe CM metabolism but also to uncover how 
the increase in myocardial FA uptake and the accumulation of lipid metabolites are interconnected 






1.6. hPSC-CM maturation: achievements and biological relevance.  
How close are we from reproducing adult CMs in vitro?  
It has been shown that hPSC-CMs remain immature in culture and resemble heart cells of 
mid-gestation human foetuses (Veerman et al., 2015). In Chapter 4 we established a novel 
method for hPSC-CM maturation based on metabolic substrate manipulation (GFAM culture). We 
showed that shifting hPSC-CMs from glucose-containing to galactose- and FA-containing media 
promotes their faster maturation, resulting in hPSC-CMs with energetically efficient oxidative 
metabolism, transcriptome signatures closer to that of adult ventricular CMs, higher myofibril 
density and alignment, improved calcium, contractility and action potential kinetics when compared 
with hPSC-CMs cultured in glucose rich medium. This method holds technical and economic 
advantages over the existing protocols due to its scalability (it can be applied to a large number of 
cells, for example cells cultured in a bioreactor), simplicity (a simple medium-exchange procedure) 
and ease of application (does not require specific equipment or addition of expensive 
factors/chemicals). Table 6.1 compares GFAM strategy with other approaches reported in the 
literature for hPSC-CM maturation that have used the same markers to assess maturation status, 
namely: structure (aspect ratio; circularity index; surface area); functionality (contractile force) and 
metabolism (metabolic substrate; oxygen consumption rate). The total time of culture is also 
indicated since it can also affect the culture outcome. It is possible to note that not all approaches 
use the same parameters to evaluate hPSC-CM maturation, making it difficult to compare the 
efficiency of different protocols. Cell metabolism, for instance, has been rarely measured and taken 
into consideration in maturation studies. Also, the methodologies used to assess maturation status, 
for example, the contractile force, typically varies which also hampers a reliable comparison of the 
results. Nonetheless, we can conclude that GFAM culture is a competitive and advantageous 
strategy, capable to induce metabolic, phenotypic and functional maturation of hPSC-CMs in a 
timely efficient manner, when compared to what has been described in the literature.  
Although, after GFAM treatment hPSC-CMs present certain features more similar to human 
adult CMs than hPSC-CMs obtained with strategies previously reported (Table 6.1), hPSC-CMs 
are still far from becoming structurally and functionally identical to adult CMs. There are certain 
features of the adult CM phenotype which have not yet been ubiquitously observed in culture, 
including the presence of: i) M-bands, a hallmark of sarcomeric structural maturation (Feric and 
Radisic, 2016), and ii) T-tubules, key structures of the excitation-contraction coupling mechanism in 
mature CMs that are important for normal Ca
2+
 handling (Yang et al., 2014). Even though it is 
speculated that probably a phenotype completely resembling adult CMs might never be attainable 
in in vitro cell culture systems, the scientific community is still pursuing strategies that more 












































































































































































































































The more immediate interest in using mature hPSC-CMs is for drug screening or cardiotoxicity 
assessment since toxic side effects on the heart often limit implementation of valuable drug 
therapies (Denning et al., 2015). Specifically, hiPSC-CMs have been differentiated from hiPSC 
lines generated from patients affected by cardiac diseases to study patient- and disease-specific 
mutations or polymorphisms and facilitate insights into disease mechanisms and therapeutic 
approaches (Bayzigitov et al., 2016; Sala et al., 2016; Sallam et al., 2015). The use of hPSC-CMs 
for cardiac tissue replacement, although actively investigated, is still far from being a routine clinical 
practice (Fox et al., 2014; Veerman et al., 2015). The key question that remains unclear is whether 
more mature cells are preferable for cell transplantation experiments. First, it was speculated that 
hPSC-CMs whose electrical and mechanical properties more closely resemble those of native 
myocardium would pose less arrhythmic risk and have enhanced contractile performance (Yang et 
al., 2014). Nonetheless, immature hPSC-CMs have been shown to be better suited for cell therapy 
applications, as they are more hypoxic-resistant and tolerant to the ischemic environment after 
transplantation (Boheler et al., 2011). Also, it has been demonstrated that immature CMs exhibit a 
markedly higher engraftment rate than more mature CMs when transplanted into the injured heart 
(Reinecke et al., 1999), and can mature in vivo after integration into the recipient myocardium 
(Chong et al., 2014; van Laake et al., 2007). It should be highlighted that a recently published case 





infarcted myocardium improved functional and clinical outcome in a patient with severe ischaemic 
heart failure without the induction of arrhythmias, tumour formation or immunosuppression-related 
adverse events (Menasché et al., 2015). This trial (ESCORT) is actually in Phase I 
(ClinicalTrials.gov: NCT02057900). In addition, the use of less differentiated but mesoderm-
committed hPSC-derived cells may constitute another solution for clinical applications, since these 
cells might restore myocardial tissue and also contribute to revascularization (Hulot et al., 2014). 
Further investigations are still needed to determine the ideal level of differentiation and/or 
maturation status for in vivo transplantation, however it is imperative to find a balance between 
safety and efficacy to obtain better engrafting and functional improvements. 
1.7. Facilitating the widespread distribution of hPSC-CMs: Improvements in short-term 
storage and shipping of hPSC-CMs 
The enhanced applicability of hPSC-CMs has increased the demand for effective methods for 
their storage and shipping. In Chapter 5, effective clinically compatible strategies for cold storage 
of hPSC-CMs cultured as 2D monolayers and 3D aggregates were established. It was shown for 
the first time that 2D monolayers and 3D aggregates of hPSC-CMs can be efficiently stored at 4°C, 
using a fully defined clinical-compatible preservation formulation, HypoThermosol® (HTS), for 3 
and 7 days, respectively, without compromising cell viability, (ultra)structure, gene and protein 
expression profile, electrophysiological profiles, and drug responsiveness. To evaluate the 
efficiency and robustness of the hypothermic storage process, we assessed cell viability and 
biological activity/potency for one week post-storage period. The storage protocol was considered 







generally acceptable for somatic cellular therapies (Food and Drug Administration, 2008). It should 
be noted that the hypothermic storage studies were performed with non-proliferative hPSC-CMs, 
therefore the high cell recovery/viability observed after storage clearly reflects the efficiency of the 
process. Importantly, this study constitutes a promising avenue for the delivery of certified, 
validated, ready-to-use monolayers and aggregates of hPSC-CMs, manufactured in specialized 
companies to customers/physicians worldwide, facilitating the use of these cells in high-throughput 
cardiac drug testing, toxicity screening or regenerative therapies. 
It is important to highlight that the hypothermic storage protocol described in Chapter 5 was 
used and validated in Chapter 2, 3 and 4. Murine and human PSC-CMs, at different culture 
timepoints (from days 13 to 35 post-differentiation induction), were shipped in these conditions, to 
our collaborators at University of Cologne (Germany) and at Harvard Medical School (Boston, 
EUA), to carry out electrophysiology and contractility studies (Chapter 2, 3 and 4). The shipping 
was performed at controlled temperature of 4°C and lasted from 2 to 5 days and no impact on cell 
viability and functionality studies was observed.  
As introduced in Chapter 1, hypothermic storage consists in the use of refrigerated 
temperatures (typically within the range of 4–10 °C) to store biologics (Baust et al., 2016). The 
principle behind this technique is that at cold temperatures metabolic activity of the cells is reduced 
in a reversible manner. In addition, preservation of cell homeostasis is facilitated by the use of 
commercially available hypothermic solutions, such as HTS, that were carefully formulated to 
maintain the ionic and osmotic balances, control of pH, supply energy substitutes, prevent cell 
swelling and the formation of free radicals at low temperatures (Brockbank and Taylor, 2006). For 
short-time storage periods and/or shipment of the cells, hypothermic preservation is preferable to 
cryopreservation, since it is simpler, safer, more versatile and with low operational/technical 
demand. Hypothermic preserved hPSC-CMs can be easily manipulated by researchers/physicians 
with minimal knowledge of hPSC culture. When using a clinical compatible solution, such as HTS, 
cells can be directly injected in patients after the shipment/storage. For other applications, 
hypothermic solution just needs to be replaced by culture medium. In contrast, the methods 
described in the literature for cryopreservation of hPSC-CMs, besides poorly efficient and 
reproducible, are time- and technically demanding, requiring: pre-treatment (heat-shock and 
incubation with specific factors), cell culture dissociation into single-cell suspension before freezing 
and several washes to remove FBS and toxic cryoprotective agents such as DMSO, after thawing 
(Preininger and Singh, 2016; Shiba et al., 2012; Xu et al., 2011). Nonetheless, the development of 
more efficient strategies to cryopreserve hPSC-CMs, also as 2D monolayers and 3D aggregates, 
will be a very important achievement, enabling to generate large and validated cell banks of hPSC-
CMs for later use in biomedical applications. 
2. Future perspectives 
This thesis contributed to progress beyond the state of the art on the stem cell field. However, 






more effective strategies for CM differentiation and maturation. Future studies mimicking even 
further the complexity of in vivo microenvironment, by combining approaches that simultaneously 
provide regulatory cues at different levels are needed. Therefore, the maturation strategy described 
in Chapter 4 should be translated to 3D aggregate cell culture strategy and combined with a 
directed differentiation process in a bioreactor protocol that could assure an increased gradient of 
oxygen throughout culture time and a cyclic mechanical rich environment, accordingly to the 
insights described in Chapter 2. Integration of all environmental stimuli investigated in this thesis 
will increase physiological relevance and hopefully provide a scalable, robust and straightforward 
bioprocess for mass production of pure and more mature hPSC-CMs in the near future.  
Looking forward, synergistic, multidisciplinary approaches bridging biology, engineering, 
physics, material sciences and mathematics should be pursued to collectively define the best path 
forward to improve efficiency, standardization and cost-effectiveness of the bioprocesses and to 
predict their outcome. Additionally, the combination of distinct high-throughput omic technologies 
will fill gaps in the understanding of the mechanisms governing cardiomyogenesis and 
cardiovascular diseases at the molecular, cellular, and organ level. This knowledge will facilitate 
the design of subtype-specific cardiac differentiation and ultimately improve prediction, prevention 
and the design of novel therapeutic treatments of cardiovascular diseases.  
3. Conclusion 
In summary, this thesis contributes to the advance of scalable hPSC differentiation towards 
CMs, hPSC-CM maturation and hypothermic storage of hPSC-CMs and simultaneously provides a 
detailed quantitative characterization of hPSC-CM phenotype, in terms of transcriptome, 
metabolome and fluxome, at different developmental states. The knowledge generated will, 
hopefully, contribute to potentiate the worldwide commercial distribution and utilization of hPSC-
CMs in applications ranging from tissue replacement in heart failure after myocardial infarction to 
basic science on heart development, cardiac disease modelling, drug discovery, and cardiac safety 
pharmacology. 
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